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ABSTRACT 
 Regulation of striated muscle differentiation and development are complex 
processes coordinated by an array of transcription factors. MEF2 is a crucial transcription 
factor required for muscle differentiation, but the roles of the individual MEF2 family 
members, MEF2A-D, have not been extensively evaluated. Acute ablation of Mef2 
expression in skeletal myoblasts revealed a required role for MEF2A activity in myoblast 
differentiation that was not shared with the other MEF2 factors. We hypothesized that a 
transcriptomic level analysis of Mef2-deficient skeletal myoblasts would reveal distinct 
regulatory roles for each MEF2 isoform. Comparative microarray analysis supported our 
hypothesis and we observed distinct gene programs preferentially-sensitive to individual 
MEF2 isoforms. While there was no variance in the consensus binding site associated 
with regulation by individual MEF2 isoforms, we did observe uniquely enriched binding 
sites for candidate co-regulatory proteins that mediate these complex regulatory patterns. 
Based on our observations in skeletal myoblasts, we performed a series of acute Mef2 
knockdowns in neonatal cardiomyocytes and uncovered a requirement for MEF2A and -
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D, but not MEF2C in cardiomyocyte survival. Comparative microarray analysis 
confirmed that, similar to skeletal myoblasts, the MEF2 family regulated distinct but 
overlapping gene programs in cardiomyocytes. Additionally, this analysis uncovered a 
previously uncharacterized antagonistic regulation of a subset of cell cycle and sarcomere 
genes. Interestingly, Mef2a and -d knockdowns caused an upregulation of cell cycle 
markers and downregulation of sarcomere genes, with the opposite regulatory pattern in 
Mef2c knockdown. Further investigation of the proximal promoter region of these genes 
revealed enriched binding sites for transcription factors associated with key signaling 
pathways in the developing embryo, Hedgehog and Notch. Overexpression of 
constitutively active components of these signaling pathways revealed that Notch 
function requires the presence of MEF2A and -D, while Hedgehog does not appear to 
interact with these two isoforms. We have shown through our studies that MEF2, a core 
muscle transcription factor, takes part in complex regulatory interactions that are critical 
for the appropriate development of striated muscle tissues. 
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CHAPTER ONE: Introduction 
1.1 Introduction 
 This dissertation focuses on understanding the interplay of regulatory roles of 
MEF2 isoforms in mammalian striated muscle. Mammalian MEF2 is composed of four 
transcription factors, MEF2A-D, that share high amino acid conservation, but have 
distinct roles in development and homeostasis. Prior literature has focused on the study of 
a single member of the family and extrapolated shared roles to the other family members. 
This research addresses the MEF2 family members as independent transcription factors. 
 The dissertation is divided into three parts. In chapter three, evidence is presented 
supporting unique roles for individual MEF2 factors in an in vitro model of skeletal 
differentiation and reveals distinct and overlapping networks regulated by each member 
of the MEF2 family. Data presented in chapter four reveals that the MEF2 family also 
regulates diverse cellular pathways in cardiac muscle, and introduces a novel antagonistic 
regulatory pattern governing a subset of genes regulated in one direction by MEF2A and 
-D, and in the opposite direction by MEF2C. We then introduce candidate regulatory 
pathways that may explain this uncharacterized pattern of regulation. Chapter five is 
focused on the direct repressive interaction of a single co-regulatory transcription factor, 
EGR1, and its role in MEF2A-mediated gene regulation. Investigating the complex intra-
family MEF2 regulatory networks that exist in striated muscle is critical for 
understanding muscle development and disease. 
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1.2 Mammalian striated muscle development 
1.2.1 Cardiac muscle development 
 The mammalian heart develops from specified mesodermal cells originating from 
the primitive streak. These cells form fields that migrate anteriorly and laterally from the 
primitive streak to form the anterolateral plate mesoderm which then migrates towards 
the midline at approximately mouse e7.5. Fusion at the midline of the embryo leads to the 
first formal cardiac structure, the linear heart tube, which is then elongated by the 
addition of the secondary heart field. After fusion of the secondary heart field the linear 
heart tube becomes functional and begins pumping blood from the venous region towards 
the arterial region at approximately e8.5 (Paige et al. 2015). The heart tube then 
undergoes looping morphogenesis and begins to expand outward as the chambers of the 
heart begin to mature by e9.5, with distinct ventricles forming by e10.5 (Paige et al. 
2015). 
1.2.2 Skeletal muscle development 
 The cell lineage that develops into the skeletal muscles of the body wall and limbs 
resides in the maturing somites. The somites are a series of mesodermal discs that arise 
from the presomitic mesoderm in a rostral-caudal progression (Molkentin et al. 1996). 
The formation of the somites from the presomitic mesoderm begins at e8.0 in mice 
(Edmonson et al. 1994). The induction of myogenesis in the body wall muscles occurs 
through activation of two myogenic bHLH factors, Myf5 and MyoD downstream of 
external signaling cues from the surrounding tissues (Braun et al. 1996, Molkentin et al. 
1996). External signaling cues from the notochord, neural tube, and lateral mesoderm 
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induce compartmentalization of the somite into several discrete substructures responsible 
for the development of various body tissues (Molkentin et al. 1996). 
1.3 Myocyte Enhancer Factor-2 Transcription Factors 
1.3.1 Discovery and structure of MEF2 factors 
 The MEF2 family was discovered as DNA binding activity on an A/T-rich 
sequence upstream of the transcriptional start site of the mck promoter (renamed Ckm; 
creatine kinase, M-type) (Gossett et al. 1989). Expression of the protein binding this site 
preceded the expression of mck and other muscle-specific transcripts (Gossett et al. 1989, 
Pollock et al. 1991, Yu et al. 1992), establishing a role in early regulation of skeletal 
muscle gene expression. Initial investigations suggested an overlap in binding specificity 
with Serum Response Factor (SRF) (Pollock et al. 1991) due to the presence of a MADS 
box, a conserved DNA binding domain that is shared by proteins in the MADS box 
family: yeast mating-type selection factor MCM1, plant leaf identity homeodomain factor 
Agamous Deficiens, and human serum response factor SRF (Pollock et al. 1991, Yu et al. 
1992). Further analysis revealed MEF2 activity was specific to a unique consensus 
sequence, CTA(A/T)4TAG, which differed from the SRF consensus sequence (Pollock et 
al. 1991). 
 Mammalian MEF2 is composed of four members expressed from distinct genes 
(Figure 1.1). The highly conserved N-terminal region of each MEF2 factor shares 
approximately 95% amino acid sequence similarity in the MADS box and MEF2 
domains (Black et al. 1998, Santelli et al. 2000). The MADS box and MEF2 domain are 
required for DNA binding and dimerization, and play a key role in the binding of co-
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regulatory factors (Black et al. 1998, Santelli et al. 2000, Potthoff et al. 2007). The C-
terminal region of each MEF2 factor contains the transcriptional activation domain and 
exhibits considerable amino acid divergence (Potthoff et al. 2007), sharing between 6 and 
16% amino acid sequence identity. This divergence occurs throughout the region with the 
exception of an alternatively spliced exon designated β, shared among all four MEF2 
isoforms. Inclusion of the β is enriched in tissues with known MEF2 function, and 
appears important in MEF2-mediated transcriptional activation (Figure 1.2) (Zhu et al. 
2005).  
1.3.2 MEF2 developmental expression patterns 
 MEF2 family members display a complex developmental expression pattern in 
striated muscle (Figure 1.3). In mammalian embryos, the heart begins as a curved stripe 
of cardiac precursor cells, i.e. the cardiac crescent, that have been specified to develop 
into the heart. Spatiotemporal in situ hybridization analysis on developing mouse 
embryos revealed that Mef2b and Mef2c are the first Mef2 isoforms expressed in the 
cardiac mesoderm at embryonic day 7.5 (E7.5) prior to expression of sarcomeric genes 
such as cardiac α-actin (Edmonson et al. 1994, Molkentin et al. 1996). Mef2c is also 
expressed in the sinus venosus which contributes to the cardiac atria. Mef2a and Mef2d 
are subsequently expressed in the linear heart tube between E8.0 and E8.5, and after E8.5 
all four Mef2 genes are expressed throughout the developing heart (Figure 1.3). Mef2b 
and Mef2c expression begins to decline at E11.5, whereas Mef2a and Mef2d continue to 
be expressed. Additionally, Mef2a and Mef2c are expressed in the cardiac outflow tract as 
early as E9.5 and their expression seems far more prominent than that of Mef2d 
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(Edmonson et al. 1994). Postnatally, Mef2a and Mef2d are the most abundant isoforms in 
the heart. However, Mef2c expression has also been detected in postnatal 
cardiomyocytes, and is believed to play a role in homeostasis (Pereira et al. 2009) 
 The induction of myogenesis of the body wall muscles occurs through activation 
of two myogenic bHLH factors, MYF5 and MyoD (Braun et al. 1996, Molkentin et al. 
1996). Induction of Mef2 expression occurs concurrently with the appearance of the 
myogenic bHLH factors. Mef2b and Mef2c are the first Mef2 transcripts detected in 
developing skeletal muscle at E9.0 (Figure 1.3), with the expression of Mef2a and Mef2d 
following soon thereafter at E9.5 (Molkentin et al. 1996). Expression of all Mef2 
transcripts persists through skeletal muscle development and into mature tissue 
(Edmonson et al. 1994). 
1.3.3 MEF2 transcriptional activity in development 
 The spatiotemporal readout of MEF2 transcriptional activity in developing and 
adult mice was determined by generating transgenic mice harboring the lacZ gene driven 
by 3 copies of the desmin MEF2 site and surrounding flanking sequences (Naya et al. 
1999). Reporter expression was restricted primarily to the muscle and neuronal lineages, 
tissues expressing high levels of MEF2 (Figure 1.4). In the heart, activity of the transgene 
was detected in a cluster of cardiogenic precursors in the cardiac crescent as early as E7.5 
consistent with the expression of Mef2c. At E8.5, βgal expression appeared to be 
restricted to myocytes and was observed in the aortic sac, conotruncus, and the 
developing ventricles and atria. Transgene expression continued to be detected uniformly 
throughout the developing heart in both the atrial and ventricular chambers through 
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E14.5. However, despite abundant expression of Mef2a and Mef2d at this time point and 
postnatally, βgal expression begins to decline in late fetal cardiac development, and is 
greatly diminished postnatally. The reduction in postnatal MEF2-dependent reporter 
expression stems, in part, from the repression of MEF2 activity by histone deacetylases 
(HDACs) (McKinsey et al. 2001, McKinsey et al. 2002). Despite the potent repression of 
MEF2 activity on the transgene, high expression levels of MEF2A and MEF2D and 
robust in vitro DNA binding activity in postnatal cardiac extracts suggest that MEF2 
protein isoforms still retain essential transcriptional function in muscle gene regulation in 
postnatal cardiomyocyte homeostasis. Indeed, as described below, MEF2A and MEF2D 
are required for proper gene regulation and survival in neonatal cardiomyocytes. 
 Concurrently, analysis of the lacZ reporter transgenic mice reveals robust MEF2 
activity in the somites, a developmental structure that will eventually give rise to the 
body wall muscles of the organism (Figure 1.4). The discovery of MEF2 binding activity 
upstream of the expression of muscle-specific genes implicates the MEF2 family as 
central co-regulators of the skeletal and cardiac differentiation programs (Gossett et al. 
1989, Pollock et al. 1991, Yu et al. 1992, Potthoff et al. 2007). MEF2 binding sites were 
discovered on promoters containing E-box binding sites, the consensus binding sequence 
of the myogenic bHLH factors (Wright et al. 1991, Black et al. 1998, Puri et al. 2000). 
The presence of both binding sites on muscle-specific promoters suggests coordinate 
regulation of muscle specific genes by the MEF2 family and the myogenic bHLH factors 
(Black et al. 1998, Puri et al. 2000). Additionally, protein-protein interactions between 
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the MEF2 factors and myogenic bHLH heterodimers are sufficient to induce synergistic 
transcriptional activation in the presence of only a single binding site (Black et al. 1998). 
1.3.4 Regulation of MEF2 transcriptional activity 
 The transcriptional activity of the MEF2 transcription factors integrates signals 
from a variety of signaling cascades, including muscle-specific calcium signaling and 
more general receptor signal transduction pathways. Multiple calcium signaling pathways 
converge to regulate the post-translational activity of the MEF2 family (Black et al. 1998, 
Potthoff et al. 2007).  
 Class II HDACs repress MEF2 family members through interaction with a short 
amino acid sequence conserved among MEF2 factors (Han et al. 2005). Activation of the 
calcium modulated protein kinase (CaMK) signaling pathway precludes association of 
these HDACs with MEF2, allowing for subsequent MEF2 transcriptional activation (Lu 
et al. 2000, McKinsey et al. 2001). 
 Mitogen-activated protein kinases (MAPKs) are known activators of MEF2 
transcriptional activity. Activation of p38 leads to phosphorylation of a conserved 
sequence in the C-terminal transcriptional activation domain of MEF2 leading to 
increased activity (McKinsey et al. 2002). In parallel, ERK5 is a known MEF2 co-
activator and its activation leads to the formation of a complex with MEF2, leading to 
transcriptional activation (Lu et al. 2000). 
 In the years following the reported links between MEF2 and chromatin modifiers 
(Sartorelli et al. 1997, Miska et al. 1999, Sparrow et al. 1999), the MEF2-HDAC 
interaction has been the most extensively investigated pathway in pathophysiological 
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processes in the heart. It is now firmly established that dissociation of class II HDACs 
from MEF2 downstream of hypertrophic signaling is a key event in the stimulation of 
postnatal MEF2 transcriptional activity (Lu et al. 2000, Zhang et al. 2002, McKinsey et 
al. 2005), a process that ultimately contributes to the genomic reprogramming observed 
in cardiac pathology. Briefly, these pathological signals activate a number of protein 
kinases to promote sequestration of class II HDACs in the cytoplasm. Most, if not all, of 
these protein kinases such as calcium-calmodulin kinases and protein kinase D 
phosphorylate class II HDACs on specific amino acid residues which serve as docking 
sites for adaptor protein 14-3-3, resulting in their nuclear export and subsequent MEF2 
activation (Backs et al. 2006, Parra et al. 2010). Additionally, the PKA signaling pathway 
including the A-kinase anchoring protein, AKAP, have been shown to modulate HDAC 
and MEF2 activity (Carnegie et al. 2008, Lehmann et al. 2014). Apart from the 
pathological findings, the MEF2-HDAC pathway has been implicated in cardiovascular 
development. Inhibition or activation of HDACs in P19 cells was shown to enhance and 
impair cardiomyocyte differentiation (Karamboulas et al. 2006). 
1.3.5 Invertebrate loss of function models 
 1.3.5.1 Drosophila 
 This classic and powerful animal model has been extensively used to decipher the 
gene regulatory networks of cardiac development and function (Bryantsev et al. 2009, 
Vogler et al. 2015). Drosophila has an open circulatory system and hemolymph is 
pumped throughout the organism by the dorsal vessel, a linear heart-like tube. Despite its 
apparent simplicity, the dorsal vessel has a well-defined aorta and primary contractile 
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region, and the developing dorsal vessel consists of two cardiac cell types: cardioblasts 
and non-muscle pericardial cells. Drosophila Mef2 (D-Mef2) is expressed in cardioblasts, 
the lineage that will give rise to the myocardial cells that perform the contractile activity 
of the dorsal vessel (Lilly et al. 1994).  
 Seminal studies in this invertebrate model system unambiguously demonstrated 
the importance of MEF2 for the differentiation of all muscle types: cardiac, somatic, and 
visceral. Null mutations of Drosophila-Mef2 (D-Mef2) were generated by genetic 
deletion or chemical mutagenesis with similar phenotypic results (Bour et al. 1995, Lilly 
et al. 1995). Although the dorsal vessel formed in both mutant lines, D-Mef2 mutant 
cardiomyocytes failed to express differentiation genes (Table 1.1) (Bour et al. 1995, Lilly 
et al. 1995). Recent studies have now implicated D-Mef2 in the regulation of cardiac cell 
fate, and it was shown to collaborate with the cardiac transcription factors Tinman 
(Nkx2.5) and Pannier (GATA4) to expand the cardiogenic pool of cells from mesoderm 
(Lovato et al. 2015). Additionally, D-Mef2-null flies have a severe body muscle 
phenotype in which muscle precursors are appropriately specified but fail to differentiate 
(Ticho et al. 1996, Durham et al. 2006).  
 1.3.5.2 C. elegans 
 Nematodes do not have a heart-like organ, but striated muscle cells in the pharynx 
exhibit cardiomyocyte-like contractile properties. Like flies, nematodes encode a single 
Mef2 gene that is ubiquitously expressed (Dichoso et al. 2000). Interestingly, two 
different mutant alleles of Mef2 were generated, but these mutations did not overtly 
impair embryonic development or muscle differentiation (Table 1.1) (Dichoso et al. 
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2000). Epistatic analysis was performed to determine the extent to which Mef2 could 
modulate known muscle phenotypes. Genetic crosses of C. elegans-Mef2 (CeMef2) 
mutants to MyoD, Twist, or pha-1 mutant worms, defective in mesoderm or muscle 
development failed to exacerbate those muscle defects (Dichoso et al. 2000). Despite the 
lack of obvious morphological defects a more detailed genomic and cellular analysis may 
be needed to address its specific requirement in muscle in this organism. 
1.3.6 Zebrafish loss of function models 
 Zebrafish have a two chambered heart with a single atrium and ventricle 
(Moorman et al. 2003). The zebrafish genome encodes orthologs of the four mammalian 
Mef2 genes, and their expression is largely restricted to muscle and the brain lineages 
(Ticho et al. 1996, Hinits et al. 2007, Lazic et al. 2011). Zebrafish also encode additional 
mef2a and mef2c paralogs, likely due to additional genome duplication events in this 
evolutionary branch. The paralogs mef2ca and mef2cb are most closely related to Mef2c 
whereas mef2aa and mef2ab are likely orthologs of Mef2a (Hinits et al. 2012). In situ 
expression analysis revealed that mef2c (mef2ca) transcripts are the earliest detectable 
mef2 transcripts expressed in the cardiac primordia (16 h post fertilization [hpf]) whereas 
mef2a (mef2aa) transcripts are detected a few hours later (18 hpf) at the time of 
myocardial differentiation. Mef2a and mef2c expression is sustained through late 
development (48 hpf). Surprisingly, despite its abundant expression in skeletal muscle 
(Hinits et al. 2007), mef2d transcripts have not been detected at early cardiac 
developmental time points. Expression analysis of the apparent Mef2b homolog remains 
to be determined. 
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 Several groups have analyzed the in vivo role of zebrafish mef2 genes using 
morpholino oligonucleotides and/or mutant lines derived from large scale mutagenesis 
screens (Table 1.1). Mef2a morphants were generated by using two different morpholino 
oligonucleotides. These morphants display normal cardiac morphology but Mef2a-
deficiency caused a significant reduction in cardiac contractility and disorganized 
sarcomere structure (Wang et al. 2005). 
 The zebrafish mef2c genes have also been extensively analyzed in cardiac 
development. Morpholino inhibition of the mef2cb paralog resulted in defects in the 
second (anterior) heart field as these morphants lacked a subset of cardiomyocytes in the 
arterial pole of the developing heart (Lazic et al. 2011). In a subsequent study, the role of 
both mef2c paralogs, mef2ca and mef2cb, were analyzed using gain-of-function and loss-
of-function approaches. A genetic mutation in mef2ca (b1086) resulted in delayed 
cardiomyocyte differentiation marker expression, but ultimately the hearts developed 
normally (Hinits et al. 2012). By contrast, mef2cb morphants displayed shortened hearts 
characterized by reduced atrial and ventricular volume. However, a mef2cb mutant allele 
(fh288), which causes a premature stop in the MADS box DNA binding domain, 
displayed no overt cardiac phenotype. Combinatorial mef2ca and mef2cb deficiency, 
using various combinations of individual mef2c genomic mutant lines and morpholino 
approaches, resulted in pericardial edema, and impaired cardiomyocyte differentiation 
and heart tube formation in a substantial percentage of mutant embryos (Hinits et al. 
2012). A broader ablation of all mef2 isoforms using a single morpholino (mef2d/c) 
yielded a more severe cardiac phenotype (Hinits et al. 2012). These morphants lacked all 
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myosin heavy chain expression, and most cardiomyocytes failed to differentiate. As the 
vast majority of mef2 mutant analyses in this animal model were performed with 
morpholino oligonucleotides, the distinct cardiac phenotypes associated with each 
isoform knockdown will need to be further clarified using mutagenized zebrafish lines 
harboring bona fide loss-of-function or null alleles of the mef2 genes. 
 Conversely, to determine whether overexpression of Mef2c is sufficient to 
promote cardiomyocyte determination the Mef2cb isoform was injected at the 1–2 cell 
stage of zebrafish development. Curiously, Mef2cb caused ectopic skeletal, but not 
cardiac, muscle formation in the head region. When Mef2cb overexpression was 
restricted to lineages with endogenous Mef2cb expression, ectopic expression of 
cardiogenic markers was observed but no skeletal muscle cells were observed, suggesting 
that the skeletal myogenic effect of Mef2cb overexpression is restricted to cells that do 
not normally express Mef2cb (Hinits et al. 2012). These overexpression experiments 
suggest that we still fail to have a complete molecular understanding of the cardiac 
regulatory role of Mef2 in zebrafish. 
1.3.7 Mammalian loss of function models 
 To determine the in vivo role of the mammalian MEF2 transcription factor family, 
knockout (KO) mice have been published for three of the four murine MEF2 genes by 
deleting the second coding exon (encoding the MADS box DNA binding and MEF2 
domains). This deletion effectively abrogates DNA-binding ability and renders the 
mutant proteins nonfunctional. Additionally, a variety of other genetic MEF2 
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manipulations have been published, a compiled list of interesting manipulations and their 
gross morphological phenotypes is described in Table 1.2. 
1.3.7.1 MEF2A 
 The global MEF2A loss of function model revealed an important role for this 
isoform in the postnatal heart. The majority of MEF2A-null mice exhibit sudden perinatal 
lethality and display an enlarged heart (Naya et al. 2002). Detailed analyses of 
cardiomyocytes from these mutants revealed severe myofibrillar defects likely resulting 
from the dysregulation of a MEF2A-dependent costamere gene program (Durham et al. 
2006, Huang et al. 2006, Ewen et al. 2011). Neonatal cardiomyocytes depleted of 
MEF2A using RNA interference (RNAi) also display widespread apoptosis likely 
resulting from deficiencies in focal adhesion contacts (Ewen et al. 2011). To understand 
the transcriptional mechanisms involved in MEF2A-dependent regulation of costamere 
genes our group used bioinformatics to identify candidate cofactor binding sites in 
MEF2A-regulated costamere gene regulatory regions. One of these sites belonged to the 
EGR1 transcription factor, a factor known to play a regulatory role in cardiovascular 
pathology (Khachigian 2006). Functional characterization of this computational 
prediction revealed that EGR1 and MEF2A interact and represses MEF2-dependent 
reporters (Feng et al. 2015). Additionally, overexpression and depletion of Egr1 in 
neonatal cardiomyocytes resulted in downregulated and upregulated costamere gene 
expression, respectively. Finally, while a small percentage of MEF2A KO mice are 
viable and survive to adulthood, their hearts display mitochondrial deficiency and 
conduction defects. The genetic basis of survival in a subset of MEF2A KO mice and 
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molecular mechanisms of the mitochondrial and conduction abnormalities remain to be 
determined (Naya et al. 2002). 
 Interestingly, while loss of MEF2A activity has a drastic phenotype in cardiac 
tissue, Mef2A KO mice do not appear to have a skeletal muscle phenotype. It is only upon 
skeletal muscle injury that an impaired regeneration phenotype emerges. Impaired 
skeletal muscle regeneration in MEF2A KO mice is due to dysregulation of Wnt 
signaling mediated by MEF2A activation of a microRNA program (Snyder et al. 2013)  
 1.3.7.2 MEF2B 
 While Mef2b transcripts are detected early in cardiac development, and 
ubiquitously expressed, the Mef2b-null mouse reveals very little about the role of Mef2b. 
The Mef2b-null mouse is viable and lacking any muscle phenotype. Further 
characterization is not reported (Black et al. 1998). Characterization of the Mef2b-null 
mouse model remains to be published. 
 1.3.7.3 MEF2C 
 Of the mammalian MEF2 genes, the MEF2C KO is the only one that results in 
embryonic lethality. MEF2C KO mice display defective cardiac looping morphogenesis 
and vascular malformations (Lin et al. 1997, Lin et al. 1998, Bi et al. 1999). However, 
cardiomyocyte-specific deletion of MEF2C at approximately E10.5 using αMHC-Cre 
transgenic mice results in viable embryos and normal cardiac development (Vong et al. 
2005). These findings suggest that MEF2C is dispensable after early embryonic 
development or that its transcriptional function is compensated for by the remaining 
MEF2 factors. Given the similarities in their embryonic cardiac developmental defects, 
mice with a combinatorial deficiency of MEF2C and the cardiac transcription factor, 
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Nkx2.5, were generated. These double homozygous null embryos developed a heart with 
a single cardiac chamber expressing atrial and second heart field markers but lacking 
ventricular markers (Vincentz et al. 2008). These results indicate that MEF2C and 
Nkx2.5 function in the same genetic pathway for the specification and differentiation of 
ventricular myocytes. Recently, floxed MEF2C have been used to delete this mammalian 
isoform in the anterior second heart field. These mice display a wide range of outflow 
tract defects such as overriding aorta and double outlet right ventricle reinforcing the 
important role of this mammalian MEF2 isoform in embryonic cardiac morphogenesis 
(Barnes et al. 2016). 
 Targeted KO of Mef2c expression in skeletal muscle exhibits normal embryonic 
development, but leads to rapid perinatal loss of muscle tissue, associated with improper 
sarcomere organization (Potthoff et al. 2007), suggesting that MEF2C plays an integral 
role in the maintenance of skeletal muscle fibers after birth. 
 1.3.7.4 MEF2D 
 Global deletion of MEF2D was generated by crossing floxed MEF2D mice to 
Meox-Cre, which is active in the three germ layers. Loss-of-function of MEF2D resulted 
in viable mice with normal cardiac structure and function. However, when adult MEF2D 
KO mice were subjected to cardiac stressors these hearts display attenuated hypertrophy 
and fibrosis (Kim et al. 2008). Additionally, despite the apparent lack of a cardiac 
phenotype in MEF2D-deficient hearts in homeostasis, we have shown that acute 
depletion of MEF2D in neonatal cardiomyocytes in vitro results in cell cycle re-entry and 
programmed cell death (Estrella et al. 2015). Perhaps these differences relate to the 
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temporal requirement of MEF2D in postnatal cardiomyocytes or differences between in 
vitro and in vivo approaches in analyzing MEF2D deficiency. 
 The regulatory roles of alternatively spliced MEF2D isoforms have recently been 
investigated in muscle differentiation (Sebastian et al. 2013). Two alternatively spliced 
MEF2D isoforms, α1 and α2, are expressed in skeletal muscle but the MEF2D α2 
isoform appears to be required for differentiation. This α2 isoform includes a coding exon 
that is resistant to inhibitory phosphorylation mediated by PKA (Du et al. 2008) thereby 
activating muscle transcription. Along these lines, a number of mammalian MEF2 splice 
isoforms have been previously described (Zhu et al. 2005). In particular, an exon (the β+ 
isoform) near the 3’ end of Mef2a, -c, and -d resulted in more potent transactivation 
compared to MEF2 isoforms lacking this domain. Although the above experiments were 
performed in skeletal muscle, given the overlapping gene programs in striated muscle, it 
is tempting to speculate that alternatively spliced isoforms of MEF2 proteins display 
distinct regulatory properties in cardiomyocytes. Much remains to be determined 
regarding alternative splice isoforms within each of the MEF2 genes and their specific 
role in cardiac gene regulation. 
 Mef2d-null mice do not exhibit a morphological skeletal muscle phenotype (Kim 
et al. 2008). While binding activity is identical among the MEF2 family members, loss-
of-function analysis reveals largely non-overlapping phenotypes associated with the loss 
of each individual MEF2 factor. 
 1.3.7.5 Additional studies relating aberrant MEF2 expression and activity 
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 In addition to ablation of individual MEF2 isoform activity, a series of dominant 
negative approaches were used to determine the collective role of MEF2 in 
cardiomyocytes (Table 1.2). Interestingly, these manipulations yielded different 
outcomes. Inhibition of MEF2 activity in cardiomyocytes derived from P19 embryonic 
carcinoma cells resulted in impaired differentiation (Karamboulas et al. 2006). This study 
generated a dominant negative construct of MEF2 by fusing the DNA binding domain of 
MEF2C (aa1–105) with the potent repressor domain from the Engrailed transcription 
factor (EnR) and driven by the Nkx2.5 enhancer, which is active at the onset of cardiac 
development at E7.5. Transient overexpression of this dominant negative construct in 
vivo supports the cardiomyocyte differentiation defect, and yielded two distinct 
phenotypes classified by the severity of the impact on cardiac development (Karamboulas 
et al. 2006). The most severe transgenic embryos failed to form a heart, but myosin heavy 
chain (MHC) positive cardiomyocytes were detected, while less severe displayed thin 
walled myocardium. These results are consistent with an earlier study demonstrating the 
differentiation promoting effects of MEF2C when overexpressed in P19 embryonal 
carcinoma cells (Skerjanc et al. 1998). 
In contrast to the severe cardiac defects in transient mouse embryos, stable 
transgenic mice expressing dominant-negative forms of MEF2C did not display cardiac 
developmental defects, but did present a postnatal phenotype. One study described 
attenuated postnatal growth of the myocardium overexpressing the DNA binding domain 
of MEF2C (amino acids 1–95) driven by the αMHC promoter (Kolodziejczyk et al. 
1999). In another independent study, stable transgenic mice harboring a different 
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dominant negative MEF2 (MEF2C aa 1–117; DNA binding defective R24L mutant) had 
no measurable phenotypic effects on heart size or function (van Oort et al. 2006). 
However, there were key differences in the approaches that could account for the distinct 
phenotypes. The truncated MEF2C and MEF2C-EnR constructs are capable of DNA 
binding whereas the R24L mutant cannot bind to DNA. Moreover, MEF2C R24L 
transgene was induced using a “floxed ON” approach by crossing to αMHC-Cre 
transgenic mice. Despite its effectiveness in inducing loxP recombination, transgene 
levels in the heart may not have been expressed at sufficiently high levels to induce a 
phenotype.  
Conversely, individual mammalian MEF2 proteins have also been overexpressed in 
neonatal cardiomyocytes and the heart. In vitro overexpression of MEF2A, -C, and –D 
yielded similar morphological phenotypes in neonatal cardiomyocytes, including 
sarcomere disorganization and focal elongation (Xu et al. 2006). Individual 
overexpression of these MEF2 proteins in the mouse heart using the cardiomyocyte-
specific αMHC promoter, which is active in development but massively upregulated 
postnatally, also resulted in comparable phenotypes. MEF2A and MEF2C overexpression 
induced dilated cardiomyopathy (Durham et al. 2006, van Oort et al. 2006, Xu et al. 
2006), whereas MEF2D overexpression resulted in atrial enlargement and extensive 
fibrosis (Kim et al. 2008). While these results suggest functionally redundant roles of 
MEF2 family members in postnatal cardiomyocytes it should be noted that the proteins 
were expressed at supra-physiological levels potentially overcoming isoform-specific 
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gene regulatory effects. A summary of MEF2 mutant phenotypes in mammalian models 
systems are listed in Table 1.2. 
1.4 Functional genomic analysis of MEF2 in striated muscle 
 While there is no doubt that MEF2 is an essential transcription factor in the 
regulation of the muscle cytoarchitectural gene program in virtually all animal model 
systems (Black et al. 1998, Potthoff et al. 2007, Estrella et al. 2014), a much broader 
gene regulatory function for MEF2 has recently been uncovered through comprehensive 
genome-wide studies. Initial studies were carried out primarily in Drosophila somatic 
muscle and the murine C2C12 skeletal myoblast cell line. Findings in these model 
systems expanded the traditional view of MEF2 from that of an exclusive transcriptional 
regulator of structural genes to one harboring broader regulatory function through its 
regulation of varied gene programs in muscle. More recently, next generation genomic 
technologies have been applied to investigate the role of MEF2 in global gene regulation, 
i.e., genome-wide binding and target gene expression, in cardiomyocytes. Given the 
limitation of isoform-specific reagents for mammalian MEF2 proteins, the majority of the 
genomic studies performed in vertebrate model systems have focused primarily on a 
single MEF2 isoform or generalized its genome-wide role based on a representative 
member of the family. 
 The first in vivo, global analysis of MEF2 genome binding was performed in 
Drosophila (Sandmann et al. 2006). This study performed chromatin 
immunoprecipitation followed by genomic DNA microarray (ChIP-on chip) at multiple 
time points in muscle development. These experiments revealed hundreds of genomic 
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regions bound by MEF2 at all stages of muscle development and not restricted to 
terminal differentiation. A number of these bound regions were found to function as 
enhancers in vivo and to drive MEF2-dependent reporter expression in somatic muscle. 
MEF2 bound to genomic regions predicted to regulate a variety of pathways including 
myoblast fusion, extracellular matrix-muscle attachment, and somatic and cardiac muscle 
identity genes such as those belonging to the Notch-Delta signaling pathway, in addition 
to the previously characterized structural genes. Several MEF2 bound enhancers in the 
aforementioned study were previously identified in Drosophila by combining 
computational prediction of muscle enhancer elements with ChIP using a MEF2 antibody 
(Junion et al. 2005), lending support to the efficacy of these global analyses. 
 In vertebrates, genome-wide analyses on muscle regulatory factors including 
MEF2 were first performed in C2C12 skeletal myoblasts (Paris et al. 2004, Blais et al. 
2005). Consistent with the findings in Drosophila, these ChIP-on-chip studies revealed 
that MEF2 binding was not limited to structural genes but included genes belonging to 
signal transduction cascades, transcription factors, muscle differentiation, and the 
neuromuscular junction. It is worth noting that while both groups used the same MEF2 
antibody one was reported to be MEF2A-specific and the other MEF2C. Nevertheless, 
both studies arrive at the conclusion that the MEF2 transcription factor family regulates 
an array of cellular processes in muscle. Additionally, the distinct functions of MEF2D 
isoforms were examined in C2C12 myoblasts by subjecting MEF2D isoform specific 
antibodies to ChIP followed by high-throughput sequencing (ChIP-seq) (Sebastian et al. 
2013). Despite the different activities of each MEF2D alternatively spliced isoform in 
 21 
myogenic differentiation, this study revealed similar binding site preferences and 
extensive overlap of target genes bound by MEF2D isoforms suggesting additional 
regulatory mechanisms beyond DNA binding. Finally, our group performed a global 
analysis of the target genes regulated by the four mammalian MEF2 factors in C2C12 
myoblasts (Estrella et al. 2015). In stark contrast to the longstanding notion of functional 
redundancy in the family, we discovered that only a small percentage of genes were co-
regulated by all four isoforms. Moreover, transcription factor binding site enrichment 
analysis of the promoters of these genes revealed that individual MEF2-regulated gene 
sets harbor a distinct cohort of co-regulators.  
 To investigate genome-wide binding of the mammalian core cardiac transcription 
factors in cardiomyocytes, an integrative systems level analysis was performed in HL-1 
cells, a cardiac atrial cell line. Using a variety of genome scale technologies such as 
ChIP-on-chip and RNAi, common and unique target genes regulated by GATA4, 
MEF2A, Nkx2.5, and SRF were determined (Schlesinger et al. 2011). This global 
analysis revealed that different cohorts of target genes in the cardiomyocyte genome were 
regulated by distinct combination of cardiac transcription factors. For example, MEF2A 
and Nkx2.5 were found to co-regulate genes belonging to muscle cell differentiation and 
heart looping pathways. A similar study used HL-1 cells to identify genomic binding of 
core cardiac transcription factors by inducible overexpression of biotinylation peptide-
tagged versions of these regulatory factors, allowing biotinylation by BirA, followed by 
streptavidin pulldown and ChIP-seq (He et al. 2011). These findings revealed co-
occupancy of cardiac enhancers with various combinations of GATA4, MEF2A, TBX5, 
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SRF, and Nkx2.5. Additionally, a number of cardiac enhancers associated with heart 
development and function were found to be co-regulated by GATA4 and MEF2A. Given 
the important and common role of GATA and MEF2 transcription factor families in 
cardiac development and disease, further genomic dissection of this coregulatory 
pathway is warranted. Finally, genome-wide analysis of Tbx20 bound regions in the heart 
of transgenic mice overexpressing epitope-tagged Tbx20 revealed a significant 
enrichment of MEF2 binding sites in these enhancers (Shen et al. 2011). Gene ontology 
analysis of these regions revealed genes associated with ion transport, calcium signaling, 
and contraction, cellular processes previously attributed to the MEF2 family. 
 Recently, ChIP-exo, a modification of ChIP-seq that improves sequencing 
resolution by digesting unbound DNA regions using exonuclease, was used to identify 
and compare the genome-wide, direct target genes of MEF2A in neonatal cardiomyocytes 
and C2C12 myoblasts (Wales et al. 2014). While there was modest overlap in target 
genes, the MEF2A bound regions in cardiomyocytes had an overrepresentation of AP-1, 
CREB, BACH, and ERE transcription factor binding sites. Furthermore, gene ontology 
analysis revealed that the most significantly enriched genes bound by MEF2A in neonatal 
cardiomyocytes are involved in actin organization. These results are consistent with the 
role of MEF2A the regulation of the costamere/focal adhesion complexes which are 
intimately associated with the actin cytoskeleton (Ewen et al. 2011, Estrella et al. 2014). 
 Finally, a mathematical modeling approach was used to identify putative cardiac 
enhancers in the human genome. A combination of Gibbs sampling and linear regression 
was utilized to identify significantly enriched transcription factor binding sites from a 
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large data set of previously validated enhancers active in cardiac development and 
differentiation (Narlikar et al. 2010). Among the known and de novo transcription factor 
binding motifs, MEF2 and SRF binding sites obtained the maximum positive weight 
scores. In a complementary set of computational experiments, co-occurring binding 
motifs, including MEF2, and other sequence features were used to predict thousands of 
putative cardiac enhancers in noncoding regions of the human genome. This study 
supports extensive experimental data that MEF2 is a major player in cardiac gene 
regulatory networks. 
1.5 Hedgehog and Notch signaling in the heart 
 1.5.1 Hedgehog signaling 
 Hedgehog (HH) signaling is a critical pathway in a wide array of mammalian 
tissues including skeletal and cardiac muscle (Lee et al. 2016). Initiation of HH signaling 
is mediated by the processing and secretion of one of three mammalian hedgehog 
ligands: Sonic hedgehog (SHH), Indian hedgehog (IHH), or Desert hedgehog (DHH). 
Secreted HH ligands interact with the Patched-1 (PTCH1) transmembrane receptor to 
induce HH signal transduction in the target cell (Figure 1.5). 
 In the absence of HH ligand, PTCH1 prevents HH signaling through an 
uncharacterized mechanism that prevents Smoothened (SMO), a critical HH signaling 
activator, from being integrated into the cell membrane (Figure 1.5, right). In the absence 
of SMO activity, HH downstream effectors Glioma-associated oncogene 2 and 3 (GLI2 
and -3, respectively) are bound by a repressive protein complex. Persistence in this 
complex leads to proteosomal degradation of the GLI factors. GLI2 is a positive 
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transcriptional regulator, and targeting for proteosomal degradation leads to complete 
destruction of the protein. On the other hand, GLI3 is a transcriptional repressor, and 
upon targeting for proteosomal degradation, yields a truncated GLI3 protein which is 
capable of entering the nucleus and repressing expression of HH-dependent genes (Lee et 
al. 2016, Pak et al. 2016) 
 Upon HH ligand binding to PTCH1, SMO repression is relieved and GLI2 and 
-3 escape cytoplasmic sequestration and enter the nucleus (Figure 1.5, left). GLI2 acts as 
a transcriptional activator and induces the expression of a number of downstream 
effectors including GLI1, a GLI-family homolog that acts as an additional transcriptional 
activator. Full-length GLI3 retains its repressive characteristics and acts as a brake and 
negative feedback loop to maintain signal integrity (Lee et al. 2016, Pak et al. 2016). 
 1.5.2 Role of HH signaling in cardiac development 
 HH signaling appears to play a key role in cardiac specification and development. 
Several of loss-of-function mice have been created to assess the roles of the various 
members of the HH signaling cascade in cardiac development. Shh-null and Gli2-
null/Gli3-heterozygous mice both show cardiac looping defects (Motoyama et al. 1998, 
Tsukui et al. 1999). Additionally, Smo knockout models were embryonic lethal with 
severe cardiac abnormalities (Zhang et al. 2001) and a constricted expression pattern of 
the early cardiac marker, Nkx2.5. Conversely, Ptch1-null mice exhibited an expanded 
field of Nkx2.5 positive cardiac precursors during embryonic development (Zhang et al. 
2001). 
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 Additionally, work performed in zebrafish and mouse has shown that activation of 
HH-signaling in cardiac precursor cells is required for cardiac specification and reduction 
in SHH expression led to fewer cardiomyocytes. Ectopic SHH expression was sufficient 
to increase cardiomyocyte number in the developing zebrafish heart. This study also 
shows that SHH ligand binding by cardiac progenitors and HH signaling is required in a 
cell autonomous manner, suggesting that activation of HH signaling is required in the 
cells that will give rise to the cardiomyocyte population in the developing heart (Thomas 
et al. 2008). 
 In vitro investigation of HH signaling has supported its role in cardiac 
specification and development. Most notably, overexpression of SHH in P19 embyronal 
carcinoma cells is sufficient to induce commitment to a cardiac lineage with concordant 
expression of myosin heavy chain 7 (MYH7) and cardiac α-actin (ACTC1), and 
morphological changes that closely recapitulate that of a cardiomyocyte. Additionally, 
SHH overexpression was sufficient to induce expression of core cardiac transcriptional 
regulators: Mef2c, Nkx2.5, and Gata4 (Gianakopoulos et al. 2005). 
 Previous in vitro analysis implicated HH signaling as a potential regulator of core 
cardiac transcription factors, including MEF2 (Gianakopoulos et al. 2005). Further 
analysis revealed that GLI2 and MEF2C appear to be capable of regulating the other’s 
expression in P19 embryonal carcinoma cells, and mouse embryonic stem cells. 
Additionally, protein interaction assays have revealed a direct complex of GLI2 and 
MEF2C in P19 cells that was capable of synergistic activation of a luciferase reporter in 
vitro (Voronova et al. 2012). 
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 1.5.3 Notch signaling 
 Notch signaling is mediated by four mammalian Notch receptors that are 
composed of a heterodimeric combination of an extracellular ligand binding domain with 
a transmembrane and intracellular transcriptional activation domain. Interaction of the 
extracellular receptor with transmembrane ligands of the Delta-like and Jagged family 
induces cleavage of the intracellular domain from the transmembrane region by 
prenisilin-γ-secretase. The released Notch intracellular domain (NICD) translocates into 
the nucleus where it interacts with the RBP-Jκ transcriptional activation complex to 
induce transcription of Notch target genes, including Hey and Hes families (Figure 1.6) 
(Ntziachristos et al. 2014). 
 1.5.4 Notch signaling in cardiac development 
 The role of Notch signaling in cardiac development has been well studied. Notch 
signaling components are expressed in all three tissue layers of the developing heart 
(D'Amato et al. 2016), and are key mediators of tissue cross-talk within the developing 
heart. Additionally, appropriate Notch signaling activation is required for appropriate 
specification of cardiac sub-structures including valve and trabeculation formation 
(D'Amato et al. 2016). In vitro studies support the importance of Notch signaling in 
cardiac development. RBP-Jκ-mediated NICD transcriptional activation is sufficient to 
induce cell-cycle reentry in quiescent neonatal ventricular cardiomyocytes via 
modulation of Cyclin D1 expression and nuclear localization (Campa et al. 2008). 
Additionally, ectopic activation of Notch signaling reveals G2/M checkpoint activation 
that prevents older cardiomyocytes from proceeding into mitosis downstream of Notch 
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activation, shedding potential light on the mechanism mediating the loss of regenerative 
capacity of the adult heart. G2/M checkpoint override with caffeine led to mitotic 
catastrophe and apoptosis in Notch-induced cardiomyocyte cell cycle re-entry, suggesting 
DNA replication defects associated with G0 exit (Campa et al. 2008).  
 Unfortunately, the regulatory interactions between Notch signaling and the MEF2 
family have not been characterized in cardiac development. Interestingly, the Hes and 
Hey families of transcriptional repressors are both direct targets of Notch signaling and 
play a role in the repression of cardiac differentiation (Campa et al. 2008), though this 
has yet to be analyzed with respect MEF2 transcriptional activity. On the other hand, the 
Notch and MEF2 interactions in skeletal muscle have been the subject of quite a bit of 
analysis. NICD has been shown to directly interact and inhibit the function of MEF2C, 
but not MEF2A, -B, or –D in skeletal myocytes (Wilson-Rawlins et al. 1999). The direct 
interaction of NICD inhibits the DNA-binding ability of MEF2C and appears to be 
associated with a divergent region of the MEF2C protein that isn’t conserved in other 
MEF2 isoforms (Wilson-Rawlins et al. 1999). 
 Additionally, in the absence of Notch signaling, the Notch co-activator MAML1 
exists in a complex with MEF2C and cooperates in the activation of MEF2C target gene 
expression (Shen et al. 2006). As is the case with NICD interaction, MAML1 interaction 
appears to be isolated to MEF2C and may occur through the same uncharacterized 
interaction domain that is missing in other MEF2 isoforms (Shen et al. 2006). Upon 
Notch activation, MAML1 is sequestered by the N1ICD/RBP-Jκ transcriptional complex 
and MEF2C mediated gene expression is further inhibited. 
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1.6 Statement of thesis rationale 
 The MEF2 family represents a core striated muscle transcription factor at the 
center of muscle differentiation and homeostasis. The purpose of this study is to provide 
an unbiased characterization of the complex interplay among the MEF2 family members 
in the context of global striated muscle gene regulation. While previous in vitro 
characterization fails to yield meaningful differences between the transcriptional 
activities of the MEF2 factors, in vivo loss-of-function analyses suggest distinct roles for 
each MEF2 factor in skeletal and cardiac muscle differentiation and homeostasis. 
 The primary goal of this study is to investigate the MEF2 family in much higher 
resolution than previously performed, and in so doing provide new understanding of the 
complex regulatory patterns that are required for a complex functional tissue to develop 
from precursor to terminally differentiated mature tissue. Additionally, further insight 
into the transcriptional regulation of muscle cellular processes by the MEF2 family will 
afford the field a new angle with which to understand striated muscle disease. 
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Figure 1.1 Comparison of MEF2 protein conservation. The mammalian family of 
MEF2 proteins shares high sequence similarity (~95%) in the N-terminal region 
containing the MADS box and MEF2 domains responsible for DNA-binding, 
dimerization, and co-factor recruitment. The amino acid sequences diverge considerably 
in the C-terminal transcriptional activation region. Additionally, yeast, Drosophila and C. 
elegans MEF2 homologs share considerable N-terminal conservation with the human 
MEF2 proteins. Adapted from (Potthoff et al. 2007). 
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Figure 1.2 Mef2 transcripts undergo multiple alternative splicing events. Mef2a, -c, 
and –d transcripts can undergo alternative splicing of an exon, denoted α, directly 
downstream of the MEF2 domain. Inclusion of the α2 exon is associated with 
transcriptional activity in MEF2 target tissues. Additionally, all four Mef2 transcripts 
undergo an alternative splicing event in a conserved C-terminal exon, denoted β, and 
inclusion of the β exon is associated with positive transcriptional activity (Zhu et al. 
2005). 
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Figure 1.3 MEF2 factors display complex temporal expression in striated muscle. In 
mouse embryonic cardiac development, Mef2b and –c transcripts are observed first at 
embryonic day 7.5-8 (E7.5-8). Mef2a and –d transcripts appear about a day later at E9.0. 
Expression of the four Mef2 transcripts persists until Mef2b transcripts drop to 
undetectable levels at approximately E14.0 and Mef2c levels drop concurrently. The 
expression pattern in mouse skeletal muscle is similar with the exception that all four 
Mef2 isoform transcripts persist throughout development and into adulthood. Adapted 
from (Edmonson et al. 1994). 
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Figure 1.4 Expression of a 3x-Des-MEF2-lacZ reporter construct in the embryonic 
development of transgenic mice. Whole mount mouse embryos with X-gal staining at 
different embryonic time points. A, Mouse E9.5 embryos show early robust staining of 
MEF2 transcriptional activity in the heart (h), somites (s), neural tube (nt), 
mesencephalon (me), and trigeminal ganglia (t). B, Mouse E11.5 embryo shows 
persistent MEF2 activity in somites (s) and heart (h), and emergence of MEF2 activity in 
the developing limb buds (lb). C, Mouse E14.5 embryo shows MEF2 activity is expanded 
and persistent all the developing musculature of the embryo including the trapezius (t), 
lattisimus dorsi (l) and deltoid (d) muscles (Naya et al. 1999). 
  
 33 
 
Figure 1.5 Hedgehog signaling pathway. Hedgehog (HH) signaling is a critical 
pathway in a wide array of mammalian tissues including skeletal and cardiac muscle  
Initiation of HH signaling is mediated by the processing and secretion of one of three 
mammalian hedgehog ligands: Sonic hedgehog (Shh), Indian hedgehog (Ihh), or Desert 
hedgehog (Dhh). Secreted HH ligands interact with the Patched-1 (PTCH1) 
transmembrane receptor to induce HH signal transduction in the target cell (Yu et al. 
2012). 
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Figure 1.6 Notch signaling pathway. Notch signaling is mediated by four mammalian 
Notch receptors. Interaction of the extracellular receptor with ligands of the Delta-like 
and Jagged family induces cleavage of the intracellular domain. The released Notch 
intracellular domain (NICD) translocates into the nucleus where it interacts with the 
RBP-Jκ transcriptional activation complex to induce transcription of Notch target genes, 
including Hey and Hes families (Yu et al. 2012). 
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Table 1.1 Compilation of MEF2 LoF phenotypes in invertebrates and Zebrafish.  
Summary of cardiac-related phenotypes of MEF2 family transcription factor family 
misexpression in model systems with one, two, and three-chambered hearts. Global 
DMef2 LoF mutants yielded specified cardioblasts that failed to differentiate and mature 
into the dorsal vessel. Loss of CeMef2 expression had no observable phenotype. Loss of 
mef2 expression in D. rerio shows complicated transcriptional activity regulated by the 
mef2 family that appears to be focused around the mef2a and mef2c subfamilies. Adapted 
from (Desjardins et al. 2016).  
  
Model MEF2 
Isoform
Manipulation Phenotype Ref
Drosophila DMef2 Global Loss-of-function (LoF) Cardioblasts are specified, failure to differentiate Lilly et al.  1994, 1995
C. elegans CeMef2 Deletion No observed phenotype Lovato et al.  2015
D. rerio mef2aa Morpholino knockdown Normal cardiac morphology
Significant decrease in cardiac contractility Lazic et al.  2011
Morpholino knockdown (Bmp2) Significant loss of Mef2a expression
Decrease in cardiac contractility rescued by Mef2a 
overexpression Hinits et al.  2007
mef2ca Morpholino knockdown Delayed cardiomyocyte marker expression
Cardiac development delayed, normal heart Hinits et al.  2007
Global LoF Delayed cardiomyocyte marker expression
Cardiac development delayed, normal heart Hinits et al.  2007
mef2cb Morpholino knockdown Secondary heart field defects
Loss of cardiomyocytes in arterial poles
Chamber shortening Lazic et al.  2011
Global LoF No observed phenotype Ticho et al.  1996
mef2ca/cb Global LoF Pericardial edema
Impaired cardiomyocyte differentation
Impaired heart tube formation Ticho et al.  1996
All mef2 Morpholino knockdown Loss of cardiomyocyte differentiation
Lack of α-MHC expression Ticho et al.  1996
 36 
 
Table 1.2 Compilation of MEF2 modulations in mouse models. Summary of cardiac-
related phenotypes of MEF2 family transcription factor family modulations in mouse 
model systems (four chambered hearts). LoF phenotypes in mice are dependent on the 
MEF2 isoform being manipulated. Loss of MEF2A activity led to perinatal lethality with 
cardiac abnormalities, loss of MEF2C was embryonic lethal prior to E10.5 and appeared 
to be dispensable in the heart after E10.5. Loss of MEF2D activity had no overt cardiac 
phenotype but showed a blunted remodeling response to cardiac stress. Adapted from 
(Desjardins et al. 2016). 
  
Model MEF2 
Isoform
Manipulation Phenotype Ref
M. musculus Mef2A Global Loss-of-function (LoF) 80% Perinatal lethality
Severe myofibrillary defects
Dysregulated costamere gene expression
Naya et al.  2002, 
Ewen et al. 2011
20% Survival to adulthood
Mitochondrial deficiency
Conduction abnormalities
Naya et al.  2002, 
Ewen et al. 2011
Global overexpression Dilated cardiomyopathy Durham et al.  2006, 
van Oort et al.  2006, 
Xu et al.  2006
Mef2C Global LoF Embryonic lethality
Defective cardiac looping morphogenesis
Vascular malformations
Lin et al.  1997, 
Lin et al.  1998, 
Bi et al.  1999
CM-specific LoF @~E10.5 Viable embryo
Normal cardiac development Vong et al.  2005
Double LoF (Mef2C/Nkx2.5) Development of a single chamber heart
Expression of atrial and secondary heart field 
markers Vincentz et al.  2008
SHF LoF Outflow tract defects 
Overriding aorta and double outlet right ventricle Barnes et al.  2016
Cardiac overexpression Dilated cardiomyopathy Xu et al.  2006
Mef2D Global LoF Viable, normal cardiac structure and function
Attenuated hypertrophy and fibrosis in response 
to stress Kim et al.  2008
Global Mef2D overexpression Atrial enlargement
Extensive fibrosis Kim et al.  2008
All Mef2 Dominant Negative In vitro : impaired cardiomycyte differentiation
In vivo : failure to form a heart (severe)
            thin-walled myocardium (mild) Karamboulas et al.  2006
Transgenic Dominant Negative No observable phenotype Kolodziejczyk et al.  1999, 
van Oort et al. 2006
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CHAPTER TWO: Materials and Methods 
2.1 Recombinant DNA techniques 
2.1.1 Transformation of DH5α E.coli 
 DH5α E. coli cells were made chemically competent for transformation with 
recombinant DNA as follows. E. coli were plated on Luria Broth (LB) Agar and inbuated 
overnight at 37°C. A single colony was isolated and used to inoculate 3 mL of LB and 
incubated overnight at 37°C in a shaking incubator. The 3 mL culture was then used to 
inoculate 200 mL of pre-warmed LB and allowed to grow at 37°C while shaking until 
early log phase. The culture was then centrifuged at 4000 rpm (Beckman centrifuge, JA-
14 rotor) for 5 min at 4°C and the pellet was resuspended in 20 mL of chilled 10mM 
NaCl. Chilled CaCl2 was added to a final volume of 100 mL and cells were centrifuged at 
4000 rpm for 5 min at 4°C. The pellet was resuspended in 80 mL chilled 100 mM CaCl2 
and incubated on ice for 1 hr. Cell were centrifuged at 4000 rpm for 5 min at 4°C and 
resuspended in 20 mL of CaCl2/glycerol solution (17 mL of chilled 100mM CaCl2 + 3 
mL glycerol). Cells were aliquoted (100µL) into 1.7 mL microcentrifuge tubes, and snap-
frozen in liquid nitrogen. Long term storage was at -80°C. 
2.1.2 Preparation of DNA 
 2.1.2.1 MiniPrep 
 For preliminary recombinant DNA analysis, 1.5 mL of a 3 mL transformed E. coli 
culture was transferred to a 1.7 mL microcentrifuge tube and centrifuged for 30 sec at 
13500 rpm (Eppendof 5417C). Supernatant was discarded and pellet was resuspended in 
100 µL of resuspension buffer (50 mM glucose, 10 mM EDTA pH 8, 25 mM Tris pH 8) 
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by vortexing. Bacterial cells were lysed by adding 200 µL of lysis solution (200 mM 
NaOH, 1% SDS) and mixed by inversion 10 times. Lysis reactions were incubated at 
room temperature for 4 min. Bacterial lysis was stopped with the addition of 150 µL of 
neutralization buffer (3M potassium acetate, 11.5% acetic acid) and mixed by inversion 
10 times. Plasmid DNA was purified using phenol:chloroform extraction (see below) and 
pellets were allowed to air dry for 10 min before resuspension in 20 µL of de-ionized 
water (dH2O) containing 40 µg/µL RNAse and incubated at room temperature for 30 
min. 
 2.1.2.2 MidiPrep 
 For medium scale DNA preparations for cloning/recombinant DNA transfection 
use, NucleoBond
®
 PC (ClonTech) columns were used with preparations made according 
to manufacturer’s protocols. 
 2.1.2.3 Phenol/Chloroform extraction 
 An equal volume of 1:1 phenol/chloroform solution was added to nucleic acid 
sample to be purified. Samples were then vortexed and centrifuged for 1 min at 13500 
rpm (Eppendorf 5417C). The aqueous upper phase containing plasmid DNA was 
transferred to a new 1.7 mL microcentrifuge tube and 2.5 volumes of ice cold 100% 
ethanol (~1 mL), 1/10
th
 volume 3M sodium acetate (pH 5.2), and 1 µL glycogen was 
added. Solution was mixed by inversion and incubated at -20°C for 30 min to precipitate 
the DNA. Solution was centrifuged at 13500 rpm for three min and DNA pellets were 
washed twice with 70% ethanol, with centrifugation at 13500 rpm for three min between 
 39 
each wash. Supernatant was discarded and DNA pellets were dried for 10 min in inverted 
tubes. 
2.1.3 Cloning 
 2.1.3.1 Preparation of DNA fragment 
 For routine cloning and sub-cloning a desired DNA fragment was produced via 
Polymerase Chain Reaction (PCR) amplification and electrophoresed on a 0.8% agarose 
gel containing ethidium bromide. DNA was visualized using UV light and fragment of 
interest was excised and gel extracted using the QIAquick gel extraction kit (QIAGEN) 
according to the manufacturer’s protocol and resuspended in 30 µL of elution buffer 
provided with purification kit. 
 2.1.3.2 Restriction digest 
 Destination plasmid and DNA fragment were then digested with restriction 
endonucleases (New England Biolabs) to expose complimentary overhangs. Generally 1-
5 µg of plasmid or up to 30 µL of insert were digested for 4 hr at 37°C. After digestion, 
the destination plasmid and DNA fragment were electrophoresed on a 0.8% agarose gel 
containing ethidium bromide. Bands were visualized and excised for gel extraction and 
phenol/chloroform extracted as described above. Purified digested destination vector and 
DNA fragment were ligated in a 20 µL consisting of a 1:5 vector to insert ratio, 1 µL T4 
DNA ligase buffer, and 1 µL T4 DNA ligase and brought to final volume with dH2O. 
Ligations were incubated at 16°C for 4 hr and maintained at 4°C overnight in a 
thermocycler. 
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 2.1.3.3 PCR for cloning 
 The Expand Long Template PCR System (Roche) was used for cloning. 
Generally, 1 µg DNA was used in a 25 µL reaction containing 2.5 µL 10x PCR Buffer 
#2, 2 µL 2.5 mM dNTP mixture, 1 µL 25 µM primer mix, 0.5 µL Taq polymerase, and 
sterile dH2O to a final volume of 25 µL. PCR reaction was performed in a thermocycler 
using a program determined by the size of the fragment and the characteristics of the 
primers. Generally, the cycle is designed with an initial incubation at 94°C for 4 min, 
followed by 94°C for 30 sec, 57-62°C (based on the melting temperature of the primer 
set) for 30 sec, and 68°C for 30 sec (time varies based on desired fragment size). Steps 2 
through 4 are repeated 29 times, and the program ends with the final extension incubation 
at 68°C for 5 min. PCR reactions are then stored at -20°C. 
2.1.4 Adenoviral amplification and purification 
 2.1.4.1 Generation of crude lysate 
 Adenoviral expression plasmids were digested with PacI overnight and 
phenol/chloroform extracted. Linearized plasmid was transfected into HEK293A seeded 
at a density of 5 x 10
5
 cells/well in a 6-well dish. The next day the media was exchanged 
for fresh media and the following day cells were transferred to a 10 cm tissue culture 
plate containing 10 mL of media. Culture medium was changed every 2-3 days until 
cytopathic effect (CPE) was observed (usually 7-10 days post-transfection). Cells were 
allowed to develop approximately 80% CPE then were harvested into 15 mL conical 
tubes for preparation of crude lysate. 
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 Crude lysate was created by incubating crude adenoviral cell solution at -80°C for 
30 min, and then thawed at 37°C in a water bath for 15 min. This freeze/thaw cycle was 
repeated twice, and then the cell lysate was centrifuged at 3000 rpm for 15 min at room 
temperature. The resulting supernatant was aliquoted (1 mL) and stored at -80°C. 
 2.1.4.2 Adenoviral purification 
 Prior to transduction, HEK293A cells were plated and allowed to grow until 
approximately 80% confluent (about 3 x 10
6
 cells per 10 cm dish). Upon reaching target 
confluency cells were transduced with either crude viral lysate (50-100 µL) or previously 
purified virus (0.1-0.2 µL) and incubated until CPE is visible. Cells were then harvested 
and stored in 50 mL conical tubes at -80°C until purification.  
 If frozen, cell suspensions are thawed at 37°C, and then pooled. Triton X-100 (or 
another non-ionic detergent) was added to a final concentration of 0.5% and cell 
suspension was incubated at room temperature on an orbital shaker for 10 min to induce 
lysis. Lysate was then centrifuged for 15 min at 20000xg (Beckman centrifuge, JA-14 
rotor). Supernatant was transferred to a new flask and 0.5 volumes of precipitation 
solution (20% PEG8000, 2.5M NaCl) were added to supernatant. Precipitation was 
allowed to proceed overnight at 4°C on an orbital shaker. 
 The resulting precipitated virus was centrifuged for 15 min at 20000xg (Beckman 
centrifuge, JA-14 rotor) and supernatant was discarded. Resulting viral precipitate 
adhered to the walls of centrifuge bottle was resuspended in 1x phosphate-buffered saline 
(PBS) to a final volume of 4.5 mL. Resulting viral suspension was modified to a final 
density of 1.34 g/mL using cesium chloride salt and a final volume of approximately 
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5mL. The suspension was then loaded into an ultracentrifuge tube and centrifuged using 
the NVT-90 rotor at 70,000 rpms for at least 16 hr to create a cesium chloride density 
gradient. The densest viral band was extracted from the ultracentrifuge tube using a 21 
gauge needle and transferred to a 1.7 mL microcentrifuge tube and kept on ice. 
 Purified virus was then desalted with two dialysis steps of no less than 250 mL of 
dialysis solution (10 mM Tris-HCl pH 8 autoclaved, 1 mM MgCl2, and 10% glycerol) for 
at least 2 hr each on a stir plate at 4°C. Dialyzed virus was then removed from dialysis 
membrane and stored in 100 µL aliquots in cryovials at -80°C until titering. 
 2.1.4.3 Titering and storage of adenovirus 
 Viral titering is determined using the End-Point Dilution Assay. Briefly, one day 
prior to titer transduction HEK293A cells are seeded on a 96-well plate at a density of 
10000 cells/well in 100 µL of media using a multi-channel pipettor. On the day of 
transduction, serial dilutions between 10
-5
 and 10
-12
, one per row from A-H on the 96-
well plate, were created using purified adenovirus and serum-free Dulbecco’s Modified 
Eagle Medium (DMEM). The virus-containing media (100 µL) was added to columns 1-
10 of rows A-H, and columns 11 and 12 were used as negative controls and 100 µL of 
serum-free media was added to each well in these columns. Plates were incubated in 
37°C incubator for 10 days, and then each well was scored for CPE. The fraction of CPE-
positive wells for each dilution was added together and this sum was used to calculate 
titer based on the Spearman-Karber method, where the viral titer equals 10
X + 0.8 
pfu/mL. 
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 Once thawed, the 100 µL aliquots of purified virus were further aliquoted into 10 
µL aliquots and each smaller aliquot was thawed only twice to ensure minimal loss of 
efficacy due to repeated freeze-thaw cycling. 
2.2 Cell/Tissue culture 
2.2.1 Maintenance of mammalian cell lines 
 Cos1, C2C12, HEK293A, and HEK293T cells were grown in DMEM containing 
10% fetal bovine serum (FBS), 1% penicillin/streptomycin, and 1% L-glutamine and 
maintained in a humidified incubator at 37°C with 5% CO2. Cells were passaged at 
approximately 75% confluency. First, growth media was aspirated and cells were washed 
once with 1x PBS, the 1x PBS was aspirated, and 0.25% Trypsin-EDTA was added to the 
cells and allowed to incubate at room temperature for 4 min. Media was added to plates 
and cells were detached and cell suspensions were plated at between 1:5 and 1:20. 
2.2.2 Isolation of neonatal rat ventricular myocytes (NRVMs) 
 2.2.2.1 Ethics statement 
 Experimental procedures on animals used in this study were reviewed and 
approved by the Institutional Animal Care and Use Committee (IACUC) of Boston 
University (Protocol # 16-019). These studies were conducted in accordance with the 
principles of animal care and experimentation in the Guide For the Care and Use of 
Laboratory Animals. 
 2.2.2.2 Isolation 
 NRVMs were extracted from ten approximately two day old Sprague Dawley 
neonatal rats (Charles River Labs, Strain Code 400). Rats were sacrificed by decapitation 
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and hearts were exposed by incision down the sternum, and excised using forceps. Hearts 
were immediately placed in ice-cold Hank’s Buffered Saline Solution (HBSS) until entire 
litter was dissected. After all hearts were collected, hearts were moved to a sterile tissue 
culture hood where the HBSS was aspirated and the hearts were deposited in a 60 mm 
dish containing 5 mL of fresh HBSS. Hearts were cleaned of blood, and atria and vessels 
were removed using fine scissors. The remaining ventricular region was transferred to a 
new 60 mm dish with 5 mL of HBSS. Ventricles were then cut into 3 or 4 fragments 
using single clean cuts to minimize tissue shearing. Once all the ventricles are processed, 
a 5 mL serological pipette was broken near its tip and the heart fragments were extracted 
from the HBSS and dispensed into a new 60 mm dish with 5 mL of HBSS with minimal 
transfer of old HBSS to the new 60 mm dish. This process is repeated twice more to wash 
the ventricles, then the ventricles are deposited in a glass bottle with 25 mL HBSS 
containing 0.6 mg/mL trypsin and incubated overnight at 4°C. 
 After overnight incubation in trypsin, ventricle fragments were treated with 10 
mL of pre-warmed growth media, and incubated shaking at 37°C for 3 min to inactivate 
trypsin. Supernatant was aspirated and 10 mL of pre-warmed 10mg/mL collagenase II 
(Worthington Biochemical) in HBSS was added to isolate cardiomyocytes. Ventricle 
fragments were incubated in a shaking incubator for 6 min at 37°C at 125 rpm. The 
supernatant from this incubation was collected in a 50 mL conical vial and stored on ice 
until entire protocol is complete. This process is repeated seven more times for a total of 
eight collagenase digestion. The two 50 mL conical tubes containing the NRVM 
suspension were centrifuged at 1000 rpm for 4 min and the supernatant was carefully 
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aspirated making sure no to disturb the fragile cell pellet. Cell pellets were resuspended 
in 20 mL of pre-warmed growth media and centrifuged at 1000 rpm for 4 min. The 
supernatant was again removed and the cell pellets were resuspended in 10 mL of growth 
media for a total of 20 mL of NRVM suspension. This cell suspension was pre-plated 
onto a 10 cm dish for 1 h at 37°C to remove fibroblasts. Pre-plating was repeated once 
more with an incubation of 45 min – 1 hr to further enrich the NRVM population. 
 The cell suspension was then transferred to a new 50 mL conical tube and cell 
density was determined by making a 1:10 dilution of NRVM cell suspension and 
counting using a hemocytometer. Cells were plated in growth media at a density of 4 x 
10
6
 cell/ 10 cm dish on gelatinized plates (0.1% gelatin). After 24 hr in recovery, growth 
media was removed, NRVMs were washed with 1x sterile PBS and DMEM containing 
0.1% Nutridoma-SP (Roche) was added to the dishes. 
2.2.3 Polyethylamine (PEI) transfection 
 Transfections with PEI (Polysciences, Inc.) were performed at a 6:1 ratio of PEI 
to DNA. Transfections for reporter assays were performed on COS1 or HEK293T cells 
seed onto 6-well plates at a density of 75,000 to 100,000 cells/well. PEI was mixed with 
serum-free DMEM and incubated at room temperature for five min. This mixture was 
then added to DNA and incubated at room temperature for 15 min. The resulting 
complexes were added to the cells and cells were incubated for 48 hr prior to harvesting. 
2.2.4 siRNA transfections 
 Rat siRNAs were acquired from Invitrogen. Transfections using an siRNA 
component were performed using a 1:3 ratio of Lipofectamine
®
 RNAiMAX Reagent. For 
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a 6 well format, 90 pmol/well of siRNA was diluted into 150 µL/well of Opti-MEM
®
 
Medium (Gibco), and 9 µL/well of RNAiMAX reagent was diluted into 150 µL/well of 
Opti-MEM Medium. These two dilutions were then pooled and incubated for 5 min at 
room temperature, and 250 µL of the resulting mixture was added to each well. 
2.2.5 Adenoviral transductions 
 Adenoviral shRNA constructs targeting Mef2a, -b, -c, and -d were transduced at 
an MOI of 25 and 50, for C2C12 myoblasts and NRVMs respectively. MEF2A, -C, and -
D overexpression constructs were transduced at an MOI of 50 in C2C12 myoblasts and 
an MOI of 15 for NRVMs, with the exception of the MEF2A overexpression construct 
which was used at an MOI of 2.5. β-gal, MEF2A, -C, -D, and -VP16 overexpression 
constructs were generously provided by Jeff Molkentin (Children’s Hospital, Cincinnati) 
and Ken Walsh (Boston University Medical School). The SHH-N overexpression vector 
was generously provided by Ronald G. Crystal (Cornell Medical Center) and used at an 
MOI of 25. N1ICD overexpression virus was generously provided by Igor Prudovsky 
(Maine Medical Center Research Institute) and was used at an MOI of 2.5. Transduced 
C2C12 cells were harvested for RNA 96 hr after transduction (3 days after induction of 
differentiation). NRVMs were harvested for RNA 48 hr after transduction, and viability 
assays were performed 72 h after transduction. 
2.2.6 CellTiter-Blue
®
 cell viability assay 
 NRVMs were cultured in 24-well plates at a cell density of 8x10
4
 cells/well and 
transduced with adenovirus 24 hr after seeding. NRVMs were cultured for 48 hr, then 20 
µL of CellTiter Blue
®
 reagent (Promega) was added to each well. Plates were incubated 
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for 16 h in a humidified 37°C incubator, and then 200 µL of media was extracted from 
each well and transferred to a 96-well dish. Fluorescence was measured at 560/590 nm 
using a Victor 3 plate reader (Perkin Elmer). Data were normalized to untreated control 
wells lacking NRVMs, and experiments were performed in biological triplicate. 
2.2.7 Propidium iodide DNA quantification 
 DNA content was measured using propidium iodide staining and flow cytometry. 
NRVMs were plated at a cell density of 1x10
6
 cells/well onto 6-well plates. NRVMs 
were transduced and allowed to culture for 72 hr. Cultures were then scraped into their 
existing media to retain any cells that had already detached from the plates, and 
centrifuged at 1000 xg for 5 min at 4°C. Cell pellets were re-suspended in 3.33x PBS and 
ice cold 100% ethanol was added to suspension to a final volume of 1x PBS. Cells were 
stored for up to 2 weeks at 4°C. 
 On the day of flow cytometry analysis, permeabilized NRVMs were centrifuged 
at 1000 xg for 5 min at 4°C and washed once with 1x PBS. The NRVM cell pellet was 
then re-suspended in a freshly prepared propidium iodide staining solution (50 µg/mL 
propidium iodide + 2x PBS + 10 µg/mL RNase A) for 30 min at room temperature in the 
dark. Cells were then analyzed using a FASCalibur flow cytometer (488nm excitation/ 
585 emission). 
2.3 RNA Analysis techniques 
2.3.1 Isolation of total RNA  
 Total RNA was isolated from samples using TRIzol
®
 reagent (Invitrogen) 
according to the manufacturer’s specifications. Briefly, cells were washed once with 1x 
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PBS, and an appropriate volume of TRIzol reagent was added directly to the well. Cells 
were scraped into the TRIzol, transferred to a 1.7 mL microcentrifuge tube and stored on 
ice until all well were collected. Cells were then incubated at room temperature for 5 min. 
RNA was isolated using chloroform phase separation per manufacturer’s protocol, and 
RNA was washed once with 70% ethanol and allowed to dry inverted for 10 min. RNA 
was then re-suspended via pipetting into 30 µL of sterile dH2O. RNA integrity was 
evaluated through gel electrophoresis with ethidium bromide and visualized using UV 
light. RNA concentrations were determined by measuring optical density of a 2 µL 
sample with a NanoDrop 1000 spectrophotometer (Thermo Scientific). Samples were 
kept on ice and stored at -80°C. 
2.3.2 Transcriptional expression microarray 
 RNA quality for microarray analysis was evaluated using a Bioanalyzer
®
 2100 
(Agilient). C2C12 cells were harvested 72 hr after induction of differentiation, and total 
RNA from shLacZ, shMef2a, shMef2b, shMef2c, and shMef2d-treated C2C12 cells (n=6, 
pooled to yield n=3 biological replicates, 15 arrays total, GEO accession number 
GSE63798) was harvested. Biological replicates were hybridized to the Mouse 
GeneChip
®
 Gene 1.0 ST Array (Affymetrix). NRVMs were harvested 48 hr after 
transduction and total RNA from shLacZ, shMef2a, shMef2c, and shMef2d-treated 
NRVMs was hybridized to the Rat Gene 2.0 ST array (n=3 biological replicates, 12 total 
arrays, GEO accession number GSE92861). Array hybridization and analysis was 
performed by the Microarray Core at Boston University Medical Center. The technical 
quality of the microarrays was determined using relative log expression and normalized 
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unscaled standard error. Relative log expression and normalized unscaled standard error 
values greater than 0.1 and 1.05, respectively, are considered out of normal limits. All 
arrays had median values within the normal limits of these test. Microarray data was 
normalized using the Robust Multiarray average algorithm and were Log2 transformed. 
2.3.3. Quantitative real-time PCR (qRT-PCR) 
 2.3.3.1 cDNA synthesis 
 Total RNA extracted from cell culture was used to synthesize cDNA using 
reverse transcriptase (M-MLV) with random hexamers (Promega). qRT-PCR was 
performed in biological and technical triplicate using Power SYBR
®
 Green Master Mix 
(Applied Biosystems) with the 7900HT Sequence Detection System (Applied 
Biosystems). List of qRT-PCR primers can be found in Tables 2.1-2.3. Data were 
analyzed using SDS 2.2.4 software (Ambion) and CT values were compared between 
gene specific primers and reference gene controls. The CT value for each transcript were 
averaged and subtracted from the average internal control (Gapdh) CT value to determine 
the transcript Δ CT of the control sample set. Fold changes between samples were 
calculated using the formula F.C.=2-ΔΔCT. Differences in relative gene expression were 
analyzed for significance using a Student’s T-test, and a p-value of less than 0.05 was 
considered statistically significant. 
 2.3.3.3 Measuring intra-sample relative transcript expression 
 To assess the relative expression levels of different transcripts within the same 
sample, we first verified the efficacy of the primer pairs. This was done by performing a 
quantitative RT-PCR analysis on a series of serial two-fold dilutions of cDNA (at least 6 
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dilutions) synthesized from total NRVM RNA. Primers were considered 100% efficient if 
the slope of the CT value vs. log2 scale of the dilutions yielded a slope of |1|±0.1. Primers 
that were 100% efficient can be compared to express the relative differences in transcript 
expression within a sample. 
 2.3.3.4 Primer design 
 qRT-PCR primers were designed using either Primer3 (Untergasser et al. 2012) or 
Primer-Blast (NCBI) with a product size between 50 and 200 bp with a primer crossing 
an exon-exon junction to ensure omission of genomic DNA contaminants. Additionally, 
primers were required to have at least 2 mismatches to unintended targets, a GC% 
between 40 and 60%, and self-complementarity and 3’ self-complementarity score as low 
as possible, but not above 4. Unless specified, default parameters were used. 
2.4 Protein techniques 
2.4.1 Protein isolation 
 Plated cells were washed with 1x PBS and scraped into fresh 1x PBS. Cell 
suspension was centrifuged at 13,000 rpm for 10 min at 4°C. Supernatant was discarded 
and cells were Dounce homogenized in ELB (50 µM HEPES, 250 mM NaCl, 5 mM 
EDTA, 0.1% NP-40, 1 mM PMSF, 1 mM DTT, and 1x complete protease inhibitor 
[Roche Diagnostic]). Homogenized samples were placed on ice for 10 min, then 
centrifuged at 13,500 rpm for 10 min. Pellet was discarded and remaining supernatant 
was stored at -80°C. 
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2.4.2 Quantification of protein concentration using the Bradford assay 
 Protein concentration was determined using the Bradford assay. A standard curve 
of bovine serum albumin (BSA) was created between 1 mg/mL and 0.2 mg/mL. 10 µL of 
each standard and all proteins samples to be measured was transferred to a 96-well plate 
and 200 µL of 1x Bio-Rad Bradford Protein Assay Dye (Bio-Rad Laboratories) was 
added to each well. Samples were allowed to incubate for 5 min at room temperature, 
then absorbance was measured at 595nm and the standard curve was used to determine 
the concentration of unknown protein lysate. 
2.4.3 Western blotting 
 2.4.3.1 Protocol 
 Between 10 and 20 µg of proteins was mixed with SDS loading buffer and 
electrophoresed on a polyacrylamide gel composed of a lower separating gel (10% 
acrylamide, 375 nM Tris-HCl pH 8.8, 0.1% SDS) and an upper stacking gel (5% 
acrylamide, 125 mM Tris-HCl pH 6.8, 0.1% SDS). Protein samples were electrophoresed 
at 190 volts in 1x SDS running buffer (25 mM Tris-HCl, 190 mM glycine, 0.1% SDS) for 
approximately 45 min. After electrophoresis, stacking gel was excised and discarded. The 
separating gel was equilibrated for 10 min in 1x transfer buffer (20mM Tris-HCl, 150mM 
glycine, 20% methanol). Proteins were transferred to an Immuno-blot PVDF membrane 
(Bio-Rad Laboratories) by electroblotting overnight at the lowest setting (~20-50 mA). 
After transfer, the protein blot was blocked in the appropriate blocking buffer (5% nonfat 
dry Carnation milk in 1x TBS, or 5% BSA in 1x TBS/0.1% Tween-20) for 1h at room 
temperature or overnight at 4°C. Membranes were then incubated for 1 hr with 
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appropriate primary antibody in fresh blocking solution. The membrane was washed 
three times for 5 min in 1x TBS/0.1% Tween-20 then incubated with the appropriate 
secondary antibody conjugated to HRP in 1x TBS/0.1% Tween-20 for 30 min at room 
temperature. The membrane was then washed again three times for 5 min in 1x 
TBS/0.1% Tween-20 and treated with Western Lighting Chemiluminescent Reagent 
(Perkin-Elmer) for 1 min. Protein was visualized through exposure to X-ray film for 
between 5 min and 30 sec. 
 2.4.3.2 Antibodies used 
 Antibodies used for Western blotting included: anti-GAPDH (1:1000, Santa 
Cruz), anti-MEF2 (1:1000, Santa Cruz), anti-MEF2C (1:1000, Sparrow Biosciences), 
anti-MEF2D (1:1000, BD Biosciences), anti-FLAG (1:10,000, Sigma Aldrich). Blots 
were incubated with HRP-conjugated secondary antibodies (1:10,000, Sigma Aldrich). 
2.4.4 Co-immunoprecipitation 
 Transfected cells were harvested 36-48 hr post-transfection in modified AT buffer 
(20% glycerol, 1% Triton X-100, 20 mM HEPES pH 7.9, 1 mM EDTA, 150 mM NaCl, 1 
mM DTT, 1 µg/mL PMSF, and 1:25 complete protease inhibitor [Roche]). 
Approximately 35 µL of Protein G sepharose beads (GE Healthcare) and 1 µg of anti-
Myc antibody was added and incubated with AT buffer precursors (modified AT buffer 
excluding DTT, PMSF, and protease inhibitor). The beads, protein, and antibodies were 
incubated rotating at 4°C overnight. The next day, samples were boiled and loaded onto 
an 8% acrylamide gel. Normal Western blot procedures (as described above) were 
performed. 
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2.4.5 Cleaved caspase 3 activity assay 
 NRVMs were seeded at a cell density of 1 x 10
6
 cells/well and total protein lysate 
was collected as described above. Protein lysates were then treated with a fluorogenic 
caspase-3 substrate, Ac-DEVD-7-amido-4-methylcoumarin (BD Biosciences) to a final 
concentration of 50 µM. Lysates were then incubated at 37°C for 1 hr. Fluorescence was 
measured at 440/460 nm using a Victor3 plate reader (Perkin Elmer). Data were 
normalized to total protein concentration of the lysate as determined by Bradford assay. 
2.4.6 Luciferase activity assay 
 Cells were harvested for luciferase assays 48 h after transfection. Cells were 
washed once with 1x PBS, then lysed in 1x Passive Lysis Buffer (Promega) by shaking 
for 15 min at room temperature. Lysates were mixed by pipetting and transferred to a 1.7 
mL microcentrifuge tube. Firefly luciferase activity was measured by transferring 10 µL 
of protein lysate to a new 1.7 mL microcentrifuge tube and mixed with 50 µL luciferase 
activity reagent (Promega). Samples were mixed by pipetting and readings were 
measured on a luminometer. Luciferase readings were normalized to β-gal activity to 
control for transfection efficiency. 
2.4.7 β-galactosidase activity assay 
 Cells were harvested for luciferase activity as described above. β-galactosidase 
activity assay was performed using the J.H. Miller method, by incubating whole cell 
protein lysate with a reaction mixture of 15 µL Z Buffer (60 mM Na2HPO4.7H2O, 40 mM 
NaH2PO4.H2O, 10 mM KCl, 1 mM MgSO4, 50 mM β-mercaptoethanol) + 16.5 µL 
ONPG (8 mg/mL), and brought to a final concentration of 150 uL with dH2O. Samples 
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were incubated in a 37°C water bath until yellow color is noticeable. The reaction was 
then quenched by adding 250 µL Na2CO3. Absorbance was measured at 415 nm and 
values were used to normalize luciferase readings. 
2.4.8 Immunocytochemistry 
 NRVMs were cultured on acid-etched coverslips and transduced with the 
appropriate shRNA adenoviruses for 48 h. Cells were then washed with 1x PBS and fixed 
in freshly prepared 4% paraformaldehyde. Cells were then blocked with Mouse on 
Mouse Blocking solution (Vector Labs) for one hr at room temperature. Cells were 
incubated with primary antibody diluted in antibody dilution buffer (1x PBS, 1% BSA, 
0.3% Triton X-100) overnight at 4°C. The following day, cells were washed three times 
for 5 min with 1x PBS. Cells were then incubated with fluorochrome-conjugated 
secondary antibody diluted in antibody dilution buffer for two hr at room temperature in 
the dark. Cells were washed three times for 5 min in 1x PBS and mounted on slides with 
VECTASHIELD Mounting Medium with DAPI (Vector Labs). Slides were sealed with a 
thin layer of nail polish and stored at 4°C in the dark. Slides were imaged with an 
Olumpus DSU scanning confocal microscope. α-actinin antibody was used as primary 
antibody (1:500, Sigma), secondary antibody was Alexa fluor 568 donkey anti-mouse 
H+L (1:500, Invitrogen). 
2.5 Computational and bioinformatics analysis 
2.5.1 Construction of differentially expressed gene sets 
 Significant dysregulation of gene expression was determined using a one-way 
analysis of variance and the Benjamini-Hochberg false discovery rate correction was then 
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applied to obtain corrected q-values, and a q threshold of less than 0.05 was used to 
determine significant dysregulation. Tukey’s honest significant difference post hoc test 
was used to identify significantly dysregulated genes and correct for multiple testing 
errors across all intergroup comparisons. A corrected q value of less than 0.05 was used 
to determine statistically significant gene dysregulation among treatment groups. 
2.5.2 Functional genomic analysis 
 Statistically distinct gene sets sensitive to individual MEF2 isoforms were 
analyzed using three independent analysis algorithms. Gene Ontology term analysis 
(Ashburner et al. 2000) and Kyoto Encyclopedia of Genes and Genomes (KEGG) 
(Kanehisa et al. 2017) were performed using the DAVID bioinformatics database with 
default parameters and entries were considered statistically significant if the p-value was 
less than 0.05. Ingenuity Pathway Analysis (Qiagen Bioinformatics) was used to 
determine the canonical cellular pathways associated with each gene set. Parameters for 
the IPA analysis were Reference Set: Ingenuity Knowledge Base (Genes Only); 
Relationship to include: Direct and indirect; pathways considered statistically significant 
if p-value was less than 0.05. 
2.5.3 Regulatory region sequence determination 
2.5.4 Consensus binding site variance 
 MEF2-binding site comparisons were performed by identifying putative MEF2-
binding sites in the proximal promoter regions (5 kb upstream of putative transcriptional 
start site) of gene sets preferentially-sensitive to each MEF2 isoform using the FIMO tool 
from the MEME suite (Grant et al. 2011). Identification was performed by scoring 10 bp 
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motifs against the MEF2 motif stored in the JASPAR database (MA0052.1) using a p-
value threshold of less than 0.0001. The output position-weight matrices were then used 
to compile a sequence logo using the WebLogo (Doerks et al. 2002) applet. 
2.5.5 Candidate Co-regulatory Proteins 
 Transcription factor-binding motif enrichment analysis was performed on the 
proximal promoter region of genes preferentially sensitive to each MEF2 isoform using 
MatInspector from the Genomatix software suite (Quandt et al. 1995). A default 
background composed of a cross-section of genomic promoter sequences was used to 
discriminate between enriched features and non-specific promoter regions. The resulting 
transcription factor motifs were then sorted by Z-score, and motifs with a Z score greater 
than 2.0 were considered significantly enriched (Ho Sui et al. 2005). Additional data for 
each enriched motif was extracted from the Genomatix Matbase and NCBI databases. 
Paired enriched motif analysis was performed for proximal promoter regions of 
antagonistically regulated genes. The analysis is similar to described above but restrains 
the search for motifs to within 50bp of a putative MEF2 binding site to enrich for 
potential direct interaction partners. 
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Table 2.1 List of mouse quantitative RT-PCR Primers used in Chapter Three. 
  
Gene Forward Reverse
Cdkn1c 5’ CCAATGCGAACGACTTCTTCGC 5’ AACTAACTCATCTCAGACGTTTGCGC
Sept4 5’ TACACTCATGGTGGCAGGAGAATCTG 5’ CACTCTGTGTTGTTGACTGCATCC
Hspb7 5’ GCTGAGAAGCTGGCAGCTGATG 5’ ATCTCAGTCCGGAAGGTCTGCTG
Myom1 5’ CTACTCTGGACGGCAAGTGCAC 5’ GTGGTCCGTTTGGAGGTTGC
Stc2 5’ CTGCAGAACACAGCGGAGATCC 5’ CTGGGCATCGAATTTTCCAGCGT
Tex16 5’ CTTCTTGCCCTTTCAAGGTGT 5’ TACCTGTTTGGAGTCTGAGCTGAA
Selp 5’ TACACAGCCTCCTGCCAGGA 5’ CTGAAGGTGCACTGTGAGTTGAAGG
C1ql1 5’ GGTCACCAACCTAGGCAACAACTAC 5’ CTCCATCCAGCTTGATGAAGACCTC
Bace2 5’ ACTCAGAGAGCTCCAGCACATACC 5’ GCCAAAGCAGCATAAGCAAGTCC
Pi16 5’ CTGCAGATGAGGTGGGATG 5’ GCCGTGCTGAAATTGTAATACTC
Themis 5’ CTACGGACGACCTTTTTGAAAT 5’ CTAAGATCCTCGAAGCCTGGTA
Glipr1 5’ ACTCAGGTTGTTTGGGCAGACAG 5’ TGCAGAGACTGTTGAGACACTTGTCA
Cpa4 5’ GTACACGCAAAGCCAGAACC 5’ CCATGGTACACTTCAGAGCAAG
Fam78a 5’ AGCAGGGCATGTCTAGCTGG 5’ CACGTGGTGAAGCTCTGGTC
Ppp1r3 5’ GCTAGACTTGATGATAAACCAACGG 5’ CCCATGAACAAGTCAGTGTTGA
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Table 2.2 List of rat quantitative RT-PCR primers used in Chapter Four. 
  
Gene Forward Reverse
Gapdh 5'-TGGCAAGTGGAGATTGTTGCC 5'-AAGATGGTGATGGGCTTCCCG
Mef2a 5'-GAACTCAGTGTGCTCTGTGACTGTGAG 5'-GCCAGTGCTTGGTGGTCTCT
Mef2b 5'-GAAAGAAAGCCGCTCTGCACAG 5'-ACCTTCTGGCCCCTCCTCCATA
Mef2c 5'-CAGGGACGAGAGAGAGAAGAAAC 5'-CAATCTTTGCCTGCTGATCATTAG
Mef2d 5'-CTTTCCTCTCTGGCACTAAGGAC 5'-CCAGTCTATAACTCTGCATCATC
Dnm3 5'-TAACCACATCCGTGAGCGAG 5'-GCGGAAGATTGGTTCCCTGA
Ccl5 5'-GCTTTGCCTACCTCTCCCTC 5'-TCCTTCGAGTGACAAAGACGA
Filip1 5'-GCAGGAGCGAGAGAGGTTGA 5'-CATCAGGGCGAAGGACTTGA
Lrrc39 5'-CACGGAGAACAGAAGACCAAG 5'-CATGATGTCTTCCACAAGCAAA
Cirbp 5'-AGACTACTATGCCAGCCGGA 5'GGACGCAGAGGGCTTTTACT
Adamtsl2 5'-CTCACAAGGCAAGGACCAGAC 5'-CCACTTCAACGCCATCGTAG
Cdh8 5'-GGAGCCCGACCTGAGAAAT 5'-TCTAAGCAGCTTTTCCAAGACCA
Mdga2 5'-CTCATCGTGCAGTATCCCCC 5'-ACGCCATTCGTAAGTCAGCA
Kit 5'TTTAAAGGTAACAGCAAAGAGCAA 5'-GTGACCACGAAGCCAATGAG
Sept4 5'-GGACTGAAGCTGGGGATGAC 5'-CCGATCCCGGTACAAGTCAG
Upk1b 5'-CAGCCAGTCCAGTGGGAAAT 5'-GGCGATCCCACACATACCAA
Pten 5'-ACTGCAGAGTTGCACAGTATCCTT 5'-GCCTCTGACTGGGAATAGTTACTCC
Mcm3 5'-AACCCGTTCCAAGGATGTCTTTGAG 5'-GGTTTCCTGTCTGTGGTGACG
Mcm5 5'-GGACATGATGCTGGCCAAACATGT 5'-GGCTGCAGTTTCATCTTGCTGAGG
Mcm6 5'-GACTTCCTGGAAGAGTTCCAGGG 5'-CGATCCTGGAGGAAGTGAGCTC
Pcna 5'-CGTGAACCTCACCAGCATGTCC 5'-CCAAGTTGCTCAACGTCTAAGTCCA
Ccne1 5'-CCAGGATAGCAGTCAGCCTTGG 5'-TGCTCTCATCCTCGCCTGC
Ccne2 5'-AATTGTTGGCCACCTGTACTGTCTG 5'-ACTTCACAGACCTCTAAAAGCCAGTCT
E2f3 5'-AGGAGCGAGAGATGAGAAAGG 5'-GTGGTGAGGATCTGGATGTACG
Myh7 5'-GGAAGAACCTACTGCGACTGCAGGACC 5'-TGTTTCAAAGGCTCCAGGTCTCAGGGC
Myl2 5'-GAAGGCCGACTATGTCCGGG 5'-TGGGGATGGAGAACAGGCTA
Myom1 5'-GAGAAAAATCGGGCTCGGGT 5'-GCAGGTGAGATTGAGTGCCT
Myom2 5-AAGCCTCTTTGTCTCCCGAA 5'-TCCCAGAAAGATGAGGAGTACC
Ttn 5-CACCACCAGTCCCAGAAGTT 5'-AGACTGCTTCCTTCCGTTCA
Ptch1 5'-AAGTGTTGCCCCAAACTCCA 5'-AACAGGCGTAGGCAAGCATC
Gli1 5'-CTGGTCTGCCCTTTTGCCAC 5'-GAAAGAGTGACCCCTCAGTGCAG
Gli2 5'-TCACCATCCATAAGCGGAGC 5'-GTTGCTCCTGTGTCAGTCCA
Gli3 5'-TTCCTCCATTACACGTGCCT 5'-GTGCAAGGAGCGGATGTAGT
Hey2 5'-AGGGTGTCCGTAGCTCTTCT 5'-ACTGTGCCCCGGAGTAATTGT
Hes1 5'-AGCACAGAAAGTCATCAAAGCC 5'-CTTGGAATGCCGGGAGCTAT
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Table 2.3 List of rat quantitative RT-PCR primers used in Chapter Five. 
  
Gene Forward Reverse
Egr1 CACCTGACCACAGAGTCCTT ACAAGGCCACTGACTAGGCT
Ank2 AGATTACTGTGCAGCATAACAGG TGGTTGTAAAGGAAACACACTCA
Dmd CGAGACCCAAACCACTTGTTG GCGGAGAACCTGACATTATTCA
Dysbind TGGGCAGTGTGAGTTAGAAAGA TGCTCTGTATCGAGTTCAGCTT
Fhl2 AGCAGCCCATTGGAACCAAG CTCCTGTGGTGATAGGCTTTTT
Lamb2 GAACTTCGCTTGGGCCTACTT GGTGGCTGGATAGCAGCTT
Obscn AATTTGCTGGTGGTCGTGAGAGAGCC AATTGCCTGCCTTGAACAGAGAGCT
Pdlim1 TCGATGGGAAGATACCAGCA TCTGTTCAGACCTGGATACTGTG
Pdlim5 AGCGTCAAGTCACCTAGCTG TTGCCCCGCTGGAATGTGTT
Sgca ATCGAGACGTTTTGACACCACTA CCTTAATGTATACCCCTTCCTTCC
Sgcb ATCGTCCTCCTGTTTATCCTGG GTGGAACTCCATGCTATCACAC
Sgcg TCACCGAGGGCACTCACATA CGAGCAGGAGAAGAACGAATAGG
Tcap GATGCGCCTGGGTATCCTC GATCGAGACAGGGTACGGC
Xirp2 TGAGACCATCGCGGCTAAGA GTGTCGGTATTCCATCATCTCC
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CHAPTER THREE: MEF2 transcription factors regulate distinct gene programs in 
mammalian skeletal muscle differentiation 
Parts of this research were originally presented in the Journal of Biological Chemistry. 
Estrella, NL. Desjardins, CA. Nocco, SE. Clark, AL. Maksimenko, Y. Naya, FJ. MEF2 
transcription factors regulate distinct gene programs in mammalian skeletal muscle 
differentiation J Biol Chem.2015; 290:1256-1268. © by the American Society for 
Biochemistry and Molecular Biology. 
 
3.1 Introduction 
 Skeletal muscle development is characterized by the complex coordination of a  
diverse group of gene regulatory networks to attain the complex contractile structures 
required for its appropriate functioning. These events require the regulation of vast gene 
programs mediated by a set of core transcription factors. The MEF2 family of 
transcription factors plays a critical role in the processes of myogenesis and muscle 
homeostasis (Black et al. 1998, Sandmann et al. 2006, Potthoff et al. 2007). MEF2 exists 
as a single gene in invertebrate genomes, and plays a critical role in myogenic 
specification in Drosophila (Lilly et al. 1994). The MEF2 family has diverged through 
evolution into a four member family composed of MEF2A through –D in mammals 
(Edmonson et al. 1994). The expansion of the MEF2 gene family has added complexity 
to its regulatory role in skeletal muscle development. Early in vitro analysis of the MEF2 
family suggested that all four family members shared transcriptional activity (Gossett et 
al. 1989, Pollock et al. 1991, Yu et al. 1992), and were able to recognize and bind the 
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same consensus sequence in DNA. While the in vitro data suggested a high degree of 
redundant function, in vivo loss of function mouse models revealed drastically different 
mutant phenotypes. Loss of MEF2B (Black et al. 1998) or MEF2D (Kim et al. 2008) 
expression appears to have little effect on skeletal myogenesis and homeostasis. On the 
other hand, mice lacking MEF2A exhibited impaired regenerative capacity after injury 
(Snyder et al. 2013), and mice bearing a conditional skeletal muscle depletion of MEF2C 
developed normally, but sustained rapid loss of skeletal muscle tissue perinatally 
(Potthoff et al. 2007), suggesting a role for MEF2A and –C in myofiber homeostasis.  
 While in vivo data suggests distinct regulatory roles not shared by every MEF2 
factor, previously efforts have typically focused on a single MEF2 factor, and 
extrapolated shared effects to the entire family. Here we present a comprehensive 
transcriptomic analysis of the four mammalian MEF2 factors in the C2C12 cell culture 
model of skeletal muscle differentiation. We first observed a myotube fusion defect upon 
the depletion of MEF2A that is not shared by depletion of the other family members. 
Additionally, overexpression of the MEF2 family members was unable to rescue the 
fusion defect, but a constitutively active fusion, MEF2-VP16, was sufficient to rescue 
appropriate differentiation. These results support our hypothesis that the MEF2 family 
regulates distinct but overlapping gene regulatory networks. We proceeded with an 
analysis of transcriptome effects of depletion of individual MEF2 factors and observed a 
surprising lack of overlap in the genes sensitive to loss of each MEF2 family member. 
Upon further bioinformatics analysis these genes played roles in very different pathways. 
While the molecular mechanism through which this differential regulation can occur is 
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not obvious, we determined that it is unlikely to be MEF2 isoform binding site 
preferences and have determined a subset of enriched transcription factor binding sites 
that might help mediate differential regulation of genes by the MEF2 family.  
3.2 Acute depletion of MEF2 isoforms in skeletal myoblasts 
 Adenoviral shRNA transduction was used to assess the effects of targeted MEF2 
depletion on gross morphological features of C2C12 myoblast differentiation. The 
mammalian MEF2 factors display different temporal expression during C2C12 
differentiation (Ramachandran et al. 2008, Snyder et al. 2013); therefore our analysis was 
restricted to 3 days post-induction of differentiation, a time point at which all four MEF2 
isoforms are known to be expressed in normal development. Briefly, C2C12 myoblasts 
were transduced, then differentiated for three days, then evaluated for gross 
morphological defects in MEF2 depletion. As previously reported, depletion of MEF2A 
resulted in impaired myotube formation (Figure 3.1 A). Interestingly, depletion of 
MEF2B, -C, and –D failed to yield a gross morphological defect. Myosin heavy chain 
(MHC) was used as a protein marker for skeletal myofiber differentiation, and we 
observed a decrease in MHC expression only in the Mef2a-deficient myotubes (Figure 
3.1 B-C). These results support the hypothesis that MEF2A is required for myoblast 
differentiation, and other MEF2 isoforms are dispensable for this process. We then 
assessed whether overexpression of MEF2C, -D, or a constitutively-active MEF2-VP16 
was sufficient to restore myotube formation in the MEF2A-depleted myoblasts. 
Transduction of MEF2C and -D overexpression constructs failed to rescue the myotube 
formation defect in the MEF2A-depleted myoblasts (Figure 3.2). Interestingly, 
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overexpression of the constitutively-active MEF2-VP16 construct was sufficient to 
restore normal differentiation to MEF2A-deficient myoblasts (Figure 3.2). These data 
support the hypothesis that individual MEF2 isoforms play distinct regulatory roles in 
skeletal myoblast differentiation. Specifically, MEF2A is required for appropriate 
myotube formation, and other MEF2 isoforms are not required for this process. 
Additionally, overexpression of a constitutively-active MEF2 construct was sufficient to 
rescue the defect, but not overexpression of MEF2C or -D. 
3.3 Transcriptomic analysis reveals that MEF2 isoforms regulate distinct but 
overlapping gene sets. 
 The emergence of a MEF2A-specific function in myoblast differentiation 
suggests that the individual MEF2 family members may play distinct regulatory roles in 
skeletal muscle. To elucidate other potential roles for individual MEF2 isoforms, we 
performed global gene expression analysis of myoblasts for each MEF2-depletion. 
Briefly, microarray analysis was performed on C2C12 myotubes depleted of individual 
MEF2 proteins (n=3 arrays for each shRNA), and dysregulation was determined by one-
way analysis of variance using the Benjamini-Hochberg false discovery rate correction 
with a threshold q value of 0.05. The statistical analysis yielded 7685 significantly 
dysregulated genes across all MEF2 isoform depletions when compared to negative 
shLacZ-treated myoblasts (Figure 3.3). Interestingly, approximately 50% of all 
dysregulated genes were shown to be sensitive to MEF2A depletion, suggesting that 
MEF2A plays a prominent role in the transcriptional coordination of skeletal muscle 
cells. Additionally, MEF2B and -C depletions are responsible for the dysregulation of 
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approximately 14 and 13% of genes, respectively, and MEF2D depletion had strikingly 
few dysregulated genes (~1.5%, 110 genes, Figure 3.3). Dysregulation on the microarray 
was validated by quantitative RT-PCR analysis of a subset of the most dysregulated 
genes (both up- and down-regulated) from each MEF2 depletion experiment. The 
majority of genes validated in this manner displayed the expected dysregulation (Figure 
3.4). 
 We began by identifying genes sensitive to a single MEF2 isoform. Preferentially 
sensitive genes were defined as genes whose dysregulation by depletion of one MEF2 
isoform was significantly different than dysregulation by depletion of the other three 
MEF2 isoforms using Tukey’s honest significant difference post hoc test. Based on this 
statistical testing, a subset of genes dysregulated by each MEF2 isoform was clearly 
found to be significantly more sensitive to a specific MEF2 isoform than to other 
members of the family. As shown in Figure 3.3A, these non-overlapping cohorts included 
3248 genes (81% of total dysregulated by MEF2A), 126 genes (12%) for MEF2B, 101 
genes (10%) for MEF2C, and 28 genes (25%) for MEF2D. Additionally, this analysis 
revealed that 75-90% of genes dysregulated in MEF2B, -C, and -D depletion were 
dysregulated in one or more other MEF2 depletions. Finally, only 21 of 7685 genes 
(<0.003%) were in all of the MEF2 factor depletion cohorts. These results suggest that 
only a small fraction of MEF2-sensitive genes in C2C12 cells are sensitive to all four 
MEF2 factors, but many can be regulated by two or more factors, likely in homo- and 
heterodimeric combinations. 
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3.4 Genes sensitive to depletion of each MEF2 factor show complicated regulatory 
patterns 
 We next closely examined the subset of genes that was dysregulated by depletion 
of all MEF2 factor. Because this subset of genes is sensitive to all MEF2 isoforms, we 
hypothesized that, based on their largely indistinguishable transcriptional activities in 
vitro, these genes would be similarly regulated by each isoform and provide a logical 
starting point to mechanistically dissect MEF2-dependent gene regulation in C2C12 cells. 
Analysis of the pattern of dysregulation of these 21 genes revealed that only five of the 
24 potential regulatory patterns are represented (Figure 3.5). Interestingly, genes that 
were downregulated in MEF2A or MEF2D depletion and upregulated in MEF2B and 
MEF2C depletion were the most prevalent group (14 genes, 66.67%). In contrast to our 
hypothesis, no genes were upregulated with the loss of each MEF2 factor, and only one 
gene, Dpy19l1 (Dumpy19-like-1), was downregulated in every MEF2 depletion. Dpy19l1 
is an apparent ortholog of a C. elegans gene, dpy19, which encodes for a transmembrane 
protein with C-mannosyltransferase activity involved in neuroblast migration (Watanabe 
et al. 2011, Buettner et al. 2013). Dpy19 may also function upstream muscle 
development genes in worms, making it an exciting MEF2-dependent gene for further 
investigation (WormBase). Our analysis of the commonly dysregulated genes among all 
MEF2 depletions reveals complex intrafamily regulatory mechanisms that go beyond the 
in vitro transcriptional capacity of the MEF2 family described in the literature. 
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3.5 Identification of functional pathways in MEF2 depletion sensitive gene sets 
 The emergence of significant gene sets preferentially sensitive to individual 
MEF2 factor depletion and the paucity of shared dysregulated genes led us to investigate 
the functional roles played by these disparate gene sets in C2C12 cells. A survey of 
functional pathways represented in these gene sets was performed using three 
bioinformatics algorithms: Ingenuity Pathway Analysis (IPA), Gene Ontology (GO), and 
Kyoto Encyclopedia of Genes (KEGG). 
 Analysis of functional pathways using IPA reveals that genes preferentially 
sensitive to individual MEF2 knockdowns operate in vastly different cellular processes 
(Table 3.1). Roles distinct to genes preferentially sensitive to MEF2A depletion include 
calcium signaling, Germ cell-Sertoli cell junction signaling, and actin cytoskeletal 
signaling. It is interesting the two pathways most closely related to skeletal muscle 
functioning (calcium signaling, actin cytoskeleton signaling) are in the cohort of genes 
preferentially sensitive to MEF2A depletion. Genes preferentially sensitive to MEF2B 
are associated with hepatic fibrosis, ovarian cancer signaling, and human stem cell 
pluripotency, whereas genes preferentially sensitive to MEF2C are involved in control of 
the G1/S cell cycle checkpoint, eicosanoid signaling, and estrogen-mediated S phase 
entry. Due to the dearth of genes preferentially sensitive to MEF2D depletion in C2C12 
cells, only two pathways, JAK-2 and hypoxic response signaling, were statistically 
significant, but other pathways that may be distinct to MEF2D sensitive genes, including 
RhoA signaling and AMPK signaling, appear to suggest that MEF2D may have a distinct 
role in mediating signal processing in skeletal muscle cells. 
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 In addition to functions that are distinct to each MEF2 isoform, several pathways 
are shared among multiple MEF2 gene cohorts even though the dysregulated genes differ 
and are preferentially sensitive to only a single MEF2 isoform depletion (Table 3.1). 
These include canonical pathways related to cancer, which are shared by MEF2A 
(molecular mechanisms of cancer) and MEF2C (ovarian cancer signaling), and Rho 
signaling shared by MEF2A (Rho family GTPases) and MEF2D (RhoA Signaling). 
These results likely reflect regulation of distinct proteins by individual MEF2 factors that 
play a role in the same pathway.  
 IPA was also performed on the subset of 21 genes sensitive to depletion of 
individual MEF2 factors (Table 3.1). Three of the top five canonical pathways appear to 
have skeletal muscle relevance. Integrin and FAK signaling have been shown to play 
critical roles in adhesion and signaling at the myofiber membrane (Mayer 2003), and 
calpain proteases are calcium-regulated protease important for skeletal muscle 
homeostasis (Sorimachi et al. 2012). 
 Investigation of enriched GO terms associated with each preferentially regulated 
gene set yielded muscle specific terms in the MEF2A regulated set (Table 3.2), including 
heart development, muscle cell differentiation, and striated muscle differentiation, as well 
as several actin cytoskeletal GO terms. Genes preferentially regulated by MEF2B were 
predominately associated with development of the vasculature, including blood vessel 
morphogenesis/development, and angiogenesis, but also contained the muscle organ 
development group. Genes preferentially regulated by MEF2C play a role in many 
metabolic processes including metabolism of various fatty acids, but surprisingly did not 
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contain any muscle specific pathways. Finally genes preferentially regulated by MEF2D 
had far fewer associated GO terms, likely due to far fewer dysregulated genes in MEF2D 
depletion, but there was a surprising uniformity of GO terms involved in the cell cycle 
(Table 3.2). When the KEGG algorithm was used to analyze the preferentially regulated 
gene sets, MEF2A regulated genes were associated with cancer and included several 
pathways involved in cardiac dysfunction (Hypterophic cardiomyopathy and 
Arrhythmogenic right ventricular cardiomyopathy) (Table 3.3). Far fewer KEGG 
pathways were associated with the remaining MEF2 factors, but MEF2B and -C gene sets 
both played a role in cancer pathways as well, and the MEF2D sensitive gene set played a 
role in RNA degradation (Table 3.3). Extensive bioinformatics analysis of the gene sets 
preferentially sensitive to a single MEF2 factor reveals largely distinct roles for each 
MEF2 isoform in C2C12 cells. Additionally, there was considerable variation in the 
enriched processes depending on which algorithm was used, suggesting that a more 
extensive analysis is necessary to understand the full breadth of the pathways associated 
with MEF2 in skeletal muscle cells. 
3.6 Consensus binding site analysis 
 Functional pathway analysis confirmed our hypothesis that genes preferentially 
sensitive to individual MEF2 isoform depletion regulate many distinct cellular pathways. 
We began our mechanistic analysis of this differential sensitivity by investigating 
variations in MEF2 DNA-binding sites within 5kb of the putative transcriptional start site 
of genes preferentially sensitive to each MEF2 isoform. The proximal promoter sequence 
was extracted, and FIMO analysis was used to identify potential MEF2 binding sites. 
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Sequences were considered putative MEF2 binding-sites if they were significantly similar 
to the JASPAR consensus MEF2 binding site (CTA(A/T)4TAG) with a p-value ˂10
-4
. 
This statistical criterion led to the analysis of 3814 putative MEF2A binding sites, 152 
putative MEF2B binding sites, 137 putative MEF2C binding sites, and 36 putative 
MEF2D binding sites (Figure 3.6). Composite sequence logos of each group of 
preferentially sensitive MEF2 binding sites yielded the same MEF2 DNA binding site, 
which is not distinct from the JASPAR consensus sequence for MEF2 DNA-binding 
(Figure 3.6). These results suggest that preferential transcriptional regulation of these 
gene sets is unlikely to be mediated by variations in the binding preference of the MEF2 
isoforms.  
3.7 Candidate co-regulatory factors using de novo motif analysis 
 The lack of a measurable variance in the MEF2 binding site between gene sets 
preferentially sensitive to individual MEF2 isoforms suggests that the differential 
transcriptional potential of each MEF2 factor might be mediated by interacting co-
regulatory factors. We hypothesized that an analysis of co-regulatory binding sites in the 
proximal regulatory region of genes preferentially sensitive to individual MEF2 factors 
will reveal distinct candidate binding partners which may explain the observed regulatory 
effects. We performed transcription factor binding site enrichment analysis (Genomatix) 
to compile a list of distinct co-regulatory proteins which may mediate the MEF2-specific 
regulation of these gene sets. We considered a binding site with an enrichment score of 
>2 to be considered significantly enriched in these analyses. 
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 We focused our initial analysis on the frequency with which enriched binding 
sites were shared between genes that were preferentially sensitive to different MEF2 
factors (Figure 3.7A). As expected, the vast majority of binding sites was present in 
genes from different preferentially sensitive cohorts. These likely represent members of 
core regulatory families and transcriptional machinery. Specifically, we observed that 
43% of binding sites were present in genes in all four MEF2-specific cohorts, 32% were 
shared by at least 3 preferentially sensitive cohorts, and 18% of binding sites were 
observed in two preferentially sensitive cohorts. The remaining 7% of enriched binding 
sites represent the potential co-regulatory factors that may explain the preferentially 
regulatory effect of an individual MEF2 factor for its distinct cohort. These enriched 
binding sites were then parsed into MEF2 factor pairwise, three-way, and completely 
shared cohorts (Figure 3.7B). Interestingly, we observed many enriched binding sites 
shared between genes preferentially sensitive to MEF2A and genes preferentially 
sensitive to MEF2B, -C, and -D, but we observed no enriched binding sites that were 
only shared between MEF2B, -C, and -D in all conformations. These data suggest that in 
addition to the distinct enriched binding sites we were investigating, there may exist a 
common set of co-regulatory factors, and MEF2A may play a more prominent role in 
transcriptional regulation than the other four factors in C2C12 cells. 
 We also examined this data from the perspective of each MEF2 factor and 
uncovered interesting patterns. Specifically, genes preferentially sensitive to MEF2A had 
a far greater number of unique co-regulatory binding sites (15, representing 14% of all 
binding sites enriched in the MEF2A cohort, Figure 3.7). Additionally, distinct binding 
 71 
sites are rare in MEF2B (1, 1.43%) and MEF2D (2, 5%), and no binding site was found 
to be enriched only in the MEF2C-sensitive gene cohort. It is obvious from these data 
that while the presence of a single co-regulatory factor may explain some of the distinct 
transcriptional regulation between MEF2 family members, it is unlikely to be the 
explanation for all differential transcriptional activity. 
 We then compiled a list of candidate co-regulatory factors that may help explain 
our interesting transcriptional regulation difference between MEF2 family members 
(Table 3.4). As mentioned previously, a binding site was only considered enriched if the 
Z-score (enrichment score) exceeded 2.0. The majority of candidate proteins are 
members of the C2H2 zinc finger or homeodomain transcription factor superfamilies 
(Doerks et al. 2002, Svingen et al. 2006, Liu et al. 2008). On the other hand, this analysis 
did reveal a subset of specific factors that are associated with genes preferentially 
regulated by individual MEF2 factors (Table 3.4). Through de novo enriched binding site 
analysis of regulatory regions preferentially sensitive to individual the MEF2 factors, we 
believe we have uncovered candidate co-regulatory transcription factors that may 
partially mediate the differential regulatory control of muscle genes within the MEF2 
family.  
3.8 Discussion 
 Here we present a comprehensive analysis of the regulatory patterns of a family 
of core striated muscle transcription factors. Previous in vitro MEF2 studies have focused 
on dissecting single members of the family, but failed to consider the concurrent and 
diverse roles that other MEF2 isoforms might be playing in skeletal muscle tissue. Based 
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on the variety of phenotypes revealed in in vivo global loss-of-function mouse models, 
we hypothesized that individual MEF2 isoforms were responsible for regulating diverse 
functions in skeletal muscle. 
 Interestingly, in vitro MEF2 factor depletion experiments uncovered a required 
role for MEF2A in C2C12 myotube formation. Other MEF2 factors were dispensable for 
this pathway, but overexpression of a constitutively-active MEF2-VP16 fusion construct 
was sufficient to rescue myotube fusion. These results support a previously described role 
for MEF2A in skeletal muscle regeneration (Snyder et al. 2013). Global MEF2A KO was 
associated with an impaired regenerative capacity after muscle injury. Here we show that 
the defect may be associated with impaired myoblast differentiation and myotube fusion. 
These observations are encouraging because they validate the use of the C2C12 in vitro 
model as a means to further dissect the gross morphological phenotypes that we observe 
in vivo. 
 The fusion defect provided evidence that the MEF2 family members may regulate 
distinct transcriptional programs in skeletal muscle cells. These findings motivated us to 
perform a comparative transcriptomic analysis of genes dysregulated by individual MEF2 
depletion in C2C12 cells. This analysis yielded a surprising paucity of overlap in the 
genes dysregulated by each MEF2 factor (Figure 3.3). While we are certain that each 
overlapping regulatory group has interesting transcriptional regulation, we focused our 
initial analyses on the gene cohorts preferentially-sensitive to individual MEF2 factor 
ablation (i.e. genes that were only significantly dysregulated in the loss of MEF2A, but 
not -B, -C, and -D), and the gene cohort that are sensitive to loss of each MEF2 factor 
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individually. We hypothesized that the gene sets preferentially sensitive to individual 
MEF2 factors would reveal differently regulated cellular pathways, and in addition, may 
provide information critical to our understanding of how a family of highly related 
transcription factors can regulate transcriptional activity in so diverse a manner. 
 We first wanted to understand the cellular pathways that are regulated by these 
preferentially-dysregulated gene cohorts. We felt that a single algorithm might be 
insufficient to capture the interesting gene interactions in these cohorts, so we performed 
IPA, GO term, and KEGG pathway analyses with the hope of understanding the breadth 
of pathways that were represented in each gene set. Considering MEF2’s role in striated 
muscle development and differentiation, we were initially surprised by the lack of 
prominent muscle-specific pathways in these analyses. Upon inspection of the more 
classically muscle-associated genes, we observed that these genes were, in fact, 
dysregulated in these knockdown experiments, they were most often dysregulated in 
multiple MEF2 depletions, suggesting that intrafamily regulatory relationships influence 
the regulation of these genes. Additionally, the MEF2A-senstive gene cohort did yield 
several GO terms associated with striated muscle gene programs (Table 3.2) including 
heart development, striated muscle cell differentiation, and actin cytoskeleton 
organization. The emergence of these pathways suggests that MEF2A may be a focal 
point for the regulation of canonical muscle specific pathways.  
 In parallel to these analyses, we began analyzing the genes that were 
preferentially sensitive to the individual depletion of every MEF2 factor. This group is of 
particular interest because it may represent a group where all the MEF2 factors play a 
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relevant regulatory role. This group is a departure from the canonical thinking about 
MEF2, which suggests a high degree of redundancy in transcriptional regulation by the 
MEF2 family, yet we observed a small subset of genes that might portray quite the 
opposite, a total lack of ability of MEF2 factors to compensate for each other in the 
regulation of these genes. The gene cohort was first parsed into groups based on the 
shared direction of dysregulation in individual MEF2 depletions. Constructing these 
pattern based sets yielded a surprising set of enriched regulatory patterns (Figure 3.5). Of 
the 24 possible regulatory combinations, we only observed 5 patterns that were 
represented in the gene sets. Notably, two thirds of all the genes in this cohort (14 genes) 
are downregulated in MEF2A and –D depletion, and upregulated in MEF2B and -C 
depletion, suggesting a distinct regulatory pattern where members of the MEF2 family 
regulate gene expression in opposite directions. Additionally, only a single gene, DumPY-
19-like-1 (Dpy19l1), was dysregulated in the same direction by individual MEF2 
depletions. While ceMEF2 depletion itself has no obvious phenotype in C. elegans (ref), 
Dpy19l1, is a gene that has a putative role in regulation of muscle development 
(Watanabe et al. 2011, Buettner et al. 2013). 
 We proceeded through an extensive literature search to determine the cellular 
function of the candidate cofactors and potentially further highlight key candidates for 
further investigation (Table 3.4). Four of the enriched binding sites are bound by 
transcription factors that play a role in skeletal muscle differentiation. In the MEF2A-
sensitive cohort, distal-les homeobox factors Dlx1-6 were among the most enriched 
factors. Dlx factors play a pivotal role in craniofacial development, and while a muscle 
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specific role for Dlx factors has yet to be characterized, a closely related cousin, Msx1, is 
associated with maintenance of an undifferentiated state during the developmental 
migration of skeletal muscle precursors (Bendall et al. 2000). Zfhx3/Atbf1, another 
enriched binding site in the MEF2A-sensitive cohort is a well characterized inhibitor of 
myogenic differentiation whose primary function is to inhibit binding of pro-myogenic 
bHLH factors by occupying E-box binding sites (Berry et al. 2001). Additionally, one 
splice variant, Zfhx3-B, as a transcriptional activator and promotes myogenic 
differentiation (Berry et al. 2001). 
 The two families of transcription factors that bind the enriched sites in MEF2D-
sensitive genes regions also play roles in myogenic differentiation. Specifically Meis1 
and Pknox2 are members of a small transcription factor family that function as pioneer 
transcription factors in skeletal muscle to stabilize MyoD/E12 DNA-binding on 
suboptimal E-box sites (Knoepfler et al. 1999, Heidt et al. 2007, Grade et al. 2009). 
Finally, Gtf2ird1/Gtf3 is the second transcription factor family associated with enriched 
binding sites in MEF2D-sensitive regulatory regions. This factor shares high similarity to 
TFII-1, potentially playing an important role in the integration of muscle-specific 
transcriptional signaling and the general transcriptional apparatus (O'Mahoney et al. 
1998). Interestingly, the human ortholog of Gtf3 is found in a region that is deleted in 
Williams-Beuren syndrome, a disease that is associated with muscle weakness and 
atrophy (Tassabehji et al. 1999). Of the genes localized to this deleted region, Gtf3 is the 
only one associated with skeletal function, supporting our analysis that this transcription 
factor may play an important role in skeletal muscle (Tassabehji et al. 1999). Through de 
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novo enriched binding site analysis of regulatory regions preferentially sensitive to 
individual MEF2 factors; we believe we’ve uncovered candidate co-regulatory 
transcription factors that may partially mediate the differential regulatory control of 
muscle genes within the MEF2 family.  
 Unfortunately, our analysis did not uncover any enriched transcription factor 
binding sites yielding candidates that might explain the MEF2C preferentially sensitive 
gene set. We suspect that this may be due to issues arising from not being able to 
determine which of the dysregulated genes direct MEF2 targets are, and which secondary 
effects are. Since this is the case, it is possible that either MEF2C sensitive regulation is 
caused by some unique combination of cofactors, or that we lack the analytical resolution 
to truly assess what may be a very small number of unique co-regulatory transcription 
factor reactions in the case of MEF2C. 
 This study reveals complex isoform-specific transcriptional regulatory networks 
focused on the mammalian MEF2 transcription factors in C2C12 differentiation. While 
we acknowledge that the in vitro C2C12 model is distinct from primary skeletal 
myogenesis, we believe that the patterns we have observed will shed additional light on 
the complicated coordination of myogenesis in mammalian skeletal muscle tissue. 
Additionally, our comprehensive computational analyses introduce a new level of 
understanding of the intrafamily dynamics of the MEF2 factors, and reveal that 
reductionist analysis of these factors in isolation fails to appropriately encompass the 
features of this transcription factor family. 
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Figure 3.1 Depletion of Mef2a, but not -b, -c, or -d transcript caused a myotube 
fusion defect. C2C12 myoblasts were transduced with Mef2 shRNA adenovirus then 
allowed to differentiate for three days. A, Bright field microscopy of differentiating 
myotubes in each Mef2 shRNA treatment. Only depletion of Mef2a caused a noticeable 
phenotype. B, Loss of myotube fusions is concurrent with decreased Myosin heavy chain 
(MHC) protein expression. C, Quantification of MHC protein expression in Mef2 
shRNA-treated myotubes reveals a significant reduction in MHC expression only in 
Mef2a-depleted C2C12 myotubes. Data are means (n=3) ± S.E.M. (error bars). *, p˂0.05; 
** p˂0.01; *** p˂0.001. 
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Figure 3.2 Overexpression of a constitutively-active MEF2 construct rescues 
myotube fusion. Mef2a shRNA adenovirus was co-transduced with MEF2 
overexpression adenoviruses in C2C12 myoblasts. Myoblasts were then induced to 
differentiate for three days and myotube fusion was assessed. A, Bright-field microscopy 
of transduced C2C12 reveals restored myotube fusion with MEF2-VP16 overexpression 
in Mef2a-depleted C2C12 cells. B, A representative immunoblot shows restoration of 
Myosin heavy chain (MHC, a marker of myocyte differentiation) in MEF2-VP16 
overexpression. C, Quantification of MHC protein expression in C2C12 cells shows 
restored MHC expression only in the MEF2-VP16 treatment. Data are means (n=3) ± 
S.E.M. (error bars). *, p˂0.05; ** p˂0.01; *** p˂0.001. 
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Figure 3.3 Comparative analysis of MEF2 knockdown gene sets. Comparative 
microarrays were performed in triplicate for each Mef2 shRNA virus and dysregulation 
was compared to the shLacZ negative control. Microarray analysis reveals that C2C12 
cells are differentially sensitive to depletion of the MEF2 isoforms. A, A summary of the 
significantly dysregulated (p˂0.05) genes sensitive to the depletion of each MEF2 
isoform shows that over 50% of genes dysregulated by MEF2 depletion are sensitive to 
the loss of MEF2A. B, a composite Venn diagram incorporating all overlapping gene sets 
as determined by Tukey’s honest significant difference post-hoc test (q˂0.05). 
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Figure 3.4 Quantitative RT-PCR validation of microarray gene dysregulation. A 
subset of genes dysregulated (up- and downregulated) in each MEF2 isoform depletion 
was quantified using RT-PCR. Cdkn1c, cyclin-dependent kinase inhibitor 1c; Sept4, 
septin 4;Hspb7, heat shock protein family member 7(cardiovascular); Myom1, myomesin 
1; Stc2, stanniocalcin 2; Tex16, testis expressed gene 16; Selp, selectin (platelet); C1ql1, 
complement component 1, q subcomponent-like-1; Bace2, beta-site APP-cleaving enzyme 
2; Pi16, peptidase inhibitor 16; Themis, thymocyte selection associated; Selp, selectin 
(platelet); Glipr1, GLI pathogenesis-related 1 like 1; Cpa4, carboxypeptidase A4; 
Fam78a, family with sequence similarity 78, member A; Ppp1r3a, protein phosphatase 1, 
regulatory (inhibitor) subunit 3a. Data are means (n=3) ± S.E.M. (error bars). *, p˂0.05; 
** p˂0.01; *** p˂0.001. 
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Figure 3.5 Regulatory patterns of genes sensitive to the depletion of each MEF2 
isoform. Only 21 genes were dysregulated upon the depletion of each MEF2 isoform. 
These genes were parsed into groups based on the direction of dysregulation upon 
depletion of each MEF2 isoform. Only five of the possible patterns of dysregulation are 
represented, and nearly 67% of genes were downregulated in the loss of MEF2A or -D, 
and upregulated in the loss of MEF2C, or –D. Additionally, only a single gene, Dpy19l1 
(DumPY19-like 1), is downregulated in each MEF2 factor depletion. 
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Figure 3.6 Putative MEF2 binding sites from gene preferentially sensitive to 
individual MEF2 factor depletion. FIMO (MEME suite) analysis extracted putative 
MEF2 binding sites from the proximal 5kb upstream region of the transcriptional start 
site of each gene dysregulated in MEF2 depletion. The analysis identified 3814 potential 
sites in MEF2A-sensitive genes, 152 sites in MEF2B sensitive genes, 137 sites in 
MEF2C sensitive genes, and 36 sites in MEF2D sensitive genes. These sites were 
compiled into position-weight matrices describing binding sites associated with 
preferential sensitivity to loss of a single MEF2 factor, and sequence logos were built. 
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Figure 3.7 Identification of distinct transcription factor binding sites associated with 
each MEF2 knockdown gene set. Transcription factor binding site enrichment analysis 
(Genomatix) was performed on the proximal 5kb upstream region of genes preferentially 
sensitive to the depletion of a single MEF2 factor. A binding site was considered 
enriched if it had a Z-score ˃ 2.0. A, Nearly 43% of enriched binding sites were shared 
by all four gene sets, 32% were shared by three MEF2 gene sets, 18% were shared by 
two, and only 7% were unique to genes dysregulated by depletion of a specific MEF2 
isoform. B, Binding sites were parsed based on their presence in genes dysregulated by 
individual MEF2 factors. MEF2A showed the greatest number of distinct TF binding 
sites (14%), and MEF2C lacked any unique binding sites. 
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Canonical Pathway p-value Ratio 
MEF2A     
Molecular Mechanisms of Cancer 2.40E-08 92/387 (0.238) 
Calcium Signaling 2.26E-07 55/217 (0.253) 
Germ Cell-Sertoli Cell Junction Signaling 6.20E-06 46/169 (0.272) 
Actin Cytoskeletal Signaling 1.63E-05 57/242 (0.236) 
Signaling by Rho Family GTPases 1.96E-05 60/262 (0.229) 
   MEF2B     
Hepatic Fibrosis/Hepatic Stellate Cell Activation 1.31E-03 5/155 (0.032) 
Ovarian Cancer Signaling 7.57E-03 4/152 (0.026) 
Human Embryonic Stem Cell Pluripotency 7.77E-03 4/161 (0.025) 
Ceramide Signaling 1.13E-02 3/91 (0.033) 
Apoptosis Signaling 1.47E-02 3/100 (0.03) 
   MEF2C     
Cell Cycle: G1/S Checkpoint Regulation 3.14E-03 3/68 (0.044) 
Eicosanoid Signaling 3.14E-03 3/85 (0.035) 
Molecular Mechanisms of Cancer 5.49E-03 6/387 (0.016) 
Estrogen-mediated S-phase Entry 5.48E-03 2/28 (0.071) 
Sulfate Activation for Sulfonation 9.42E-03 1/8 (0.125) 
   MEF2D     
Role of JAK2 in Hormone-like  Cytokine Signaling 4.03E-02 1/37 (0.027) 
Hypoxia Signaling in the Cardiovascular System 7.69E-02 1/68 (0.015) 
RhoA Signaling 1.32E-01 1/122 (0.008) 
Artherosclerosis Signaling 1.37E-01 1/138 (0.007) 
AMPK Signaling 1.50E-01 1/180 
   All MEF2     
Regulation of Cellular Mechanics by Calpain 
Protease 3.20E-05 3/73 (0.041) 
nNOS Signaling in Neurons 1.20E-03 2/52 (0.038) 
Integrin Signaling 1.24E-03 3/208 (0.014) 
Amyloid Processing 1.41E-03 2/61 (0.033) 
FAK Signaling 4.05E-03 2/106 (0.019) 
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Table 3.1 IPA canonical pathway analysis of gene sets preferentially sensitive to 
MEF2 factor depletion. Each preferentially sensitive gene set, and the set of 21 genes 
sensitive to every MEF2 isoform were analyzed using the Ingenuity Pathway Analysis 
algorithm. The top five most significantly dysregulated canonical pathways are provided. 
All the canonical pathways were considered significantly sensitive to specific MEF2 
factor depletion (p˂0.05) with the exception of MEF2D-sensitive canonical pathways. 
The table also provides the ratio of genes dysregulated in each canonical pathway against 
the total number of genes in each pathway. 
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GO Term Count % p-value 
MEF2A       
GO:0006793~phosphorus metabolic process 215 6.65 2.10E-11 
GO:0006796~phosphate metabolic process 215 6.65 2.10E-11 
GO:0016310~phosphorylation 183 5.66 8.30E-11 
GO:0006468~protein amino acid phosphorylation 167 5.16 8.92E-11 
GO:0046907~intracellular transport 119 3.68 1.83E-09 
GO:0007049~cell cycle 144 4.45 1.63E-06 
GO:0030029~actin filament-based process 54 1.67 2.72E-06 
GO:0008104~protein localization 170 5.26 2.94E-06 
GO:0016568~chromatin modification 66 2.04 6.43E-06 
GO:0007507~heart development 63 1.95 7.53E-06 
GO:0042692~muscle cell differentiation 39 1.21 1.02E-05 
GO:0006665~sphingolipid metabolic process 25 0.77 1.71E-05 
GO:0015031~protein transport 146 4.51 2.28E-05 
GO:0006643~membrane lipid metabolic process 25 0.77 3.17E-05 
GO:0045184~establishment of protein localization 146 4.51 3.41E-05 
GO:0051146~striated muscle cell differentiation 31 0.96 3.84E-05 
GO:0034613~cellular protein localization 76 2.35 4.71E-05 
GO:0030036~actin cytoskeleton organization 48 1.48 4.75E-05 
GO:0006886~intracellular protein transport 71 2.20 5.73E-05 
GO:0070727~cellular macromolecule localization 76 2.35 5.97E-05 
    MEF2B       
GO:0048514~blood vessel morphogenesis 9 7.14 3.85E-05 
GO:0001568~blood vessel development 9 7.14 1.66E-04 
GO:0001944~vasculature development 9 7.14 1.96E-04 
GO:0007389~pattern specification process 9 7.14 4.62E-04 
GO:0060688~regulation of morphogenesis of a  
branching structure 4 3.17 5.27E-04 
GO:0001763~morphogenesis of a  
branching structure 6 4.76 1.23E-03 
GO:0042471~ear morphogenesis 5 3.97 1.42E-03 
GO:0001525~angiogenesis 6 4.76 1.62E-03 
GO:0048706~embryonic skeletal  
system development 5 3.97 1.96E-03 
GO:0048598~embryonic morphogenesis 9 7.14 2.09E-03 
GO:0008284~positive regulation  
of cell proliferation 8 6.35 2.27E-03 
GO:0001501~skeletal system development 8 6.35 2.32E-03 
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GO:0003002~regionalization 7 5.56 2.49E-03 
GO:0030878~thyroid gland development 3 2.38 3.51E-03 
GO:0042474~middle ear morphogenesis 3 2.38 3.51E-03 
GO:0048562~embryonic organ morphogenesis 6 4.76 3.71E-03 
GO:0043583~ear development 5 3.97 4.43E-03 
GO:0048568~embryonic organ development 7 5.56 4.47E-03 
GO:0007517~muscle organ development 6 4.76 5.41E-03 
GO:0043009~chordate embryonic development 9 7.14 5.49E-03 
    MEF2C       
GO:0046456~icosanoid biosynthetic process 3 3.03 6.27E-03 
GO:0006636~unsaturated fatty acid  
biosynthetic process 3 3.03 6.73E-03 
GO:0006690~icosanoid metabolic process 3 3.03 9.82E-03 
GO:0033559~unsaturated fatty acid  
metabolic process 3 3.03 1.10E-02 
GO:0030097~hemopoiesis 5 5.05 2.47E-02 
GO:0002063~chondrocyte development 2 2.02 3.48E-02 
GO:0048534~hemopoietic or  
lymphoid organ development 5 5.05 3.54E-02 
GO:0010558~negative regulation  
of macromolecule biosynthetic process 6 6.06 3.69E-02 
GO:0001501~skeletal system development 5 5.05 3.70E-02 
GO:0008610~lipid biosynthetic process 5 5.05 3.70E-02 
GO:0031327~negative regulation  
of cellular biosynthetic process 6 6.06 4.09E-02 
GO:0002520~immune system development 5 5.05 4.11E-02 
GO:0009890~negative regulation  
of biosynthetic process 6 6.06 4.23E-02 
GO:0045892~negative regulation  
of transcription, DNA-dependent 5 5.05 4.69E-02 
GO:0007242~intracellular signaling cascade 9 9.09 4.69E-02 
GO:0006631~fatty acid metabolic process 4 4.04 4.77E-02 
GO:0051253~negative regulation  
of RNA metabolic process 5 5.05 4.78E-02 
GO:0006633~fatty acid biosynthetic process 3 3.03 4.97E-02 
    MEF2D       
GO:0022402~cell cycle process 5 17.86 1.22E-03 
GO:0000279~M phase 4 14.29 4.90E-03 
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GO:0007049~cell cycle 5 17.86 6.03E-03 
GO:0022403~cell cycle phase 4 14.29 7.37E-03 
GO:0000087~M phase of mitotic cell cycle 3 10.71 2.40E-02 
GO:0000278~mitotic cell cycle 3 10.71 3.66E-02 
 
Table 3.2 Gene Ontology (GO) term analysis of gene sets preferentially sensitive to 
MEF2 factor depletion. GO term analysis was performed using the DAVID 
bioinformatics database. This table presents the top 20 dysregulated GO terms sensitive 
to specific MEF2 factor depletion. The table also includes the number of genes 
dysregulated (Count), percentage of the pathway dysregulated (%), a p-value showing 
statistically dysregulated pathways (p-value; p˂0.05 was considered significant).  
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KEGG Pathway Count % p-value 
MEF2A       
mmu04142:Lysosome 43 1.33 5.91E-08 
mmu04115:p53 signaling pathway 25 0.77 5.47E-05 
mmu04520:Adherens junction 25 0.77 3.02E-04 
mmu05410:Hypertrophic cardiomyopathy (HCM) 26 0.80 6.24E-04 
mmu05212:Pancreatic cancer 23 0.71 8.81E-04 
mmu04710:Circadian rhythm 8 0.25 1.50E-03 
mmu04810:Regulation of actin cytoskeleton 51 1.58 1.78E-03 
mmu05210:Colorectal cancer 25 0.77 2.13E-03 
mmu00310:Lysine degradation 15 0.46 2.37E-03 
mmu00051:Fructose and mannose metabolism 14 0.43 2.52E-03 
mmu05414:Dilated cardiomyopathy 26 0.80 2.59E-03 
mmu04010:MAPK signaling pathway 59 1.82 2.84E-03 
mmu00600:Sphingolipid metabolism 15 0.46 3.06E-03 
mmu04722:Neurotrophin signaling pathway 33 1.02 3.99E-03 
mmu00604:Glycosphingolipid biosynthesis 8 0.25 4.24E-03 
mmu03030:DNA replication 13 0.40 4.60E-03 
mmu04540:Gap junction 24 0.74 4.69E-03 
mmu05200:Pathways in cancer 68 2.10 5.49E-03 
mmu05211:Renal cell carcinoma 20 0.62 8.19E-03 
mmu05412:Arrhythmogenic right  
ventricular cardiomyopathy (ARVC) 21 0.65 8.35E-03 
    MEF2B       
mmu05200:Pathways in cancer 6 4.76 3.55E-02 
mmu04920:Adipocytokine signaling pathway 3 2.38 5.62E-02 
mmu03320:PPAR signaling pathway 3 2.38 7.51E-02 
    MEF2C       
mmu04630:Jak-STAT signaling pathway 5 5.05 5.17E-03 
mmu00590:Arachidonic acid metabolism 3 3.03 5.75E-02 
mmu05222:Small cell lung cancer 3 3.03 5.99E-02 
mmu05200:Pathways in cancer 5 5.05 6.22E-02 
    MEF2D       
mmu03018:RNA degradation 2 7.14 7.10E-02 
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Table 3.3 KEGG pathway analysis of gene sets preferentially sensitive to MEF2 
factor depletion. KEGG pathway analysis was performed using the DAVID 
bioinformatics database. This table presents the top 20 dysregulated KEGG pathways 
sensitive to specific MEF2 factor depletion. The table also includes the number of genes 
dysregulated (Count), percentage of the pathway dysregulated (%), a p-value showing 
statistically dysregulated pathways (p-value; p˂0.05 was considered significant).  
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Table 3.4 List of candidate co-regulatory factors from transcription factor binding 
site enrichment analysis. The Genomatix transcription factor binding site enrichment 
analysis revealed a subset of co-regulatory proteins distinct to gene sets preferentially 
sensitive to only a single MEF2 factor depletion. Here we present these candidate co-
factors with a brief description of their family, the enrichment score (Z-score ˃2 
considered enriched), the family members known to bind the enriched binding site, the 
binding domain of these proteins, and finally a brief literature search description of the of 
the function of each candidate co-factor, focusing on any roles played in skeletal or 
cardiac muscle. Interestingly, genes preferentially sensitive to MEF2C depletion did not 
have any unique enriched TF binding sites. 
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CHAPTER FOUR: Antagonistic regulation of cell cycle and differentiation gene 
programs in neonatal cardiomyocytes by homologous MEF2 transcription factors 
 
Parts of this research are in revision for a submission to the Journal of Biological 
Chemistry (1/10/17). 
4.1 Introduction 
 Cardiac development involves precise integration of specification, 
proliferation, and differentiation gene programs in cardiomyocytes and non-muscle cell 
types (Srivastava 2006, Vincent et al. 2010, Paige et al. 2015). The gene regulatory 
network that drives heart organogenesis is controlled by a core of evolutionarily 
conserved cardiac transcription factors (TFs) (Olson 2006, Waardenberg et al. 2014). 
MEF2 is a key member of this core group whose activity is essential for cardiac 
development in numerous animal species (Potthoff et al. 2007, Desjardins et al. 2016). 
Vertebrates have evolved multiple isoforms of MEF2 (MEF2A, B, C, and D), thereby 
broadening the gene regulatory potential of this cardiac TF and adding additional layers 
of complexity to the transcriptional circuitry of cardiac organogenesis. The diverse 
regulatory roles of MEF2 in the heart are exemplified by the distinct array of 
cardiovascular phenotypes associated with knockout or inhibition of individual MEF2 
genes in vertebrate model systems (Lin et al. 1997, Naya et al. 2002, Wang et al. 2005, 
Kim et al. 2008, Hinits et al. 2012, Guo et al. 2014). While there is no doubt that MEF2 
is required for differentiation and regulates structural genes in muscle (Black et al. 1998, 
Estrella et al. 2014), the repertoire of gene programs controlled by this family in 
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cardiomyocytes is largely unknown. Based on the range of cellular processes mediated by 
MEF2 isoforms in other specialized cell types such as neurons, the regulatory potential of 
this core cardiac TF has not been fully realized in cardiomyocytes. 
The perinatal period is a critical time for proper cardiac maturation during which 
differentiated cardiomyocytes with persistent proliferative capacity are programmed to 
permanently exit the cell cycle (Pasumarthi 2002, Ahuja et al. 2007, Zacchigna et al. 
2014). Cardiomyocyte quiescence will prevent further growth of the heart through cell 
division, instead promoting growth by increases in cardiomyocyte size. Perhaps not 
coincidentally, it is also the time during which the mammalian heart begins to lose its 
ability to regenerate (Porrello et al. 2011, Foglia et al. 2016). Neonatal cardiomyocytes 
also undergo radical switches in metabolic pathways and contractile protein isoforms to 
fully commit to the mature differentiated phenotype (Murphy 1996, Murray et al. 2014). 
We understand surprisingly little about the mechanisms by which cell cycle exit and 
terminal differentiation are coordinated considering the importance of precisely executing 
these processes for adult cardiomyocyte homeostasis and function.  
We have previously reported that neonatal cardiomyocyte homeostasis is 
dependent on MEF2. Cytoarchitectural (costamere/muscle focal adhesion) and cell cycle 
gene programs in neonatal cardiomyocytes were shown to be regulated by MEF2A and D 
protein isoforms, respectively (Ewen et al. 2011, Estrella et al. 2015). Interestingly, 
defects in these distinct gene programs both led to severely impaired cardiomyocyte 
survival. Based on the importance of MEF2 for cardiomyocyte survival we wanted to 
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explore the global gene programs that mediate this process further by performing an 
unbiased gene expression pathway analysis of all MEF2 protein isoforms. 
The gene regulatory function of MEF2 isoforms has typically been studied 
individually. Here we present a comprehensive morphological and genome-wide 
transcriptomic analysis on the three major cardiac MEF2 isoforms, MEF2A, C, and D, in 
neonatal cardiomyocytes under identical conditions. MEF2A and D but not MEF2C were 
found to be essential for cardiomyocyte survival. Consistent with these differential effects 
on survival, a detailed computational analysis uncovered distinct roles for these protein 
isoforms in cell cycle and structural gene regulation. The results of this study reveal an 
entirely unexpected antagonistic regulatory role among MEF2 isoforms and have 
provided a mechanistic understanding of the intricate transcriptional relationships among 
homologous proteins in a core cardiac transcription factor family. 
4.2 Quantification of relative Mef2 transcript expression in NRVMs 
 While expression of Mef2 transcripts has been qualitatively examined in mouse 
cardiac development (Edmonson et al. 1994), the relative expression of the four 
mammalian Mef2 transcripts has never been quantified specifically in cardiomyocytes. 
Using quantitative RT-PCR, we found that Mef2a is the most abundant isoform in 
neonatal rat ventricular myocytes (NRVMs) (Table 4.1). Mef2c and -d displayed similar 
expression levels and were 22- to 25-fold lower than Mef2a, respectively. Mef2b 
transcripts were largely undetectable in NRVMs, expressed at levels 350-fold lower than 
that of Mef2a. Based on these results, MEF2A, C, and D were deemed to be the 
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predominant MEF2 isoforms expressed in NRVMs and our analysis is restricted to these 
three MEF2 factors. 
4.3 Neonatal cardiomyocyte survival is dependent on MEF2A and –D but not –C 
 NRVMs were transduced with MEF2 isoform-specific shRNA adenoviruses and 
examined three days post-transduction. Analysis of MEF2 expression in each of the 
isoform knockdowns revealed efficient inhibition of the respective MEF2 isoform (Figure 
4.1). We have previously demonstrated the isoform-specificity of these shRNAs and did 
not observe cross-reactivity with other MEF2 proteins (Estrella et al. 2015). Interestingly, 
we observed downregulation of Mef2d in Mef2a deficient NRVMs, and a reciprocal 
downregulation of Mef2a in Mef2d NRVMs (Figure 4.1). In contrast, Mef2c deficiency 
did not affect endogenous expression of Mef2a or -d. Finally, with the exception of an 
upregulation of Mef2c in Mef2d deficient NRVMs, there was no compensatory 
upregulation of Mef2 isoforms in response to our acute ablation of individual MEF2 
isoform expression using these vectors. Given the previously described specificity of 
these shRNAs, we conclude that the reciprocal downregulation of Mef2a and –d 
transcripts is likely to be transcriptional co-regulation within the MEF2 family in 
NRVMs.  
 Previous studies have described distinct in vivo loss of function phenotypes for 
mammalian MEF2 family members (Lin et al. 1997, Naya et al. 2002, Kim et al. 2008). 
We evaluated whether acute Mef2 isoform knockdown caused distinct morphological 
defects in NRVMs. Knockdown of Mef2a resulted in reduced cardiomyocyte number 
(Figure 4.2), decreased viability (Figure 4.3A), and increased cleaved caspase-3 activity, 
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an indicator of programmed cell death (Figure 4.3B). Mef2d knockdown also resulted in a 
significant reduction in cardiomyocyte viability and increase in caspase-3 activity (Figure 
4.2, 4.3). By contrast, Mef2c knockdown did not impair NRVM survival. These results 
indicate that MEF2A and MEF2D are necessary for neonatal cardiomyocyte survival, and 
MEF2C is not.  
 To determine whether MEF2 proteins function redundantly in cardiomyocyte 
survival we performed double and triple MEF2 isoform knockdowns. Pairwise 
knockdowns of Mef2 isoforms did not modulate the previously observed impaired 
viability phenotype (Figure 4.3), and an effect of Mef2c knockdown did not emerge in 
combination with Mef2a knockdown, Mef2d knockdown, or Mef2a/d knockdown 
NRVMs (Figure 4.2, 4.3). These results demonstrate that MEF2C is dispensable for 
NRVM survival and does not have a role masked by the presence of MEF2A or -D in 
normal NRVM survival. However, while MEF2A and -D appear to both be required for 
NRVM survival, Mef2a-deficiency led to earlier loss of NRVM survival with adverse 
effects on viability observable at 48 hr (data not shown).  
4.4 MEF2 overexpression in MEF2A-depleted NRVMs 
 To determine if overexpression of any MEF2 isoform is sufficient to rescue the 
Mef2a deficient loss of NRVM viability, we overexpressed MEF2A, C, D, and MEF2-
VP16, a constitutive MEF2 activator, in Mef2a-deficient myocytes. Overexpression of 
MEF2A, D, or MEF2-VP16 abrogated the loss of cardiomyocytes and significantly 
decreased cleaved caspase-3 activity in Mef2a-deficient NRVMs (Figure 4.4 and 4.5). By 
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contrast, overexpression of MEF2C failed to prevent cardiomyocyte loss and did not 
significantly reduce cleaved caspase-3 activity in Mef2a knockdown NRVMs. 
 Based on this intriguing isoform-specific difference we bolstered our analysis by 
measuring DNA degradation using propidium iodide staining followed by flow 
cytometry. As shown in Figure 4.6, shLacZ control NRVMs contain a population of cells 
with diploid (2n) through tetraploid (4n) DNA content portraying the known 
heterogeneity of mono- and binucleated neonatal myocytes (Figure 4.6A, left panel). 
Mef2a knockdown resulted in a significant redistribution of this DNA content profile, 
with the emergence of a peak representing, myocytes containing sub-2n DNA content 
(Figure 4.6A, right panel), consistent with elevated DNA fragmentation observed in 
apoptosis. 
 We subsequently evaluated the ability of MEF2 isoforms to reduce the sub-2n 
fragmented DNA fraction and restore normal DNA content in Mef2a-deficient NRVMs. 
Overexpression of all MEF2 isoforms promoted similar effects on the sub-2n population. 
MEF2A, C, and MEF2-VP-16 significantly reduced the number of myocytes with this 
irregular sub-2n DNA content (Figure 4.6B, right set of bars), and MEF2D 
overexpression also reduced the sub-2n myocyte population but this difference did not 
reach statistical significance. These results demonstrate that overexpression of MEF2 
isoforms is sufficient to diminish DNA fragmentation in Mef2a-deficient NRVMs. 
Interestingly, while MEF2C overexpression failed to rescue cell viability and reduce 
cleaved caspase-3 activity in MEF2A depleted NRVMs, it had a favorable effect on 
genomic DNA integrity. These results suggest that MEF2C is distinct from other MEF2 
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isoforms in that its apparent compensatory activity is restricted to a late stage in the 
apoptotic pathway, while being unable to modulate earlier steps, or ultimately affect 
survival. 
 Further analysis of the DNA content profile revealed previously uncharacterized 
effects of MEF2 isoform overexpression on the cardiomyocyte genome. MEF2A 
overexpression in Mef2a-deficient NRVMs resulted in a significant reduction in the sub-
2n population and a modest increase in myocytes harboring 2n, 2n-4n, and 4n DNA 
content (Figure 4.6C). These increases likely represent the myocyte population that was 
rescued from apoptotic DNA fragmentation by MEF2A overexpression. A similar effect 
and profile was observed for MEF2-VP16. By contrast, MEF2D overexpression in Mef2a 
deficiency resulted in significantly more myocytes with 2n compared to MEF2A 
overexpression and fewer cells containing 2n-4n and 4n DNA content. Curiously, 
MEF2C overexpression in the MEF2A depleted background displayed a profile quite 
distinct from MEF2A, D, and MEF2-VP16. This population displayed a significant 
decrease in diploid (2n) NRVMs and a significant increase in myocytes with 2n-4n and 
4n DNA content. By thoroughly analyzing the DNA content profile of Mef2a deficient 
NRVMs overexpressing various MEF2 proteins we have demonstrated that, despite their 
ability to rescue DNA fragmentation (sub-2n), these isoforms elicited differing effects on 
the genomic DNA content. 
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4.5 Genome-wide transcriptomics and comparative analysis of individual MEF2 
knockdowns in NRVMs 
 The contrasting effect of MEF2A, C, and D on cardiomyocyte survival and DNA 
content suggested distinct regulatory functions of these isoforms despite their largely 
indistinguishable transcriptional activities in vitro. This hypothesis is also supported by 
previously characterized distinct in vivo loss-of-function phenotypes. Thus, we performed 
global gene expression profiling to determine what sets of genes and cellular processes 
are regulated by individual MEF2 proteins in neonatal cardiomyocytes. 
 Transcriptomic analysis of NRVMs depleted of individual MEF2 proteins 
resulted in overlapping but largely distinct dysregulated gene sets. Using stringent 
statistical criteria (see Chapter Two), the most striking effect on gene expression in 
NRVMs was observed in MEF2A knockdown. As shown in Figure 4.7A, knockdown of 
Mef2a revealed 3,197 significantly dysregulated genes, representing 43% of the total 
number of dysregulated genes. Knockdown of Mef2c and Mef2d resulted in only 471 and 
786 dysregulated genes, or 6.4 and 10.6% of the total, respectively. In terms of 
overlapping dysregulated genes, MEF2A and D gene sets had 20% of the genes in 
common, which was the highest percent of all the MEF2 isoform comparisons (Figure 
4.7B). This was followed by 9% of commonly dysregulated genes between MEF2A and 
C. The lowest overlap was observed in the genes shared between MEF2C and D, 
representing 2.8% of the total. Finally, only 8.2% of the dysregulated genes were shared 
in all three MEF2 isoform knockdowns (Figure 4.7B).  
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 These dysregulated gene expression levels were subsequently validated by qRT-
PCR analysis on a subset of the top dysregulated genes, top two upregulated and down-
regulated genes, from each individual MEF2 knockdown. As shown in Figure 4.8, the 
vast majority of genes in each MEF2 isoform gene set examined displayed the expected 
dysregulation. 
4.6 Classification of cellular processes in MEF2 knockdown gene sets 
 To gain insight into the distinct roles of the MEF2 family in NRVMs, the 
dysregulated, non-overlapping genes in each subgroup were categorized into cellular 
processes using Ingenuity Pathway Analysis (IPA). 
 IPA of MEF2 isoform-sensitive gene sets revealed vastly different cellular 
processes in the preferentially dysregulated target genes from each MEF2 knockdown 
(Table 4.2). Many genes distinctly sensitive to MEF2A play roles in cell-cell junction 
signaling and cancer pathways. By contrast, genes preferentially regulated by MEF2C are 
involved in energy production in mitochondria. And genes regulated by MEF2D are 
involved in cellular growth (HIPPO pathway) and survival (PI-3 kinase signaling). 
Finally, the group of genes sensitive to all three MEF2 isoforms functions in multiple 
aspects of the cell cycle including DNA replication and DNA damage checkpoints. 
Notably, this overlapping category did not have pathways in common with any of the 
significantly enriched processes in the individual MEF2 gene sets. These results reveal 
the breadth of cellular processes under MEF2 control and suggest that these gene 
programs have evolved sophisticated transcriptional mechanisms to differentiate among 
MEF2 isoforms in cardiomyocytes. 
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4.7 Complex and antagonistic patterns of dysregulated gene expression among 
MEF2 family members. 
 The emergence of a common cell cycle gene program regulated by all MEF2 
isoforms piqued our interest as this could potentially explain the effects on 
cardiomyocyte survival and genomic DNA content. Because this subset of genes is 
sensitive to all MEF2 isoforms, we hypothesized that, based on their largely 
indistinguishable transcriptional activities in vitro, these genes would be similarly 
regulated by each isoform and provide a logical starting point to mechanistically dissect 
MEF2-dependent gene regulation in cardiomyocytes. 
 Remarkably, analysis of the dysregulated patterns of the 610 common genes 
revealed that the vast majority of these genes were not similarly affected by knockdown 
of specific MEF2 isoforms (Figure 4.9). These comparisons revealed four distinct groups 
based on similarity of dysregulation in all three MEF2 knockdowns or combinations of 
two MEF2 isoforms, e.g. Shared, MEF2A/D, MEF2A/C, and MEF2C/D. Strikingly, only 
about one-third of the MEF2 isoform-sensitive genes were dysregulated in the same 
direction (Shared), but nearly two-thirds of the genes were differentially affected and 
showed the opposite dysregulation in at least one MEF2 isoform knockdown (Figure 4.9, 
right). Of these, the most predominant pattern of was the similarity in gene dysregulation 
by Mef2a and -d knockdown and the opposite dysregulation by Mef2c knockdown as 
shown in the MEF2A/D row (48%; Figure 4.9). These patterns suggest that a subset of 
pathways in cardiomyocytes dependent on all MEF2 isoforms are not regulated similarly, 
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extending the notion of isoform-specific regulation to genes functioning in common 
cellular processes. 
 Given the unexpected and disparate effects of dysregulation within the common 
group we performed IPA on those genes within the various regulatory patterns to obtain a 
comprehensive analysis of the types of cellular processes for each pattern. As shown in 
Table 4.3, the pathways for each regulatory pattern were dramatically different. Genes 
regulated in the same manner by all three MEF2 isoforms (Shared; all up- or all 
downregulated) have been shown to function primarily in fibrosis and amino acid 
biosynthesis. Those genes regulated in the same manner by MEF2A and C (A/C) and 
MEF2C and D (C/D) isoform pairs, play a role in signal transduction but the specific 
ligand-receptor pathway for each of these groups was quite distinct. The most enriched 
pathway identified in the A/C pattern of regulation belonged to ephrin signaling, a critical 
pathway in cell positioning and guidance in development. The genes present in the C/D 
regulatory pattern were enriched for cytokine and interferon pathways. The most 
intriguing result, however, was obtained for the genes exhibiting the MEF2A and D 
(A/D) regulatory pattern, where genes were similarly affected by Mef2a and -d 
knockdown but displayed the opposite dysregulation by Mef2c knockdown. Pathway 
analysis of this particular cohort, which had the largest collection of genes, revealed the 
cell cycle as the most significantly enriched pathway. This helps to explain the 
enrichment of the cell cycle program in our analysis of the 610 overlapping group of 
genes. Moreover, these data suggest a previously undescribed role for MEF2A and C 
protein isoforms in cell cycle control in cardiomyocytes, and independently confirm our 
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previous observations of MEF2D-dependent regulation of the cell cycle (Estrella et al. 
2015) 
 Based on this interesting finding we next validated the expression of select cell 
cycle genes in the individual MEF2 isoform knockdowns. These genes have been shown 
to function in DNA replication and checkpoint control. As shown in Figure 4.10, both 
MEF2A and D inhibition resulted in the upregulation of the cell cycle genes Mcm3, -5, -
6, cyclin E, and Pcna. Upregulation of the cell cycle program did not lead to increased 
proliferation but rather cell cycle re-entry followed by programmed cell death, and is 
entirely consistent with our previous characterization of MEF2D depleted NRVMs 
(Estrella et al. 2015). By contrast, Mef2c knockdown resulted in downregulation of cell 
cycle gene expression (Figure 4.10). 
 Given that cell cycle and differentiation programs are often competing forces in 
the cell, we complemented this analysis by examining the expression of representative 
sarcomere genes which are established markers of differentiated cardiomyocytes. 
Expression of the sarcomere genes myosin heavy chain 7 (Myh7), myosin light chain 2 
(Myl2), myomesin 1 and 2, and titin, in MEF2A and D depleted NRVMs was 
significantly downregulated whereas these genes were upregulated in MEF2C-depleted 
cells (Figure 4.11). These data reveal a previously unappreciated mechanism of MEF2-
dependent gene regulation in cardiomyocytes, one in which MEF2 protein isoforms 
antagonistically regulate gene programs despite their similar transcriptional activities in 
vitro. Specifically, MEF2A and -D are required for repression of cell cycle genes, and 
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activation of a subset of sarcomeric markers, and MEF2C plays an antagonistic role by 
activating cell cycle genes and repressing sarcomeric markers of differentiation. 
4.8 Identification of distinct transcription factor modules associated with MEF2-
dependent cell cycle and sarcomere genes 
 Given the lack of evidence demonstrating differences in DNA consensus 
sequence preferences of MEF2 isoforms, we hypothesized that the antagonistic 
regulatory patterns resulted from specific interactions with transcriptional coregulators. 
Therefore, upstream regulatory regions were computationally analyzed for discrete 
transcription factor (TF) modules harboring a MEF2 binding site within 50 base pairs of a 
predicted TF binding site. To identify these TF modules enriched in cell cycle genes, we 
performed module-based motif enrichment analysis (Genomatix). Modules were 
considered significantly enriched in a set of promoters if the z-score was greater than 2. 
As shown in Table 4.4, although similar TF modules were found to be overrepresented in 
both cell cycle and sarcomere genes the vast majority were unique to each gene set. 
Regarding the similar TF modules between the two groups, the basic helix-loop-helix 
(bHLH) proteins (or E-box binding factors) such as HAND, Twist, and Mesp play 
prominent and diverse roles in cardiogenesis such as specification, proliferation, and 
differentiation (Bondue et al. 2010, Conway et al. 2010, VanDusen et al. 2012), thus it is 
not surprising to find them overrepresented in both gene categories. Similarly, the MADS 
box factor SRF and the steroid receptor RXR which have pleiotropic gene regulatory 
functions (Niu et al. 2007, Evans et al. 2014), were enriched in TF modules within the 
regulatory regions of both cell cycle and sarcomere genes. Analysis of the largely unique 
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modules revealed transcriptional regulators that function downstream of Notch and 
Hedgehog signaling. These evolutionarily conserved signal transduction pathways 
emerged as the most interesting candidates because of their important role not only in 
developmental gene regulation but also in cardiogenesis (Rochais et al. 2009, de la 
Pompa et al. 2012). These upstream signals could be the linchpin to establish isoform 
selectivity in the MEF2-dependent regulation of cell cycle and sarcomere gene programs 
in cardiomyocytes in cardiac development. 
4.9 Notch and Hedgehog signaling coordinate MEF2 isoform-specific regulation of 
cell cycle and differentiation programs. 
 To determine whether Notch and/or Hedgehog signaling modulate MEF2-
dependent gene regulation in a program-specific fashion we initially evaluated the ability 
of NRVMs to respond to these pathways by examining the expression of their known 
downstream target genes, some of which are mediators of these signals. As shown in 
Figure 4.12, transduction of NRVMs with adenoviruses overexpressing constitutively 
active Sonic hedgehog (SHH-N) and the Notch intracellular domain (N1ICD) induced 
expression of the GLI (Gli1-3) and vertebrate enhancer of split (Hey2 and Hes1) TFs, 
respectively. 
 Overexpression of SHH-N was found to diminish the upregulation of cell cycle 
gene expression in NRVMs that were depleted of MEF2A and -D (Figure 4.13, left). 
SHH-N alone also had a repressive effect on cell cycle gene expression. In contrast, 
SHH-N had no significant effect on the expression of sarcomere genes either in the 
presence or absence of MEF2A and -D (Figure 4.13, right). 
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 Conversely, constitutive Notch activity further upregulated cell cycle gene 
expression in both MEF2A and D-depleted NRVMs (Figure 4.14, left). Notch alone had a 
modest effect on the expression of cell cycle genes. These data suggest that presence of 
MEF2A or -D represses the ability of Notch signaling to activate cell cycle gene 
expression. Additionally, Notch was sufficient to activate sarcomere genes, but this 
activation required the presence of MEF2A or -D (Figure 4.14, right). As depicted in the 
model in Figure 4.15, the ability of the Hedgehog signaling pathway to modulate MEF2A 
and D-dependent gene regulation is restricted to the cell cycle program. By contrast, 
Notch modulates the MEF2A and D-dependent cell cycle and sarcomere programs in 
NRVMs but in a reciprocal fashion. 
4.10 Discussion 
The mechanisms of coordinating cell cycle and differentiation programs in 
cardiomyocytes remain poorly understood. Here, we have used acute isoform-specific 
knockdown of the mammalian MEF2 proteins to demonstrate that protein isoforms of this 
evolutionarily conserved, core cardiac transcription factor have distinct regulatory roles 
in neonatal cardiomyocytes. Interestingly, we have also uncovered a previously 
uncharacterized antagonistic regulatory role between individual members of the MEF2 
family in the regulation of cell cycle and differentiation gene programs. These disparate 
roles are most evident in cardiomyocyte survival, where a differential requirement of 
specific MEF2 isoforms is observed for this process. These results reveal a mechanism 
whereby two mutually exclusive regulatory pathways can function simultaneously to 
promote proper development and growth of the heart. 
 110 
To our knowledge MEF2 represents the first transcription factor to have a dual 
and antagonistic function in the regulation of both cell cycle and differentiation 
(sarcomere) gene programs in cardiomyocytes. The forkhead box transcription factor 
family was previously demonstrated to have antagonistic roles in neonatal cardiomyocyte 
cell cycle withdrawal and proliferation (Sengupta et al. 2013). However, the opposing 
function of two family members, FoxO and FoxM1, was restricted to the cell cycle 
program. These TFs were shown to coordinate the regulation of cell cycle activators and 
inhibitors depending on nutrient availability or growth factor levels. FoxO was 
demonstrated to prevent neonatal cardiomyocyte proliferation through direct negative 
regulation of IGF1 whereas FoxM1 positively regulated this growth factor gene. In 
addition, these differential regulatory effects were mediated upstream by the activation 
status of AMPK. Since differentiation genes were not examined in that study it is 
unknown whether the forkhead TFs regulate this gene program in an antagonistic fashion. 
Another example of antagonistic transcriptional regulation is found in the 
relationship between Irx3 and Irx5. These two transcription factors share redundant 
functions during the development of the mammalian heart, but appear to play divergent 
roles in adult cardiac electrophysiology (Gabori et al. 2012). Single knockouts of each Irx 
factor leads to a loss in appropriate depolarization gradient, but double knockouts restore 
the appropriate polarization gradient. These results suggest that Irx5 is required to repress 
the function of Irx3 in specific regions of the adult heart, and provides an additional 
example of homologous cardiac transcription factors playing an antagonistic relationship 
that is required for normal cardiac homeostasis. 
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We have shown that MEF2A and MEF2D were able to rescue loss of 
cardiomyocyte viability in the context of Mef2a-deficiency. Interestingly, MEF2C 
overexpression in MEF2A depleted NRVMs failed to rescue viability and cleaved 
caspase 3 activation, but was capable of reducing apoptotic DNA degradation. 
Ultimately, MEF2C overexpression had no effect on survival, suggesting that MEF2C 
activity is not functionally redundant with and cannot compensate for MEF2A in the 
more proximal events of programmed cell death. 
We have previously described canonical pathways in the common set of 
dysregulated genes in individual MEF2 knockdowns in skeletal myoblasts (Estrella et al. 
2015). Because striated muscle cell types share many gene programs we compared the 
co-regulated MEF2 pathways between skeletal myoblasts and cardiomyocytes. Overall, 
there was no obvious overlap in the pathways regulated by all MEF2 isoforms between 
skeletal and cardiac myocytes. The co-regulated MEF2 pathways in skeletal myoblasts 
were dominated by signal transduction cascades whereas the co-regulated pathways in 
cardiomyocytes were predominately associated with cell cycle control. These 
comparisons reveal that distinct gene programs in these highly related cell types have 
evolved to largely distinct roles for MEF2 in genes transcriptionally co-regulated by all 
family members in skeletal and cardiac muscle. 
Comparison of pathways preferentially sensitive to individual MEF2 knockdowns 
in skeletal myoblast with our present data in cardiomyocytes shows distinct roles for 
MEF2 isoforms in these related striated muscle cell types. Specifically, comparison of 
gene sets preferentially sensitive to MEF2A in cardiomyocytes and skeletal myoblasts 
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revealed only two pathways, Molecular Mechanisms of Cancer and Germ Cell-Sertoli 
Cell Junction Signaling, were shared in both muscle cell types. The remaining pathways 
in NRVMs and skeletal myoblasts dependent on MEF2A did not have any obvious 
functional relationships to each other. A recently published study investigated the overlap 
of MEF2A binding in skeletal myoblasts and cardiomyocytes using ChIP-exo (Wales et 
al. 2014). While many of their enriched GO terms were distinct from our canonical 
pathways analysis, induction of apoptosis and cell death were among the enriched 
pathways in cardiomyocytes. These results support our observations that MEF2A is 
required for cardiomyocyte survival. 
Interestingly, several cell cycle pathways (G1/S Checkpoint Regulation and 
Estrogen-mediated S-phase Entry) were shown to be significantly enriched in MEF2C 
depleted skeletal myoblasts. This is in stark contrast to the enrichment of this gene 
program in MEF2A and D depleted cardiomyocytes. The most significantly enriched 
canonical pathways preferentially dysregulated by Mef2c knockdown in NRVMs are 
associated with energy metabolism, suggesting a distinct role for MEF2C in 
cardiomyocyte metabolism that is not shared in skeletal muscle. 
Knockdown of Mef2d displayed the most disparate effect on pathway enrichment 
in both striated muscle cell types. There was very little overlap between specific 
pathways preferentially dysregulated in skeletal and cardiac myocytes. For this MEF2 
isoform, cytokine, hypoxia, and AMPK signaling were enriched in skeletal myoblasts 
whereas HIPPO, PI-3kinase, and neuregulin pathways were sensitive to MEF2D in 
NRVMs. The majority of pathways preferentially dysregulated by Mef2d knockdown in 
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both models are generally associated with signal transduction, suggesting a distinct role 
for MEF2D in integrating cell signaling in both muscle cell types.  
The presence of canonical MEF2 binding sites in both cell cycle and sarcomere 
gene sets suggested that differential regulation might be mediated by program exclusive 
co-regulators. Indeed, we observed a lack of significant overlap in overrepresented 
transcription factor binding sites between the cell cycle and sarcomere genes. Among the 
most significantly enriched binding sites in cell cycle and sarcomere genes belonged to 
the TFs that mediate Hedgehog and Notch signaling, respectively. These predictions were 
validated by the ability of these upstream signals to modulate MEF2-dependent gene 
regulation. 
The Hedgehog signaling pathway has an early role in patterning of the developing 
heart (Rochais et al. 2009). Curiously, the Hedgehog signaling pathway has been shown 
to intersect with MEF2C in cardiomyocyte differentiation. That particular study showed 
that the Gli transcription factor regulates Mef2c expression to promote cardiogenesis 
(Voronova et al. 2012). In that study it was shown that the Gli transcription factor 
regulates Mef2c gene expression to promote cardiogenesis. Our present report suggests 
that Hedgehog signaling can cooperate with MEF2 to modulate cell cycle gene 
expression. 
Notch has been shown to play an important role in cardiac morphogenesis in 
multiple cell lineages in the heart including cardiomyocytes (de la Pompa et al. 2012). In 
addition, previous studies have shown that the Notch signaling pathway modulates MEF2 
activity in mammalian skeletal myoblasts (Wilson-Rawlins et al. 1999, Shen et al. 2006). 
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Notch also synergizes with MEF2 to promote proliferation in fly development (Pallavi et 
al. 2012). Although a specific function for Notch has not been ascribed to sarcomere gene 
regulation it has been shown to promote cell cycle re-entry of neonatal cardiomyocytes 
(Campa et al. 2008). Our present data suggest that Notch induction of proliferative 
markers is repressed by MEF2A and -D, introducing a potential mechanism for the loss 
of proliferative capacity observed in those studies. These results suggest a fundamental 
regulatory mechanism centered on the relative abundance of MEF2A, -C, and –D that 
mediates quiescence and terminal differentiation in cardiomyocytes. 
 We have demonstrated that protein isoforms of the mammalian MEF2 
transcription factor family antagonistically regulate cell cycle and differentiation gene 
programs in neonatal cardiomyocytes. Moreover, the ability of MEF2A and D to regulate 
disparate gene programs is modulated by Hedgehog and Notch signaling. These results 
introduce the possibility of a fundamental mechanism that determines the differentiation 
state of cardiomyocytes based on the relative expression levels of a core cardiac 
transcription factor family with respect to each other. In the future it would be interesting 
to determine whether the TFs that function downstream of Notch and Hedgehog 
physically interact with MEF2 proteins to antagonistically regulate the cell cycle and 
differentiation. 
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Figure 4.1 Mef2 shRNA adenoviral transduction efficiently and specifically depletes 
targeted Mef2 transcripts. Neonatal cardiomyocytes were transduced with Mef2 shRNA 
adenovirus for 48 hr, and Mef2 transcripts were measured. Quantitative RT-PCR analysis 
of specific shRNA knockdown efficiency shows significant knockdown of targeted Mef2 
transcripts in neonatal cardiomyocytes. Data are means (n=3) ± S.E.M. (error bars). *, 
p˂0.05; ** p˂0.01; *** p˂0.001. 
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Figure 4.2 Neonatal cardiomyocyte survival is dependent on MEF2A and –D, but 
not MEF2C. Neonatal cardiomyocytes were transduced with Mef2 shRNA adenovirus 
for 48 hr then fixed for immunocytochemistry. Immunofluorescent images of neonatal 
cardiomyocytes treated with combinations of Mef2 shRNAs shows a decrease in cell 
numbers in cultures treated with Mef2a and –d shRNA, but not Mef2c shRNA alone. 
Neonatal cardiomyocytes are characterized by α-actinin immunoreactivity (red) and 
counterstained with DAPI (blue). White arrows depict examples of typical cardiomyocyte 
morphology. 
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Figure 4.3 Mef2a and –d, but not Mef2c knockdown causes a decrease in cell 
viability and an increase in Caspase 3 activity. A, Viability of neonatal cardiomyocytes 
treated with Mef2a shRNA was measured using CellTiter Blue viability assay. Mef2a and 
–d depleted myocytes show a significant loss of viability that is not observed in Mef2c 
depleted cardiomyocytes. B, Ac-DEVD-AMC is an activated Caspase 3 substrate that 
produces fluorescence upon cleavage. Neonatal cardiomyocytes were treated with Mef2 
shRNA then lysates were incubated with Ac-DEVD-AMC to measure cleaved Caspase 3 
activity. Mef2a and –d depleted myocytes show a significant increase in Caspase 3 
activity that is not observed in Mef2c depleted cardiomyocytes. Data are means (n=3) ± 
S.E.M. (error bars). *, p˂0.05; ** p˂0.01; *** p˂0.001. 
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Figure 4.4 Overexpression of MEF2A, -D, and MEF2-VP16 reduces loss of cell 
viability caused by MEF2A knockdown. Neonatal cardiomyocytes were co-transduced 
with Mef2a shRNA and a MEF2 overexpression adenovirus for 48 hr, and then fixed for 
immunocytochemistry. Immunofluorescent images of NRVMs co-transduced with Mef2a 
shRNA and a MEF2 overexpression virus show that overexpression of MEF2A, -D, and a 
constitutively-active MEF2-VP16 increases the number of α-actinin positives cells. 
MEF2C overexpression did not appear to rescue the number of α-actinin positives cells. 
Neonatal cardiomyocytes are characterized by α-actinin immunoreactivity (red) and 
counterstained with DAPI (blue). White arrows depict examples of typical cardiomyocyte 
morphology. 
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Figure 4.5 Overexpression of MEF2A, -D, and –VP16 reduces caspase 3 activity in 
Mef2a-deficient neonatal cardiomyocytes. Ac-DEVD-AMC is an activated caspase 3 
substrate that produces fluorescence upon cleavage. Neonatal cardiomyocytes were 
treated with Mef2 shRNA then lysates were incubated with Ac-DEVD-AMC to measure 
cleaved caspase 3 activity. Overexpression of MEF2A, -D, and MEF2-VP16, but not 
MEF2C leads to a reduction in activated caspase 3 in Mef2a-deficient neonatal 
cardiomyocytes. Data are means (n=3) ± S.E.M. (error bars). *, p˂0.05; ** p˂0.01; *** 
p˂0.001. 
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Figure 4.6 Measurement of DNA content using propidium iodide staining. Neonatal 
cardiomyocytes where co-transduced with Mef2a shRNA and an overexpression virus for 
48hr. Cardiomyocytes were then fixed and stained with propidium iodide, and flow 
cytometry was performed to determine DNA content. A, Propidium iodide stained flow 
cytometry shows the emergence of a significant cell population with sub-2n DNA content 
in Mef2a shRNA treated-NRVMs. B, Quantification of flow cytometry cell populations 
measuring DNA content shows an increase in cells with sub-2n DNA content upon 
treatment with Mef2a shRNA, and a reduction of this group upon overexpression of 
MEF2 constructs. C, Measurement of neonatal cardiomyocytes containing 2n, 2n-4n, and 
4n DNA content. Data are means (n=3) ± S.E.M. (error bars). *, p˂0.05; ** p˂0.01; *** 
p˂0.001. 
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Figure 4.7 Comparative analyses of MEF2 isoform-specific transcriptomes. Neonatal 
cardiomyocytes were transduced with Mef2 shRNA for 48 hr, and then microarrays were 
performed to measure relative gene expression vs. shLacZ (negative control, n=3 arrays 
for each shRNA). A, Genes dysregulated in individual Mef2 isoform knockdowns were 
grouped into statistically related gene cohorts. A composite Venn diagram incorporating 
all overlapping gene sets (as determined by the Tukey’s HSD post hoc test , p˂0.05). B, 
A summary of total significantly dysregulated (p˂0.05) genes in each Mef2 isoform 
shRNA knockdown reveals that 43% of genes are sensitive to Mef2a knockdown, 6% are 
sensitive to Mef2c knockdown, and 10% are sensitive to Mef2d knockdown. 
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Figure 4.8 Validation of microarray gene dysregulation. Quantitative RT-PCR 
analysis of a subset of genes preferentially dysregulated in an individual Mef2 shRNA 
knockdown microarray. Dnm3, dynamin 3; Ccl5, chemokine (C-C motif) ligand 5; 
Filip1, filamin A interacting protein 1; Lrrc39, leucine rich repeat containing 39; Cirbp, 
cold inducible RNA binding protein; Adamtsl2, ADAMTS-like 2; Cdh8, cadherin 8; 
Mdga2, MAM domain containing glycosylphosphatidylinosital anchor 2; Kit, v-kit 
Hardy-Zuckerman 4 feline sarcoma viral oncogene; Sept4, septin 4; Upk1b, uroplakin 
1B; Pten, Phosphatase and tensin homolog. Gray line represents no dysregulation, data 
are means (n=3) ± S.E.M. (error bars). *, p˂0.05; ** p˂0.01; *** p˂0.001. 
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Figure 4.9 Distinct regulatory patterns of overlapping genes sensitive to all MEF2 
isoforms. Distribution of genes dysregulated in each individual knockdown based on 
pattern of dysregulation across all knockdowns. Genes dysregulated in the same direction 
in each Mef2 knockdown represent 37% of overlapping genes, genes dysregulated in the 
same direction by Mef2a and -d knockdown represent 48% of overlapping genes, genes 
dysregulated in the same direction by Mef2a and -c knockdown and Mef2c and -d 
knockdown represent 9 and 6% of overlapping genes, respectively. 
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Figure 4.10 Cell cycle related genes dysregulated in Mef2 isoform knockdown. 
Quantitative RT-PCR analysis of a subset of cell cycle related genes show upregulation 
upon the knockdown of Mef2a and -d, and downregulation in Mef2c knockdown. Mcm3, 
minichromosome maintenance component 3; Mcm5, minichromosome maintenance 
component 5; Mcm6, minichromosome maintenance component 6; Ccne1, cyclin e1; 
Pcna, proliferating cell nuclear antigen; E2f3, E2F transcription factor 3; Ccne2, cyclin 
e2. Data are means (n=9) ± S.E.M. (error bars). *, p˂0.05; ** p˂0.01; *** p˂0.001. 
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Figure 4.11 Sarcomere related genes dysregulated in Mef2 isoform knockdown. 
Quantitative RT-PCR analysis of a subset of sarcomere related genes show 
downregulation upon the knockdown of Mef2a and -d and upregulation in the knockdown 
of Mef2c. Myh7, myosin heavy chain 7, cardiac muscle, beta; Myl2, myosin light 
polypeptide 2, regulatory, cardiac, slow; Myom1, myomesin 1; Myom2, myomesin 2; Ttn, 
titin. Data are means (n=9) ± S.E.M. (error bars). *, p˂0.05; ** p˂0.01; *** p˂0.001. 
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Figure 4.12 Adenoviral overexpression of SHHN and N1ICD activate downstream 
markers. Transduction with constructs overexpressing the N-terminal SHH protein 
(SHH-N, left panel) or the Notch 1-intracellular domain (N1ICD, right panel) leads to 
efficient induction of downstream transcripts. Gli1, GLI family zinc finger 1; Gli2, GLI 
family zinc finger 2; Gli3, GLI family zinc finger 3; Hey2, hairy/enhancer-of-split related 
with YRPW motif 2; Hes1, hairy and enhancer of split 1. Data are means (n=9) ± S.E.M. 
(error bars). *, p˂0.05; ** p˂0.01; *** p˂0.001. 
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Figure 4.13 SHHN overexpression represses cell cycle genes. Quantitative RT-PCR 
analysis of a subset of cell cycle (left) and differentiation (right) transcripts in Mef2a 
shRNA alone, Mef2a shRNA and SHH-N, SHH-N overexpression alone, shRNA and 
SHH-N, and Mef2d shRNA alone (bars left to right) treatments. Data are means (n=3) ± 
S.E.M. (error bars). *, p˂0.05; ** p˂0.01; *** p˂0.001 vs. SHH-N or N1ICD treatment 
alone. 
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Figure 4.14 N1ICD overexpression represses cell cycle genes. Quantitative RT-PCR 
analysis of a subset of cell cycle (left) and differentiation (right) transcripts in Mef2a 
shRNA alone, Mef2a shRNA and N1ICD, N1ICD overexpression alone, shRNA and 
N1ICD, and Mef2d shRNA alone (bars left to right) treatments. Data are means (n=3) ± 
S.E.M. (error bars). *, p˂0.05; ** p˂0.01; *** p˂0.001 vs. SHH-N or N1ICD treatment 
alone. 
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Figure 4.15 Model of MEF2A and –D regulation of Notch and Hedgehog signaling. 
A compilation of the observed interactions of signaling and MEF2 expression 
modulations on the antagonistically regulated cell cycle and sarcomere gene sets reveals a 
putative role in MEF2A and –D in Notch-mediated signaling. 
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Table 4.1 Relative transcript expression of the Mef2 family in NRVMs. Quantitative 
reverse-transcriptase-PCR analysis of relative expression of Mef2 isoform transcripts in 
untreated NRVMs shows Mef2a transcripts are the most abundant, with Mef2b transcripts 
expressed at a 350-fold lower level, and Mef2c and –d expression at approximately 20-
fold lower levels. Data are means (n=3) ± S.E.M. (error bars). *, p˂0.05; ** p˂0.01; *** 
p˂0.001. 
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Table 4.2 Canonical pathways associated with genes preferentially dysregulated in 
individual Mef2 shRNA treatments. IPA of canonical pathways preferentially 
dysregulated by Mef2 shRNA treatment. Analyzed gene set represents genes that were 
only statistically dysregulated in knockdown of a single MEF2 factor. The top five most 
significantly regulated canonical pathways are presented with the number of genes 
dysregulated in relation to the accepted number of genes associated with each canonical 
pathway (ratio). 
Canonical Pathway p value Ratio
MEF2A
   Germ Cell-Sertoli Cell Junction Signaling 1.07E-08 50/160 (0.312)
   Molecular Mechanisms of Cancer 1.81E-08 90/365 (0.247)
   14-3-3-mediated Signaling 1.98E-07 38/117 (0.325)
   Protein Ubiquitination Pathway 2.13E-07 66/255 (0.259)
   Death Receptor Pathway 3.13E-07 32/92 (0.348)
MEF2C
   Mitochondrial Dysfunction 1.96E-07 13/171 (0.076)
   TCA Cycle II (Eukaryotic) 2.17E-05 4/23 (0.174)
   Fatt Acid-oxidation III
      (Unsatuared, Odd Number) 2.40E-05 2/3 (0.667)
   Oxidative Phosphorylation 3.05E-05 8/109 (0.073)
   Methylmalonyl Pathway 3.67E-05 2/4 (0.50)
MEF2D
   HIPPO Signaling 2.08E-04 11/86 (0.128)
   PI3k Signaling in B Lymphocytes 5.78E-04 13/128 (0.102)
   Neuregulin Signaling 1.03E-03 10/88 (0.114)
   Proline Degradation 1.23E-03 2/2 (1.00)
   Fc Receptor-mediated Phagocytosis in
      Macrophages and Monocytes 1.57E-03 10/93 (0.108)
All MEF2
  Cell Cycle Control of Chromosomal Replication 0.000000499 8/27 (0.296)
  Hepatic Fibross/ Hepatic Stellate Cell Activation 4.47E-05 17/198 (0.086)
  Antiproliferative Role of TOB in T Cell Signaling 6.70E-05 6/26 (0.231)
  Cell Cycle : G1/S Checkpoint Regulation 6.94E-05 9/64 (0.141)
  Factors Promoting Cardiogenesis in 
    Vertebrates 2.52E-04 10/92 (0.109)
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Table 4.3 Pathway analysis of regulatory patterns of genes dysregulated in each 
MEF2 knockdown. IPA
®
 canonical pathway analysis of genes dysregulated in the same 
direction in each treatment (Shared), pathways dysregulated in the same direction by 
Mef2a and –c treatment or Mef2c and –d treatment (MEF2A/C and MEF2C/D), or in the 
same direction by Mef2a and –d treatment (MEF2A/D). 
 
  
Canonical Pathway p value Ratio
Shared
   Hepatic Fibrosis/Hepatic Stellate Cell Activation 5.23E-04 8/183 (0.044)
   Phenylalanine Degradation I (Aerobic) 5.80E-04 2/4 (0.50)
   Serine Biosynthesis 9.75E-04 2/5 (0.40)
   Superpathway of Serine and Glycine Biosynthesis I 2.02E-03 2/7 (0.286)
   Antiproliferative Role of TOB in T Cell Signaling 2.16E-03 3/26 (0.115)
MEF2A/D
   Cell Cycle Control of Chromosomal Replication 1.64E-09 8/27 (0.296)
   Role of CHK proteins in Cell Cycle Checkpoint Control 8.27E-06 7/55 (0.127)
   Factors Promoting Cardiogenesis in Vertebrates 3.24E-05 8/92 (0.087)
   GADD45 Signaling 1.03E-04 4/19 (0.210)
   DNA damage-induced 14-3-3 Signaling 1.03E-04 4/19 (0.210)
MEF2A/C
  Ephrin Receptor Signaling 9.52E-03 3/174 (0.017)
  Glycerol-3-phosphate Shuttle 1.00E-02 1/4 (0.250)
  Melatonin Degradation II 1.00E-02 1/4 (0.250)
  Ephrin B Signaling 1.45E-02 2/73 (0.027)
  Glycerol Degradation I 1.50E-02 1/6 (0.167)
MEF2C/D
  Type I Diabetes Mellitus Signaling 1.01E-03 3/110 (0.027)
  Role of JAK2 in Hormone-like Signaling 1.70E-03 2/34 (0.059)
  Role of Pattern Recognition Receptors in
    Recognition of Bacteria and Viruses 1.91E-03 3/137 (0.022)
  Interferon Signaling 1.91E-03 2/36 (0.056)
  Activation of IRF by Cystolic Pattern 
    Recognition Receptors 5.57E-03 2/62 (0.032)
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Table 4.4 Genomatix enriched transcription factor binding site analysis. Binding site 
enrichment analysis was performed using the Genomatix software suite to determine 
enriched motifs adjacent (within 50 bp) of MEF2 consensus binding sites in the 
regulatory region 5kb upstream of the putative transcriptional start site of antagonistically 
regulated genes (differentiation genes top, cell cycle/proliferation genes bottom). The 
table provides a description of each candidate co-regulator for each enriched motif with a 
Z-score (Z-scores ˃ 2.0 were considered significantly enriched). The known binding 
factor and their relevant binding domains are included when known. Finally, a brief 
summary of relevant regulatory function is provided. 
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CHAPTER FIVE: EGR1 functions as a potent repressor of MEF2 transcriptional 
activity 
This research was originally presented in PLOS ONE. Feng Y*, Desjardins CA*, 
Cooper O, Kontor A, Nocco SE, Naya FJ. (2015) EGR1 Functions as a Potent Repressor 
of MEF2 Transcriptional Activity. PLOS ONE 10(6): e0131619. 
doi.org/10.1371/journal.pone.0127641 
* Equal contribution 
5.1 Introduction 
Members of the myocyte enhancer factor 2 (MEF2) family of transcription factors 
play essential and diverse roles in tissue development and function as exemplified by 
mutant phenotypes in mice and other animal model systems (Potthoff et al. 2007). The 
transcriptional function of MEF2 is primarily modulated through signaling pathways and 
interactions with co-regulators that can either enhance or abrogate its activity in specific 
biological settings (McKinsey et al. 2002). While this notion is firmly established, 
considerably less is known about the mechanism (Pak et al.) by which MEF2 
coordinately regulates defined gene programs in muscle. 
We previously reported that cardiomyocyte cytoarchitecture and survival is 
dependent on MEF2A (Naya et al. 2002, Ewen et al. 2011). MEF2A was shown to 
modulate the integrity of the cardiomyocyte cytoskeleton through its direct regulation of 
a collection of genes encoding proteins localized to the costamere, a muscle-specific 
focal adhesion which connects the myofibrils to the plasma membrane (sarcolemma) and 
functions to transmit contractile forces throughout the myocyte (Danowski et al. 1992, 
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Ervasti 2003, Ewen et al. 2011). To gain further insight into the mechanism by which 
MEF2A regulates a costamere gene program, a bioinformatics analysis of transcription 
factor binding sites was performed using the proximal promoter regions of costamere 
genes (Ewen et al. 2011). This computational approach identified a number of candidate 
cis-elements that may function as binding sites for transcriptional co-regulators of 
MEF2A-dependent costamere genes. One of these predicted sites belonged to the early 
growth response (EGR) family of zinc finger transcription factors (Delbridge et al. 1997). 
The involvement of the EGR1 transcription factor in cardiovascular and neuronal 
pathways, systems in which MEF2 functions as a central regulator, makes it a particularly 
attractive candidate coregulatory factor. For example, EGR1 is a downstream effector in 
atherosclerosis, angiogenesis, and cardiac hypertrophy (Khachigian 2006), and has been 
shown to regulate gene expression in vascular smooth muscle downstream of mechanical 
stretch (Grote et al. 2004), a stimulus that modulates costamere/focal adhesion activity. 
Additionally, like MEF2, EGR1 responds to neuronal activity and regulates expression of 
genes involved in synapse remodeling (O'Donovan et al. 1999, Li et al. 2005, Shalizi et 
al. 2005, Greer et al. 2008). 
 In this study, we examined the ability of EGR1 to modulate MEF2A 
transcriptional activity. We found that EGR1 is a potent repressor of MEF2A 
transcriptional activity on MEF2-dependent promoters in both non-cardiac and cardiac 
cells. Consistent with its function as a repressor of MEF2 activity, overexpression and 
inhibition of EGR1 resulted in down- and up-regulated expression of costamere genes, 
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respectively. Taken together, these results suggest a potential role for EGR1 to modulate 
MEF2 activity in the regulation of costamere gene expression in cardiomyocytes. 
5.2 EGR1 potently represses MEF2 transcriptional activity 
 To investigate the possibility that EGR1 functions as a coregulator of MEF2A, we 
initially examined the effect of EGR1 on MEF2A transcriptional activity using the 
proximal promoter region of the mouse Tcap gene. The Tcap gene encodes a myofibrillar 
Z-disc protein associated with the costameric protein network whose expression in 
cardiomyocytes is directly regulated by MEF2A (Ewen et al. 2011). In addition to the 
MEF2 site, the 2.0 kilobase (kb) proximal promoter region of the mouse Tcap gene is 
predicted to harbor 5 EGR binding sites located at positions -127, -646, -1407, -1533, and 
-1851, relative to the transcription start site. HEK293T cells were co-transfected with the 
Tcap-luciferase reporter and MEF2A in the presence or absence of EGR1. As shown in 
Figure 5.1A, EGR1 alone had no significant effect on the basal activity of the Tcap 
reporter, whereas MEF2A robustly activated this reporter. In contrast, co-transfection of 
EGR1 significantly repressed MEF2A activation of the Tcap reporter. It is worth noting 
that this repressive effect was not due to EGR1 inhibiting the expression of the MEF2A 
expression plasmid as there was no decrease in overexpressed MEF2A in cells 
transfected with EGR1 (Figure 5.1B). 
 In a parallel series of experiments, we asked whether EGR1-mediated repression 
of MEF2A required DNA binding as previous studies have shown that EGR1 is able to 
repress NF-κB activity in a non-DNA binding manner (Chapman et al. 2000). Therefore, 
we examined the ability of EGR1 to repress a MEF2-dependent promoter not known to 
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have EGR binding sites. For these experiments we used the 3xMEF2 reporter, which 
harbors three tandem copies of the MEF2 site from the desmin gene and flanking 
sequences that do not contain the consensus EGR DNA binding site (Naya et al. 1999). 
The 3xMEF2 reporter was transfected in HEK293T cells along with MEF2A, EGR1, or 
both. EGR1 alone had no effect on the multimerized 3xMEF2 reporter but, similar to the 
Tcap promoter, significantly repressed this reporter in the presence of MEF2A (Figure 
5.2). These results suggest that EGR1 is capable of repressing MEF2A activity in a non-
DNA binding fashion. 
 We next asked whether EGR1-mediated repression of MEF2A was restricted to 
this protein isoform or whether other MEF2 protein isoforms could also be inhibited by 
this factor. Although EGR1 was identified by analyzing the promoter regions of 
costamere associated genes regulated by MEF2A, we found that EGR1 also significantly 
repressed MEF2D transcriptional activity on the 3xMEF2 reporter (Figure 5.3). EGR1 
overexpression did not significantly repress transcriptional activity of MEF2B and 
MEF2C, but we noted a trend towards repression with these MEF2 isoforms. These 
results indicate that, in addition to MEF2A, EGR1 is capable of significantly repressing 
the transcriptional activity of an additional MEF2 isoform. 
 To determine whether EGR1 specifically represses the MEF2 family or whether it 
is able to repress other members of the MADS-box transcription factor superfamily, we 
examined the effect of EGR1 on serum response factor (SRF) transcriptional activity. 
Like the MEF2 proteins, SRF possesses a MADS box DNA binding and dimerization 
domain but is unable to dimerize with these factors and it binds to a different A/T-rich 
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consensus DNA binding sequence known as a CArG box (Miano et al. 2007). HEK293T 
cells were co-transfected with SRF and the SRF-dependent SM22-luc reporter, with or 
without EGR1. As shown in Figure 5.4A, EGR1 failed to repress SRF activity on the 
SM22-luc reporter, demonstrating that EGR1 functions as a specific co-repressor of the 
MEF2 subclass of MADS-box transcription factors. 
 To investigate if this was a reciprocal repression of transcriptional activity, we 
transfected HEK293T cells with an EGR1-specific promoter, p300, reporter construct 
(Yu et al. 2004). This promoter region lacks consensus MEF2 binding sites, and this 
promoter was selected to determine if MEF2A:EGR1 protein-protein interactions have 
similar effects on EGR1-activated genes. Unlike the MEF2-specific reporters, p300-luc 
was not repressed by the co-transduction of MEF2A and EGR1 (Figure 5.4B). These 
results demonstrate that the EGR1-mediated repressive effect on MEF2A transcriptional 
activity is not reciprocal and suggest that repression is specific for genes directly 
regulated by MEF2. 
5.3 EGR1 represses endogenous MEF2 transcriptional activity 
 To determine whether EGR1 represses endogenous MEF2 activity in cardiac 
muscle cells we examined the activity of MEF2-dependent reporters in neonatal rat 
ventricular myocytes (NRVMs) transduced with EGR1 adenovirus. Initially, we used the 
Tcap and 3xMEF2 reporters for these assays but their variable and low activities, 
respectively, in NRVMs precluded us from further analyzing the effect of EGR1 on these 
MEF2-dependent constructs. As an alternative, we used the 1.5 kb proximal promoter 
region of myomaxin/Xirp2, which has been shown to display consistently high MEF2-
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dependent activity in primary cardiomyocytes (McCalmon et al. 2010). Additionally, 
similar to the 3xMEF2 reporter, the 1.5 kb myomaxin promoter region is predicted to lack 
EGR binding sites, thus any effect on reporter activity is likely to be mediated via DNA 
binding-independent effects of EGR1. As shown in Figure 5.5, overexpression of EGR1 
significantly repressed the activity of the wild type 1.5 kb myomaxin promoter. In 
contrast, the mutant 1.5 kb myomaxin ΔMEF2 reporter, harboring a mutation in the -75 
MEF2 site which results in reduced basal activity in NRVMs, was not significantly 
repressed by EGR1. These results reveal that EGR1-mediated repression of a MEF2 
target gene in cardiomyocytes is primarily occurring through the inhibition of MEF2 
activity. 
5.4 EGR1 interacts with MEF2A 
 The DNA-binding independent mechanism by which EGR1 represses MEF2-
dependent transcription suggests that EGR1 represses MEF2 activity through protein-
protein interaction. Therefore, a co-immunoprecipitation assay was performed to 
determine whether or not EGR1 and MEF2A interact in transfected cells. 
 Co-immunoprecipitation was performed using epitope-tagged fusion proteins 
MEF2A-FLAG (C-terminal tag) and MYC-EGR1 (N-terminal tag). To confirm the 
expression of these two epitope-tagged fusion proteins, MEF2A-Flag and EGR1were 
transfected into HEK293T cells and protein was harvested 36–48 hr post-transfection. 
Western blot analysis confirmed the expression of both MEF2A-FLAG (Figure 5.6A) as 
well as MYC-EGR1 (Figure 5.6B). Lysates from cells cotransfected with empty MYC 
vector or MYC-EGR1, and MEF2A-FLAG were then subjected to a co-
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immunoprecipitation assay to test for a protein-protein interaction. As shown in Fig 3A 
left panel, MEF2A was immunoprecipated effectively indicating an interaction between 
EGR1 and MEF2A. When empty MYC vector was immunoprecipitated, no MEF2A-- 
FLAG was detectable (Figure 5.6A, right panel), suggesting that the immunoprecipitation 
of MEF2A-FLAG was mediated by interaction with EGR1 rather than nonspecific 
immunoprecipitation. 
5.5 Costamere gene expression and cardiomyocyte survival are sensitive to EGR1 
expression 
 EGR1 repression of MEF2 activity suggests that overexpression of this factor 
might impair cardiomyocyte survival in a manner similar to that observed in MEF2A-
deficient NRVMs (Ewen et al. 2011). We investigated this hypothesis by transducing 
NRVMs with adenoviruses expressing either EGR1 (AdEGR1) or a beta-galactosidase 
(Adβgal) control. Quantitative RT-PCR analysis showed increased Egr1 expression in 
AdEGR1 treated NRVMs compared to Adβgal controls (Figure 5.7). At 72 hr post 
transduction, we noted widespread cardiomyocyte detachment in EGR1-transduced 
NRVMs, similar to MEF2A-depleted NRVMs (Figure 5.8A, right panels). The cellular 
detachment phenotype suggested reduced viability of cardiomyocytes overexpressing 
EGR1. Analysis of cellular viability revealed significantly reduced survival in EGR1 
expressing cells (Figure 5.8B). Measurement of Caspase 3 activity, a marker of apoptosis, 
showed a significant increase in Caspase 3 activity in EGR1 overexpressing cells, 
suggesting induction of apoptosis as a mechanism for the decreased viability of EGR1 
overexpressing cell (Figure 5.8C). We next examined the expression of thirteen 
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costamere genes previously characterized by our lab to be downregulated in MEF2A-
depleted NRVMs (Ewen et al. 2011). Consistent with the ability of EGR1 to repress 
MEF2 activity, EGR1 overexpression in NRVMs led to significantly decreased 
expression of eleven of the thirteen MEF2-dependent costamere genes analyzed (Figure 
5.9). 
 In a complementary set of experiments EGR1 was depleted in NRVMs using an 
Egr1-specific siRNA (Ambion). Unlike EGR1 overexpression, siRNA-mediated 
knockdown of EGR1 had no obvious morphological effect on NRVMs 72 hr post-
transfection (Figure 5.10A). To determine the efficiency of EGR1 knockdown, HEK293T 
cells were transfected with pcDNA3-EGR1-Flag with either negative control siRNA or 
Egr1 siRNA. Cell lysates were probed for Flag expression and EGR1-Flag expression is 
observed at the expected size (80kD) when cotransfected with negative control siRNA, 
but expression is lost when co-transfected with Egr1 siRNA (Figure 5.10B). There is a 
confounding non-specific band just above the relevant EGR1-Flag band that is observed 
in all samples, including the untransfected control, and does not vary with siRNA 
treatment. Subsequently, expression of costamere genes was analyzed by qRT-PCR. As 
predicted by our model of EGR1-mediated MEF2 repression, MEF2-dependent 
costamere gene expression was elevated in Egr1 siRNA knockdown NRVMs (Figure 
5.11). Eight of the thirteen genes were significantly upregulated upon EGR1 knockdown. 
Taken together, the EGR1 overexpression and knockdown experiments clearly support its 
role in MEF2-dependent costamere gene expression in cardiomyocytes. 
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5.6 Discussion 
 The present report reveals that the EGR1 transcription factor interacts with 
MEF2A and functions as a potent repressor of MEF2 activity in cardiomyocytes. EGR1 
was shown to repress MEF2A transcriptional activity on MEF2-dependent promoters that 
either harbored multiple, predicted EGR binding sites or lacked a consensus EGR DNA 
binding sequence. Moreover, although we previously identified EGR1 through 
computational analysis of predicted transcription factor binding sites on costamere genes 
primarily dependent on MEF2A, our investigation revealed that EGR1 represses 
additional MEF2 protein isoforms in transient reporter assays. Finally, this repressive 
effect was found to be specific for the MEF2 subclass of MADS box transcription factors 
as EGR1 failed to repress SRF transcriptional activity. 
While EGR1 was selected as a candidate co-regulator of MEF2A through analysis 
of consensus DNA binding sequences on a collection of costamere promoters, it is 
interesting that the repressive effect of EGR1 could also occur in a DNA-binding 
independent manner. This suggests that the role of DNA-binding, as it relates to the 
repressive action of EGR1, may be to more effectively target the EGR1 protein to 
promoters that are directly bound by MEF2. It is unclear whether EGR1 DNA-binding 
plays an additional non-MEF2 related role in the regulation of cardiomyocyte costamere 
and survival, and further study is required to better understand how the repressive 
interaction of EGR1 and MEF2 is reprised in a physiological context. 
Consistent with the notion that EGR1 repressed MEF2, overexpression of EGR1 
in NRVMs resulted in significantly decreased expression of MEF2-dependent costamere 
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genes. Interestingly, overexpression of EGR1 also caused cardiomyocyte detachment and 
significantly reduced survival, which is reminiscent of the MEF2A depletion phenotype 
in NRVMs [4]. These observations support our model that EGR1 and MEF2 function in 
the same pathway to transcriptionally co-regulate MEF2-dependent costamere genes in 
cardiomyocytes. 
The ability of EGR1 to function as a repressor of gene expression in 
cardiomyocytes has been documented (McKinsey et al. 2001, McCalmon et al. 2010). 
However, EGR1 has not been previously demonstrated to regulate a distinct gene 
program or specifically interact with and repress the activity of a core cardiac 
transcription factor such as MEF2. Of particular interest is the connection of these 
transcription factors in cardiac hypertrophy pathways. MEF2 is a known downstream 
mediator of hypertrophic signaling (Chabane et al. 2009), particularly in calcineurin-
induced hypertrophy by Ca
2+
-activated NFAT signaling that promotes chamber dilation 
and loss of contractility (Wang et al. 2005). In this regard, EGR1 has been shown to 
induce Cav3.2 T-type calcium channels, which plays a role in inducing 
calcineurin/NFAT signaling during cardiac hypertrophy (Kasneci et al. 2009), to play an 
important role in adaptive response to hypertrophic stimuli (Czubryt et al. 2004), and to 
be targeted and suppressed by Atf3during endothelin-1 induced cardiomyocyte 
hypertrophy (van Oort et al. 2006). Additionally, Nab1, a repressor of EGR, has been 
shown to be a potent inhibitor of pathological cardiac hypertrophy (Hsu et al. 2013) and 
EGR1 deficient mice have a blunted catecholamine-induced hypertrophy response and 
are more sensitive to stress (Pacini et al. 2013). Given the wide variety of 
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cardiopathologies in which both EGR1 and MEF2 have been implicated, further 
investigation of EGR1’s function as a potent MEF2 repressor will provide additional 
insight into mechanisms of various cardiopathologies and into potential targets for 
treatment of cardiac disease. 
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Figure 5.1 EGR1 is a potent repressor of MEF2A transcriptional activity. A, 
HEK293T cells were transfected with the Tcap-Luc, pcDNA3-EGR1 and pcDNA1-
MEF2A. pcDNA1 and pcDNA3 were used as empty plasmid controls for the MEF2A 
and EGR1 expression vectors, resepectively. Firefly luciferase readings were normalized 
by Bradford assay. (n = 6, p<0.003). B, Western blot analysis shows that EGR1 
overexpression does not decrease the expression of MEF2A. Data are mean ± SEM. 
*p<0.05, **p<0.01, ***p<0.001, n.s. not significant. 
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Figure 5.2 EGR1 repression does not require EGR1 DNA-binding activity. 
HEK293T cells were co-transfected with a3xMEF2-luc lacking any putative EGR1 
binding sites. MEF2A alone robustly induced reporter activity, and introduction of EGR1 
was sufficient to repress MEF2A-mediated activation. Firefly luciferase readings were 
normalized by Bradford assay (n=4, p˂0.007). Data are mean ± SEM. *p<0.05, 
**p<0.01, ***p<0.001, n.s. not significant. 
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Figure 5.3 EGR1 significantly represses MEF2A and –D mediated transcriptional 
activation, but not MEF2B or –C. HEK293T cells were co-transfected with 3xMEF2-
luc and MEF2A, B, C, or D in the presence or absence of EGR1. EGR1 was sufficient to 
robustly repress MEF2A and –D transcriptional activity, but not MEF2B, or –D. Data are 
mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, n.s. not significant. 
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Figure 5.4 EGR1 repression is unidirectional and specific to MEF2. A, EGR1 does 
not repress SRF activity on an SRF-specific reporter construct. No significant difference 
was measured in the luciferase activation in the absence or presence of EGR1 (n=4, n.s.). 
B, MEF2A does not repress EGR1 transcriptional activity on a EGR1-specific promoter 
construct, p300-luc, lacking MEF2 binding sites (n = 3). Luciferase data are normalized 
to Bradford assay. Data are mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, n.s. not 
significant. 
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Figure 5.5 EGR1-mediated repression of MEF2A activity requires MEF2 DNA-
binding. NRVMs were transduced with AdEGR1 and Adβgal at an MOI of 25. Twenty 
four hr post-transduction, 1.5 kb myomaxin-Luc and 1.5 kb myomaxinΔMEF2-Luc were 
transfected. Luciferase activity was measured 48 hr after transfection. Firefly luciferase 
readings were normalized to Renilla luciferase readings. Data are mean ± SEM. 
***p<0.001, n.s. not significant. 
  
 152 
 
 
Figure 5.6 MEF2A and EGR1 physically interact in vitro. A, HEK293T cells were 
transfected with pcDNA3-myc (empty vector) or pcDNA3-Myc-EGR1 (N-terminal 
epitope tag) and pCMV-MEF2A-FLAG (C-terminal epitope tag). Whole cell lysates in 
AT buffer were incubated with Protein G Sepharose Beads (GE Healthcare) and 1 μg of 
anti-Flag and incubated at 4°C, rotating overnight on a nutator. Precipitated samples were 
fractionated on an 8% SDS-PAGE gel followed by a western blot incubated with anti-
Flag (1:2,000). B, Self-immunoprecipitation of the myc-EGR1 protein shows efficient 
expression and purification. 
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Figure 5.7 AdEGR1 transduction induces an increase in Egr1 transcripts. 
Quantitative RT-PCR analysis confirms expression of Egr1 transcripts 48 hr post-
transduction with AdEGR1; fold change is in comparison to expression levels in the 
Adβgal control, results were normalized to 18s. 
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Figure 5.8 Overexpression of EGR1 impairs NRVM viability. A, NRVMs were 
transduced with AdEGR1 and Adβgal at an MOI of 25 and observed 48 hr post 
transduction. Extensive cell detachment is seen in the AdEGR1 transduced NRVMs in 
comparison to the Adβgal transduced NRVMs. B, NRVMs were seeded in increasing cell 
densities and transduced with AdEGR1 or Adβgal at an MOI of 25 and assayed for cell 
viability 48 hr post-transduction. Cell titer blue assay shows a significant decrease in 
viability in AdEGR1 transduced NRVMs but not the control. C, NRVMs were 
transduced with AdEGR1 or Adβgal at an MOI of 25 and assayed for Caspase 3 activity 
72 hr post-transduction. The assay shows significant upregulation of Caspase 3 activity at 
72 hr post-transduction in the AdEGR1-transduced, but not Adβgal-transduced NRVMs. 
Data are mean ± SEM, n = 3, *p<0.05, **p<0.01, ***p<0.001. 
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Figure 5.9 Costamere gene expression is sensitive to EGR1 levels in NRVMs. 
Quantitative RT-PCR analysis of 13 MEF2-dependent costamere genes shows 11 of these 
genes are down-regulated when EGR1 is overexpressed in NRVMs; fold change is in 
comparison to expression levels in the Adβgal control. Results were normalized to 18s. 
Data are mean ± SEM, n = 3, *p<0.05, **p<0.01, ***p<0.001. 
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Figure 5.10 EGR1 depleted NRVMs display no obvious morphological defects. A,  
NRVMs were transfected with 100 nM EGR1 siRNA and analyzed 72 hr post 
transfection. B, HEK 293T cells were transfected with pcCMV-EGR1-Flag, and either a 
negative control or Egr1 siRNA. Western blot analysis probing for the Flag epitope 
shows loss of EGR1-Flag expression upon co-transfection with the Egr1 siRNA, though a 
confounding non-specific band is present slightly above the EGR1-Flag band. 
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Figure 5.11 Costamere gene expression is upregulated in EGR1-depleted NRVMs. 
EGR1-depletion results in upregulated costamere gene expression in NRVMs. qRT-PCR 
analysis of 13 MEF2-dependent costamere genes in EGR1 siRNA knockdown NRVMs 
shows that eight of the genes are significantly upregulated, and the majority of the 
remaining genes show a nonsignificant trend towards upregulation when EGR1 is 
knocked down; fold change is in comparison to expression levels in the negative siRNA 
knockdown controls, results were normalized to 18s. Sample size for Ank2, Dmd, 
Dysbind, Lamb2, Pdlim1, Sgcb, and 18s is n = 6. Sample size for Pdlim5, Sgca, Sgcg, 
and Tcap is n = 5. Sample size for Fhl2 and Obscn is n = 4, and the sample size for Xirp2 
is n = 3., *p<0.05, ** p<0.01, ***p<0.001. 
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CHAPTER SIX: Discussion 
6.1 Discussion 
 The position of the MEF2 as a core regulatory element in both skeletal and 
cardiac muscle has been well established. Extensive research has shown its importance in 
muscle development, homeostasis, and disease. However, genome-wide gene regulatory 
analysis of the individual roles of the four MEF2 isoforms in muscle has not been 
performed. Previous research has typically focused on a single member of the MEF2 
family and much of the research has been based on the assumption that the function of 
the family members are either largely redundant, and/or their regulatory roles are defined 
by their spatiotemporal expression patterns. Through acute isoform-specific ablation of 
MEF2 expression we have been able to reveal the requirement of individual MEF2 
isoforms in the regulation of distinct and shared gene programs in striated muscle. 
 Interestingly, acute ablation of MEF2 expression in neonatal cardiomyocytes does 
not perfectly recapitulate the observed global in vivo MEF2-deficient phenotypes in 
mouse models. The global MEF2A-deficient mouse does display cardiac abnormalities, 
but these are not characterized by the loss of cardiomyocyte viability we observe in our in 
vitro MEF2A-deficient cardiomyocytes. Additionally, while MEF2C activity was thought 
to be dispensable after early development, we show a distinct role for MEF2C in neonatal 
cardiomyocytes that isn’t shared by other MEF2 isoforms, suggesting that MEF2C 
continues to play a role in the homeostasis of differentiated cardiomyocytes. Finally, 
MEF2D-deficient mice display no overt cardiac phenotype until stressed, in response to 
which, they exhibit a blunted remodeling response. This appears to be at odds with the 
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drastic loss of cardiomyocyte viability we observe in acute Mef2d depletion in 
cardiomyocytes. It remains unclear why acute depletion of MEF2 activity leads to a 
different phenotype than chronic depletion, and we believe that reconciling these 
apparent discrepancies will allow us a greater understanding of the regulatory network 
that is at play in cardiomyocyte differentiation and homeostasis. 
 In Chapter Three we present a requirement for MEF2A expression in 
differentiating C2C12 cells that is distinct from the other MEF2 isoforms. Additionally, 
overexpression of MEF2B, -C, or -D was not sufficient to rescue the myotube 
differentiation defect observed in MEF2A-deficient C2C12 cells. This result suggests the 
presence of regulatory mechanisms that are specific to individual MEF2 isoforms in 
skeletal muscle. We hypothesized that a global analysis of genes dysregulated in C2C12 
cells acutely depleted of individual MEF2 isoforms would reveal a series of distinct 
transcriptional programs that are preferentially associated with each MEF2 isoform.  
 Comparative microarray analysis supports our hypothesis that transcriptional 
regulation by the MEF2 family is far more nuanced than previously appreciated. We 
observed gene cohorts that are preferentially regulated by a single MEF2 isoform. 
Additionally, analysis of the cellular programs dysregulated in individual MEF2 isoform 
depletion revealed very little overlap, suggesting that a large part of the function of each 
MEF2 isoform in skeletal muscle is distinct from the function of the other MEF2 
isoforms. We found this result surprising considering the substantial in vitro data 
supporting the binding and activation of a single consensus sequence by all members of 
the MEF2 family. We attempted to verify the consensus binding site by determining 
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putative MEF2 binding sites in genes preferentially dysregulated by individual MEF2 
isoforms, and a compilation of all these sites yielded the same consensus site for all four 
MEF2 isoforms. Since this analysis was based on the JASPAR position-weight matrix, 
we suspect that the site prediction analysis was already biased towards the consensus 
sequence. We believe that an unbiased approach is possible, and have begun a 
collaboration to determine the consensus MEF2 binding site for each MEF2 isoform 
using protein binding microarray (PBM) technology and an unbiased array of 
oligonucleotide sequences. 
 In light of an apparent lack of variation in the binding sequence associated with 
genes preferentially sensitive to each MEF2 isoform, we considered the alternate 
hypothesis that the complex regulatory patterns we observe are due to association with 
distinct pools of co-regulatory proteins. To assess this hypothesis we evaluated the 
enrichment of non-MEF2 consensus binding sites in the proximal 5kb region upstream of 
the putative transcriptional start site. We observed several candidate co-regulatory factors 
that could explain the differential effects of MEF2A, -B, and -D, but failed to identify any 
preferentially enriched transcriptional co-regulator associated with the MEF2C-sensitive 
gene cohorts. We suspect that additional refinement of this analysis through use of ChIP-
seq would allow us to create a dataset of genes being directly bound by the MEF2 factors, 
and potentially further refine the set of co-regulatory factors that may be mediating these 
differential regulatory effects. 
 In Chapter Four, we evaluate the requirement for MEF2A, -C, and -D in neonatal 
cardiomyocytes. Interestingly, quantitative RT-PCR analysis has allowed us to evaluate 
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the relative transcript expression levels the three other MEF2 isoforms in cardiomyocytes 
relative to Mef2a transcripts. Contrary to previously published in situ hybridization data, 
expression of Mef2c transcripts is not absent postnatally, though it is downregulated in 
late development. Additionally, we find that Mef2c and Mef2d transcripts are expressed at 
similar levels, suggesting that MEF2C maintains regulatory relevance even after its 
downregulation in development. Unlike skeletal muscle, MEF2B appears to be absent 
from neonatal cardiomyocytes and was not investigated. Abrogation of MEF2A and -D 
activity was associated with loss of neonatal cardiomyocyte viability in low-serum 
culture conditions, and overexpression of MEF2A, -D, or the constitutively-active MEF2-
VP16 was sufficient to partially rescue viability. In conjunction with our skeletal muscle 
findings, these data support the hypothesis that the individual members of the MEF2 
family regulate distinct cellular pathways in striated muscle. These observations are 
supported by comparative transcriptomic analysis which reveals genes sets that are 
preferentially dysregulated in the loss of individual MEF2 isoforms. 
 Interestingly, this analysis has allowed us to observe a previously uncharacterized 
antagonistic relationship between the MEF2 factors in the regulation of cell cycle and 
sarcomeric differentiation genes. We hypothesize that this represents a developmentally 
relevant regulatory switch which may mediate the transition from proliferative early 
cardiomyocytes into terminally differentiated mature cardiomyocytes during embryonic 
development. The temporal expression of the MEF2 family during cardiac development 
suggests that MEF2C plays a role in the maintenance of this immature cardiomyocyte 
state that shares both proliferative capacity and contractile function, and that the 
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emergence of MEF2A as the primary MEF2 isoform later in development may represent 
a switch away from proliferation and towards terminal differentiation and quiescence. 
Additionally, the ability to measure this antagonistic relationship in neonatal 
cardiomyocytes suggests that cardiomyocytes maintain an active equilibrium between 
proliferation and quiescence as they mature. While mature cardiomyocytes maintain their 
terminally differentiated state indefinitely, understanding the regulatory equilibrium 
observed in the relationship between MEF2 factors might provide insight into therapeutic 
interventions that can coerce mature cardiomyocytes to regain proliferative capacity to 
compensate for the loss of cardiomyocytes in cardiac dysfunction. 
 We hypothesize that the ability to regulate gene expression in opposite directions 
by the MEF2 isoforms is likely mediated by association with co-regulatory proteins. We 
evaluated the presence of enriched binding sites for co-regulatory proteins adjacent 
(within 50 bp) of putative MEF2 binding sites on antagonistically regulated genes and 
observed binding sites associated with two signaling pathways, Hedgehog and Notch. To 
assess the role of these pathways on MEF2-mediated regulation of the antagonistically 
regulated gene cohort we overexpressed constitutively active elements of each pathway 
in MEF2A and -D depleted NRVMs. We observed little interaction between the 
Hedgehog signaling pathway and depletion of MEF2A or -D in NRVMs, and Hedgehog 
signaling downregulated cell cycle genes universally. Additionally, we observed that 
Notch regulation of cell cycle genes was inhibited by the activity of MEF2A or -D, and 
that Notch activation of sarcomeric genes required the presence of MEF2A or -D.  
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 In Chapter Five we assessed the ability of a repressive co-regulatory protein, 
EGR1, to mediate MEF2 function on a subset of known MEF2 target genes. We observed 
a repressive effect of EGR1 on the transcriptional activity of MEF2A that did not require 
EGR1 DNA-binding activity. Additionally, we identified a direct protein-protein 
interaction between EGR1 and MEF2A in vitro. Interestingly, while the repressive 
potential of EGR1 has been documented, we believe this is the first time it has been 
characterized to repress an entire gene program through association with a core cardiac 
transcription factor. 
 Additionally, the lack of observed repressive effect of EGR1 co-expression with 
other MEF2 isoforms provides substantial evidence for the existence of MEF2 isoform 
specific co-regulatory interactions which may help explain the observed regulatory 
patterns in Chapters Three and Four. 
6.2 Future Perspectives 
6.2.1 Further refinement of the MEF2 gene cohorts 
 Comparative transcriptomics has provided us with a wealth of data about the 
transcriptional regulatory roles of the MEF2 factors in both skeletal and cardiac muscle. 
To date we have only focused on small subsets of each of these data sets, but there are 
many interactions that remain to be explored. Most notably, while we have hypothesized 
potential co-regulatory proteins that may mediate the preferential regulation of gene 
cohorts by individual MEF2 isoforms, we have yet to evaluate these candidates. 
Additionally, assessing the direct binding of MEF2 factors to their sensitive genes will be 
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an essential contribution to further refinement of these gene sets, allowing us to create 
cohorts of direct and indirect targets. 
 Additionally, pathway analysis has revealed largely distinct roles for each of the 
MEF2 isoforms, but we have not had the opportunity to truly delve into the cellular 
pathways preferentially-sensitive to the individual MEF2 isoforms. Of particular interest 
is the emergence of metabolic pathways preferentially-regulated by MEF2C in neonatal 
cardiomyocytes. These pathways are interesting because canonical literature suggests that 
MEF2C activity is dispensable in mature cardiomyocytes, yet our transcriptomic analysis 
reveals the potential for a well-defined function for MEF2C in these cells. Additionally, 
while depletion of Mef2c did not yield an overt morphological phenotype under normal 
culture conditions, we suspect that its putative role in cardiomyocyte metabolism may 
manifest as sensitivity to altered nutrient availability. We believe that characterization of 
a novel role for MEF2C in mature cardiomyocytes is an interesting avenue to continue 
investigating, especially considering the lack of studies focused on this factor in cardiac 
homeostasis. 
6.2.2 Characterization of the transcriptional landscape of antagonistically regulated 
genes 
 While the role of MEF2 in the regulation of many of the sarcomere genes has 
been characterized, very little is known about the mechanism through which MEF2 
regulated cell cycle genes. Additionally, nothing is known about the ability of the MEF2 
family to antagonistically regulate either gene cohort. While we have identified putative 
MEF2 binding sites on some of the proximal promoter regions of these genes, it is not 
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known whether MEF2 is capable of directly binding these sites, if the regulatory effects 
are indirect, or potentially some combination of both. We do know that the MEF2D is 
capable of mediating the regulation of cell cycle genes through direct regulation of PTEN 
expression, but interestingly, Pten transcripts are not affected by depletion of MEF2A or 
MEF2C activity, suggesting that there exist multiple and potentially unique regulatory 
mechanisms. 
 Further characterization of these antagonistically regulated genes will require 
assessment of direct binding using ChIP-seq technology to further define subsets that are 
direct targets. We wish to focus analysis on these direct targets because they may be able 
to shed light onto the co-regulatory proteins that are necessary to mediate this complex 
regulatory relationship. Additionally, we will proceed with analysis of the relationship 
between the MEF2 factors and candidate co-regulatory proteins. Of particular interest is 
the ability to form protein-protein complexes with individual MEF2 factors. We know 
from our analysis of EGR1-mediated repression that this co-repressor associates with 
MEF2A to mediate its repressive effect. 
 Additionally, identification of functional MEF2 sites will allow us to produce 
reporter constructs through which we can evaluate the activating or repressing activity of 
the individual MEF2 isoforms in a more controlled context. This is particularly relevant 
because standard transfection techniques are particularly ineffective in neonatal 
cardiomyocytes, leaving us only transduction as an efficient means of manipulation. The 
ability to recapitulate this system into a more permissive cell line would be technically 
beneficial and allow us more leeway for the complex manipulations of MEF2 isoforms 
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and other co-regulatory proteins that may be necessary to fully grasp the antagonistic 
relationship observed in cardiomyocytes. 
6.2.3 Is the transition from a MEF2C-dominant to a MEF2A-dominant 
transcriptional landscape developmentally relevant? 
 In addition to the biochemical analysis proposed above, consideration of the 
developmental relevance of the observed antagonistic gene regulation is also critical. Of 
particular importance is whether these genes act as we might hypothesize at the relevant 
developmental time points. Specifically, do we observe high expression of cell cycle gene 
and repressed expression of sarcomere genes in early development, and do we see a shift 
in later development. Additionally, are potential shifts in these gene programs associated 
with the ratio of MEF2 isoforms in cardiomyocytes? 
 Previous in vivo studies in mice have established a role for MEF2C early in 
development, and a role for MEF2A much later in development, but in both cases we are 
observing the effects of chronic depletion. Through the use of established MEF2-flox 
mice lines, we may be able to better asses the roles of each MEF2 factor at 
developmentally relevant time points through acute ablation of MEF2 factor activity. The 
power this affords us is the ability to pinpoint the specific developmental relevance of 
each of the MEF2 isoforms. We believe this is a necessary set of information because it 
allows us to return to the developing embryo and assess what transcriptional profiles are 
associated with that time point, specifically the relationship between proliferative and 
cardiac differentiation gene programs at these time points. These experiments will allow 
us to evaluate the hypothesis that the composition of the MEF2 factor ratio may act as a 
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phenotypic switch between pro-proliferation and pro-quiescence gene programs. 
Understanding this will also allow us to probe the induction of this process by the myriad 
developmentally relevant signaling pathways at play in the developing cardiac heart. Our 
hope is that through this precise developmental analysis, in conjunction with the above 
mentioned biochemical analysis, we can build a transcriptionally network involving 
MEF2 that describes key transcriptional events in the development of the mature 
cardiomyocyte. 
 While we feel that this is a critical facet of cardiac embryonic development that is 
lacking, we also believe that these types of analysis will provide us with knowledge 
essential to the understanding of postnatal cardiac disease. It is believed that cardiac 
disease causes adult cardiomyocytes to re-acquire fetal gene expression, and this shift 
may be due to shifts in the relative expression levels of the MEF2 family in adult cardiac 
disease. We believe that understanding the relationship between MEF2 and terminal 
differentiation may inform new therapies focused on the induction of proliferative 
capacity in the remaining cardiomyocytes after induction of cardiac disease.  
6.3 Conclusion 
 In combination, the above mentioned experiments will allow us to build a much 
more detailed cardiac transcriptional network that accounts for the differential regulatory 
roles of individual MEF2 factors in cardiomyocytes. We believe that considering 
transcription factors as discrete regulatory players rather than as members of broad 
families is essential to dissecting the underlying mechanisms of development and disease.  
  
 169 
LIST OF JOURNAL ABBREVIATIONS 
Am J Physiol Cell Physiol American Journal of Physiology - Cell Physiology 
Annu Rev Cell Dev Biol Annual Review of Cell and Developmental Biology 
Biochim Biophys Acta Biochimica et Biophysica Acta 
Bioinformatics Bioinformatics 
Can J Physiol Pharmacol Canadian Journal of Physiology and Pharmacology 
Cancer Cell Cancer Cell 
Cardiovasc Res Cardiovascular Research 
Cell Cell 
Cell Mol Life Sci Cell and Molecular Life Sciences 
Circ Res Circulation Research 
Circulation Circulation 
Cold Spring Harb Perspect 
Med 
Cold Spring Harbor Perspectives in Medicine 
Curr Opin Cell Biol Current Opinion in Cell Biology 
Curr Opin Genet Dev Current Opinion in Genetics & Development 
Curr Opin Pharmacol Current Opinion in Pharmacology 
Curr Top Dev Biol Current Topics in Developmental Biology 
Current Biology Current Biology 
Dev Biol Developmental Biology 
Dev Cell Developmental Cell 
Dev Dyn Developmental Dynamics 
 170 
Dev Genes Evol Development Genes and Evolution 
Development Development 
Differentiation Differentiation 
EMBO J EMBO Journal 
Eur J Hum Genet European Journal of Human Genetics 
FEBS Lett FEBS Letters 
Gene Gene 
Genes and Development Genes and Development 
Genes Dev Genes & Development 
Genesis Genesis 
Genome Res Genome Research 
Heredity (Edinb) Heredity (Edinb) 
J Biol Chem Journal of Biological Chemistry 
J Cardiovas Dev Dis Journal of Cardiovascular Development and Disease 
J Cell Biochem Journal of Cellular Biochemistry 
J Cell Biol Journal of Cell Biology 
J Cell Physiol Journal of Cellular Physiology 
J Cell Sci Journal of Cell Science 
J Clin Invest Journal of Clinical Investigation 
J Mol Biol Journal of Molecular Biology 
Mech Dev Mechanisms of Development 
Mol Cell Biol Molecular and Cellular Biology 
 171 
Mol Cell Molecular Cell 
Nat Cell Biol Nature Cell Biology 
Nat Genet Nature Genetics 
Nat Med Nature Medicine 
Neuron Neuron 
Nucleic Acids Res Nucleic Acids Research 
Pediatr Cardiol Pediatric Cardiology 
Physiol Genomics Physiological Genomics 
Physiol Rev Physiological Reviews 
PLoS Genet PLoS Genetics 
PLoS One PLoS One 
Proc Natl Acad Sci U S A Proceedings of the National Academy of Science of the 
United States of America  
Recent Prog Horm Res Recent Progress in Hormone Research 
Science Science 
Trends Biochem Sci Trends in Biochemical Sciences 
Trends Cardiovasc Res Trends in Cardiovascular Research 
Trends Neurosci Trends in Neuroscience 
 
  
 172 
REFERENCES 
Ahuja, P., P. Sdek and W. R. MacLellan (2007). Cardiac myocyte cell cycle control in 
development, disease, and regeneration. Physiol Rev 87(2): 521-544. 
Ashburner, M., C. A. Ball, J. A. Blake, D. Botstein, H. Butler, J. M. Cherry, A. P. Davis, 
K. Dolinski, S. S. Dwight, J. T. Eppig, M. A. Harris, D. P. Hill, L. Issel-Tarver, A. 
Kasarskis, S. Lewis, J. C. Matese, J. E. Richardson, M. Ringwald, G. M. Rubin and G. 
Sherlock (2000). Gene ontology: tool for the unification of biology. The Gene Ontology 
Consortium. Nat Genet 25(1): 25-29. 
Backs, J. and E. N. Olson (2006). Control of cardiac growth by histone 
acetylation/deacetylation. Circ Res 98(1): 15-24. 
Barnes, R. M., I. S. Harris, E. J. Jaehnig, K. Sauls, T. Sinha, A. Rojas, W. Schachterle, D. 
J. McCulley, R. A. Norris and B. L. Black (2016). MEF2C regulates outflow tract 
alignment and transcriptional control of Tdgf1. Development 143(5): 774-779. 
Bendall, A. J. and C. Abate-Shen (2000). Roles for Msx and Dlx homeoproteins in 
vertebrate development. Gene 247(1-2): 17-31. 
Berry, F. B., Y. Miura, K. Mihara, P. Kaspar, N. Sakata, T. Hashimoto-Tamaoki and T. 
Tamaoki (2001). Positive and negative regulation of myogenic differentiation of C2C12 
cells by isoforms of the multiple homeodomain zinc finger transcription factor ATBF1. J 
Biol Chem 276(27): 25057-25065. 
Bi, W., C. J. Drake and J. J. Schwarz (1999). The transcription factor MEF2C-null mouse 
exhibits complex vascular malformations and reduced cardiac expression of angiopoietin 
1 and VEGF. Dev Biol 211(2): 255-267. 
Black, B. L., J. D. Molkentin and E. N. Olson (1998). Multiple roles for the MyoD basic 
region in transmission of transcriptional activation signals and interaction with MEF2. 
Mol Cell Biol 18(1): 69-77. 
Black, B. L. and E. N. Olson (1998). Transcriptional control of muscle development by 
myocyte enhancer factor-2 (MEF2) proteins. Annu Rev Cell Dev Biol 14: 167-196. 
Blais, A., M. Tsikitis, D. Acosta-Alvear, R. Sharan, Y. Kluger and B. D. Dynlacht 
(2005). An initial blueprint for myogenic differentiation. Genes Dev 19(5): 553-569. 
Bondue, A. and C. Blanpain (2010). Mesp1: a key regulator of cardiovascular lineage 
commitment. Circ Res 107(12): 1414-1427. 
 173 
Bour, B. A., M. A. O'Brien, W. L. Lockwood, E. S. Goldstein, R. Bodmer, P. H. Taghert, 
S. M. Abmayr and H. T. Nguyen (1995). Drosophila MEF2, a transcription factor that is 
essential for myogenesis. Genes & Development 9: 730-741. 
Braun, T. and H. H. Arnold (1996). Myf-5 and myoD genes are activated in distinct 
mesenchymal stem cells and determine different skeletal muscle cell lineages. EMBO J 
15(2): 310-318. 
Bryantsev, A. L. and R. M. Cripps (2009). Cardiac gene regulatory networks in 
Drosophila. Biochim Biophys Acta 1789(4): 343-353. 
Buettner, F. F., A. Ashikov, B. Tiemann, L. Lehle and H. Bakker (2013). C. elegans 
DPY-19 is a C-mannosyltransferase glycosylating thrombospondin repeats. Mol Cell 
50(2): 295-302. 
Campa, V. M., R. Gutierrez-Lanza, F. Cerignoli, R. Diaz-Trelles, B. Nelson, T. Tsuji, M. 
Barcova, W. Jiang and M. Mercola (2008). Notch activates cell cycle reentry and 
progression in quiescent cardiomyocytes. J Cell Biol 183(1): 129-141. 
Carnegie, G. K., J. Soughayer, F. D. Smith, B. S. Pedroja, F. Zhang, D. Diviani, M. R. 
Bristow, M. T. Kunkel, A. C. Newton, L. K. Langeberg and J. D. Scott (2008). AKAP-
Lbc mobilizes a cardiac hypertrophy signaling pathway. Mol Cell 32(2): 169-179. 
Chabane, N., X. Li and H. Fahmi (2009). HDAC4 contributes to IL-1-induced mPGES-1 
expression in human synovial fibroblasts through up-regulation of Egr-1 transcriptional 
activity. J Cell Biochem 106(3): 453-463. 
Chapman, N. R. and N. D. Perkins (2000). Inhibition of the RelA(p65) NF- B Subunit by 
Egr-1. J Biol Chem 275(7): 4719-4725. 
Conway, S. J., B. Firulli and A. B. Firulli (2010). A bHLH code for cardiac 
morphogenesis. Pediatr Cardiol 31(3): 318-324. 
Czubryt, M. P. and E. N. Olson (2004). Balancing contractility and energy production: 
the role of myocyte enhancer factor 2 (MEF2) in cardiac hypertrophy. Recent Prog Horm 
Res 59: 105-124. 
D'Amato, G., G. Luxan, G. del Monte-Nieto, B. Martinez-Poveda, C. Torroja, W. Walter, 
M. S. Bochter, R. Benedito, S. Cole, F. Martinez, A. K. Hadjantonakis, A. Uemura, L. J. 
Jimenez-Borreguero and J. L. de la Pompa (2016). Sequential Notch activation regulates 
ventricular chamber development. Nat Cell Biol 18(1): 7-20. 
Danowski, B. A., K. Imanaka-Yoshida, J. M. Sanger and J. W. Sanger (1992). 
Costameres Are Sites of Force Transmission to the Substratum in Adult Rat 
Cardiomyocytes. J Cell Biol 118(6): 1411-1420. 
 174 
de la Pompa, J. L. and J. A. Epstein (2012). Coordinating tissue interactions: Notch 
signaling in cardiac development and disease. Dev Cell 22(2): 244-254. 
Delbridge, G. J. and L. M. Khachigian (1997). FGF-1-induced platelet-derived growth 
factor-A chain gene expression in endothelial cells involves transcriptional activation by 
early growth response factor-1. Circ Res 18(2): 282-288. 
Desjardins, C. A. and F. J. Naya (2016). The Function of the MEF2 Family of 
Transcription Factors in Cardiac Development, Cardiogenomics, and Direct 
Reprogramming. J Cardiovasc Dev Dis 3(3). 
Dichoso, D., T. Brodigan, K. Y. Chwoe, J. S. Lee, R. Llacer, M. Park, A. K. Corsi, S. A. 
Kostas, A. Fire, J. Ahnn and M. Krause (2000). The MADS-Box factor CeMEF2 is not 
essential for Caenorhabditis elegans myogenesis and development. Dev Biol 223(2): 431-
440. 
Doerks, T., R. R. Copley, J. Schultz, C. P. Ponting and P. Bork (2002). Systematic 
identification of novel protein domain families associated with nuclear functions. 
Genome Res 12(1): 47-56. 
Du, M., R. L. Perry, N. B. Nowacki, J. W. Gordon, J. Salma, J. Zhao, A. Aziz, J. Chan, 
K. W. Siu and J. C. McDermott (2008). Protein kinase A represses skeletal myogenesis 
by targeting myocyte enhancer factor 2D. Mol Cell Biol 28(9): 2952-2970. 
Durham, J. T., O. M. Brand, M. Arnold, J. G. Reynolds, L. Muthukumar, H. Weiler, J. A. 
Richardson and F. J. Naya (2006). Myospryn is a direct transcriptional target for MEF2A 
that encodes a striated muscle, alpha-actinin-interacting, costamere-localized protein. J 
Biol Chem 281(10): 6841-6849. 
Edmonson, D. G., G. E. Lyons, J. F. Martin and E. N. Olson (1994). Mef2 expression 
marks the cardiac and skeletal muscle lineages during mouse embryogenesis. 
Development 120: 1251-1263. 
Ervasti, J. M. (2003). Costameres: the Achilles' heel of Herculean muscle. J Biol Chem 
278(16): 13591-13594. 
Estrella, N. L., A. L. Clark, C. A. Desjardins, S. E. Nocco and F. J. Naya (2015). MEF2D 
deficiency in neonatal cardiomyocytes triggers cell cycle re-entry and programmed cell 
death in vitro. J Biol Chem 290(40): 24367-24380. 
Estrella, N. L., C. A. Desjardins, S. E. Nocco, A. L. Clark, Y. Maksimenko and F. J. 
Naya (2015). MEF2 transcription factors regulate distinct gene programs in mammalian 
skeletal muscle differentiation. J Biol Chem 290(2): 1256-1268. 
 175 
Estrella, N. L. and F. J. Naya (2014). Transcriptional networks regulating the costamere, 
sarcomere, and other cytoskeletal structures in striated muscle. Cell Mol Life Sci 71(9): 
1641-1656. 
Evans, R. M. and D. J. Mangelsdorf (2014). Nuclear Receptors, RXR, and the Big Bang. 
Cell 157(1): 255-266. 
Ewen, E. P., C. M. Snyder, M. Wilson, D. Desjardins and F. J. Naya (2011). The Mef2A 
transcription factor coordinately regulates a costamere gene program in cardiac muscle. J 
Biol Chem 286(34): 29644-29653. 
Feng, Y., C. A. Desjardins, O. Cooper, A. Kontor, S. E. Nocco and F. J. Naya (2015). 
EGR1 Functions as a Potent Repressor of MEF2 Transcriptional Activity. PLoS One 
10(5): e0127641. 
Foglia, M. J. and K. D. Poss (2016). Building and re-building the heart by cardiomyocyte 
proliferation. Development 143(5): 729-740. 
Gabori, N., R. Sakuma, J. N. Wylie, K. H. Kim, S. S. Zhang, C. C. Hui and B. G. 
Bruneau (2012). Cooperative and antagonistic roles for Irx3 and Irx5 in cardiac 
morphogenesis and postnatal physiology. Development 139: 4007-4019. 
Gianakopoulos, P. J. and I. S. Skerjanc (2005). Developmental roles and clinical 
significance of hedgehog signaling. J Biol Chem 280(22): 21022-21028. 
Gossett, L. A., D. J. Kelvin, E. A. Sternberg and E. N. Olson (1989). A new myocyte-
specific enhancer-binding factor that recognizes a conserved element associated with 
multiple muscle-specific genes. Mol Cel. Biol 9(11): 5022-5033. 
Grade, C. V., M. S. Salerno, F. R. Schubert, S. Dietrich and L. E. Alvares (2009). An 
evolutionarily conserved Myostatin proximal promoter/enhancer confers basal levels of 
transcription and spatial specificity in vivo. Dev Genes Evol 219(9-10): 497-508. 
Grant, C. E., T. L. Bailey and W. S. Noble (2011). FIMO: scanning for occurrences of a 
given motif. Bioinformatics 27(7): 1017-1018. 
Greer, P. L. and M. E. Greenberg (2008). From synapse to nucleus: calcium-dependent 
gene transcription in the control of synapse development and function. Neuron 59(6): 
846-860. 
Grote, K., U. Bavendiek, C. Grothusen, I. Flach, D. Hilfiker-Kleiner, H. Drexler and B. 
Schieffer (2004). Stretch-inducible expression of the angiogenic factor CCN1 in vascular 
smooth muscle cells is mediated by Egr-1. J Biol Chem 279(53): 55675-55681. 
 176 
Guo, Y., S. J. Kuhl, A. S. Pfister, W. Cizelsky, S. Denk, L. Beer-Molz and M. Kuhl 
(2014). Comparative analysis reveals distinct and overlapping functions of Mef2c and 
Mef2d during cardiogenesis in Xenopus laevis. PLoS One 9(1): e87294. 
Han, A., J. He, Y. Wu, J. O. Liu and L. Chen (2005). Mechanism of recruitment of class 
II histone deacetylases by myocyte enhancer factor-2. J Mol Biol 345(1): 91-102. 
He, A., S. W. Kong, Q. Ma and W. T. Pu (2011). Co-occupancy by multiple cardiac 
transcription factors identifies transcriptional enhancers active in heart. Proc Natl Acad 
Sci U S A 108(14): 5632-5637. 
Heidt, A. B., A. Rojas, I. S. Harris and B. L. Black (2007). Determinants of myogenic 
specificity within MyoD are required for noncanonical E box binding. Mol Cell Biol 
27(16): 5910-5920. 
Hinits, Y. and S. M. Hughes (2007). Mef2s are required for thick filament formation in 
nascent muscle fibres. Development 134(13): 2511-2519. 
Hinits, Y., L. Pan, C. Walker, J. Dowd, C. B. Moens and S. M. Hughes (2012). Zebrafish 
Mef2ca and Mef2cb are essential for both first and second heart field cardiomyocyte 
differentiation. Dev Biol 369(2): 199-210. 
Ho Sui, S. J., J. R. Mortimer, D. J. Arenillas, J. Brumm, C. J. Walsh, B. P. Kennedy and 
W. W. Wasserman (2005). oPOSSUM: identification of over-represented transcription 
factor binding sites in co-expressed genes. Nucleic Acids Res 33(10): 3154-3164. 
Hsu, S. C., Y. T. Chang and C. C. Chen (2013). Early growth response 1 is an early 
signal inducing Cav3.2 T-type calcium channels during cardiac hypertrophy. Cardiovasc 
Res 100(2): 222-230. 
Huang, H. T., O. M. Brand, M. Mathew, C. Ignatiou, E. P. Ewen, S. A. McCalmon and F. 
J. Naya (2006). Myomaxin is a novel transcriptional target of MEF2A that encodes a 
Xin-related alpha-actinin-interacting protein. J Biol Chem 281(51): 39370-39379. 
Junion, G., T. Jagla, S. Duplant, R. Tapin, J. P. Da Ponte and K. Jagla (2005). Mapping 
Dmef2-binding regulatory modules by using a ChIP-enriched in silico targets approach. 
Proc Natl Acad Sci U S A 102(51): 18479-18484. 
Kanehisa, M., M. Furumichi, M. Tanabe, Y. Sato and K. Morishima (2017). KEGG: new 
perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 45(D1): 
D353-D361. 
Karamboulas, C., G. D. Dakubo, J. Liu, Y. De Repentigny, K. Yutzey, V. A. Wallace, R. 
Kothary and I. S. Skerjanc (2006). Disruption of MEF2 activity in cardiomyoblasts 
inhibits cardiomyogenesis. J Cell Sci 119(Pt 20): 4315-4321. 
 177 
Kasneci, A., N. M. Kemeny-Suss, S. V. Komarova and L. E. Chalifour (2009). Egr-1 
negatively regulates calsequestrin expression and calcium dynamics in ventricular cells. 
Cardiovasc Res 81(4): 695-702. 
Khachigian, L. M. (2006). Early growth response-1 in cardiovascular pathobiology. Circ 
Res 98(2): 186-191. 
Kim, Y., D. Phan, E. van Rooij, D. Z. Wang, J. McAnally, X. Qi, J. A. Richardson, J. A. 
Hill, R. Bassel-Duby and E. N. Olson (2008). The MEF2D transcription factor mediates 
stress-dependent cardiac remodeling in mice. J Clin Invest 118(1): 124-132. 
Knoepfler, P. S., D. A. Bergstrom, T. Uetsuki, I. Dac-Korytko, Y. H. Sun, W. E. Wright, 
S. J. Tapscott and M. P. Kamps (1999). A conserved motif N-terminal to the DNA-
binding domains of myogenic bHLH transcription factors mediates cooperative DNA 
binding with pbx-Meis1/Prep1. Nucleic Acids Res 27(18): 3752-3761. 
Kolodziejczyk, S. M., L. Wang, K. Balazsi, Y. DeRepentigny, R. Kothary and L. A. 
Megeney (1999). MEF2 is upregulated during cardiac hypertrophy and is required for 
normal post-natal growth of the myocardium. Current Biology 9(20): 1203-1206. 
Lazic, S. and I. C. Scott (2011). Mef2cb regulates late myocardial cell addition from a 
second heart field-like population of progenitors in zebrafish. Dev Biol 354(1): 123-133. 
Lee, R. T., Z. Zhao and P. W. Ingham (2016). Hedgehog signalling. Development 143(3): 
367-372. 
Lehmann, L. H., B. C. Worst, D. A. Stanmore and J. Backs (2014). Histone deacetylase 
signaling in cardioprotection. Cell Mol Life Sci 71(9): 1673-1690. 
Li, L., J. Carter, X. Gao, J. Whitehead and W. G. Tourtellotte (2005). The 
neuroplasticity-associated arc gene is a direct transcriptional target of early growth 
response (Egr) transcription factors. Mol Cell Biol 25(23): 10286-10300. 
Lilly, B., S. Galewsky, A. B. Firulli, R. A. Schulz and E. N. Olson (1994). D-MEF2: a 
MADS box transcription factor expressed in differentiating mesoderm and muscle cell 
lineages during Drosophila embryogenesis. Proc Natl Acad Sci U S A 91(12): 5662-
5666. 
Lilly, B., B. Zhao, G. Ranganayakulu, B. M. Paterson, R. A. Schulz and E. N. Olson 
(1995). Requirement of MADS domain transcription factor D-MEF2 for muscle 
formation in Drosophila. Science 267(5198): 688-693. 
Lin, Q., J. Lu, H. Yanagisawa, R. Webb, G. E. Lyons, J. A. Richardson and E. N. Olson 
(1998). Requirement of the MADS-box transcription factor MEF2C for vascular 
development. Development 125(22): 4565-4574. 
 178 
Lin, Q., J. J. Schwarz, C. Bucana and E. N. Olson (1997). Control of Mouse Cardiac 
Morphogenesis and Myogenesis by Transcription Factor MEF2C. Science 276: 1404-
1407. 
Liu, J. and G. D. Stormo (2008). Context-dependent DNA recognition code for C2H2 
zinc-finger transcription factors. Bioinformatics 24(17): 1850-1857. 
Lovato, T. L., C. A. Sensibaugh, K. L. Swingle, M. M. Martinez and R. M. Cripps 
(2015). The Drosophila Transcription Factors Tinman and Pannier Activate and 
Collaborate with Myocyte Enhancer Factor-2 to Promote Heart Cell Fate. PLoS One 
10(7): e0132965. 
Lu, J., T. A. McKinsey, R. L. Nicol and E. N. Olson (2000). Signal-dependent activation 
of the MEF2 transcription factor by dissociation from histone deacetylases. Proc Natl 
Acad Sci U S A 97(8): 4070-4075. 
Lu, J., T. A. McKinsey, C. L. Zhang and E. N. Olson (2000). Regulation of skeletal 
myogenesis by association of the MEF2 transcription factor with class II histone 
deacetylases. Mol Cell 6(2): 233-244. 
Mayer, U. (2003). Integrins: redundant or important players in skeletal muscle? J Biol 
Chem 278(17): 14587-14590. 
McCalmon, S. A., D. M. Desjardins, S. Ahmad, K. S. Davidoff, C. M. Snyder, K. Sato, 
K. Ohashi, O. M. Kielbasa, M. Mathew, E. P. Ewen, K. Walsh, H. Gavras and F. J. Naya 
(2010). Modulation of angiotensin II-mediated cardiac remodeling by the MEF2A target 
gene Xirp2. Circ Res 106(5): 952-960. 
McKinsey, T. A. and E. N. Olson (2005). Toward transcriptional therapies for the failing 
heart: chemical screens to modulate genes. J Clin Invest 115(3): 538-546. 
McKinsey, T. A., C. L. Zhang and E. N. Olson (2001). Control of muscle development 
by dueling HATs and HDACs. Curr Opin Genet Dev 11(5): 497-504. 
McKinsey, T. A., C. L. Zhang and E. N. Olson (2002). MEF2: a calcium-dependent 
regulator of cell division, differentiation and death. Trends Biochem Sci 27(1): 40-47. 
Miano, J. M., X. Long and K. Fujiwara (2007). Serum response factor: master regulator 
of the actin cytoskeleton and contractile apparatus. Am J Physiol Cell Physiol 292(1): 
C70-81. 
Miska, E. A., C. Karlsson, E. Langley, S. J. Nielsen, J. Pines and T. Kouzarides (1999). 
HDAC4 deacetylase associates with and represses the MEF2 transcription factor. EMBO 
J 18(18): 5099-5107. 
 179 
Molkentin, J. D., A. B. Firulli, B. L. Black, J. F. Martin, C. M. Hustad, N. Copeland, N. 
Jenkins, G. E. Lyons and E. N. Olson (1996). MEF2B is a potent transactivator expressed 
in early myogenic lineages. Mol Cell Biol 16(7): 3814-3824. 
Molkentin, J. D. and E. N. Olson (1996). Combinatorial control of muscle development 
by basic helix-loop-helix and MADS-box transcription factors. Proc Natl Acad Sci U S A 
93(18): 9366-9373. 
Moorman, A. F. and V. M. Christoffels (2003). Cardiac Chamber Formation: 
Development, Genes, and Evolution. Physiol Rev 83: 1223-1267. 
Motoyama, J., J. Liu, R. Mo, Q. Ding, M. Post and C. C. Hui (1998). Essential function 
of Gli2 and Gli3 in the formation of lung, trachea and oesophagus. Nat Genet 20(1): 54-
57. 
Murphy, A. M. (1996). Contractile protein phenotypic variation during development. 
Cardiovasc Res 31: 25-33. 
Murray, T. V., A. Ahmad and A. C. Brewer (2014). Reactive oxygen at the heart of 
metabolism. Trends Cardiovasc Med 24(3): 113-120. 
Narlikar, L., N. J. Sakabe, A. A. Blanski, F. E. Arimura, J. M. Westlund, M. A. Nobrega 
and I. Ovcharenko (2010). Genome-wide discovery of human heart enhancers. Genome 
Res 20(3): 381-392. 
Naya, F. J., B. L. Black, H. Wu, R. Bassel-Duby, J. A. Richardson, J. A. Hill and E. N. 
Olson (2002). Mitochondrial deficiency and cardiac sudden death in mice lacking the 
MEF2A transcription factor. Nat Med 8(11): 1303-1309. 
Naya, F. J., C. Wu, J. A. Richardson, P. Overbeek and E. N. Olson (1999). 
Transcriptional activity of MEF2 during mouse embryogenesis monitored with a MEF2-
dependent transgene. Development 126(10): 2045-2052. 
Niu, Z., A. Li, S. X. Zhang and R. J. Schwartz (2007). Serum response factor 
micromanaging cardiogenesis. Curr Opin Cell Biol 19(6): 618-627. 
Ntziachristos, P., J. S. Lim, J. Sage and I. Aifantis (2014). From fly wings to targeted 
cancer therapies: a centennial for notch signaling. Cancer Cell 25(3): 318-334. 
O'Donovan, K. J., W. G. Tourtellotte, J. Millbrandt and J. M. Baraban (1999). The EGR 
family of transcription-regulatory factors: progress at the interface of molecular and 
systems neuroscience. Trends Neurosci 22(4): 167-173. 
 180 
O'Mahoney, J. V., K. L. Guven, J. Lin, J. E. Joya, C. S. Robinson, R. P. Wade and E. C. 
Hardeman (1998). Identification of a novel slow-muscle-fiber enhancer binding protein, 
MusTRD1. Mol Cell Biol 18(11): 6641-6652. 
Olson, E. N. (2006). Gene regulatory networks in the evolution and development of the 
heart. Science 313(5795): 1922-1927. 
Pacini, L., S. Suffredini, D. Ponti, R. Coppini, G. Frati, G. Ragona, E. Cerbai and A. 
Calogero (2013). Altered calcium regulation in isolated cardiomyocytes from Egr-1 
knock-out mice. Can J Physiol Pharmacol 91(12): 1135-1142. 
Paige, S. L., K. Plonowska, A. Xu and S. M. Wu (2015). Molecular regulation of 
cardiomyocyte differentiation. Circ Res 116(2): 341-353. 
Pak, E. and R. A. Segal (2016). Hedgehog Signal Transduction: Key Players, Oncogenic 
Drivers, and Cancer Therapy. Dev Cell 38(4): 333-344. 
Pallavi, S. K., D. M. Ho, C. Hicks, L. Miele and S. Artavanis-Tsakonas (2012). Notch 
and Mef2 synergize to promote proliferation and metastasis through JNK signal 
activation in Drosophila. EMBO J 31(13): 2895-2907. 
Paris, J., C. Virtanen, Z. Lu and M. Takahashi (2004). Identification of MEF2-regulated 
genes during muscle differentiation. Physiol Genomics 20(1): 143-151. 
Parra, M. and E. Verdin (2010). Regulatory signal transduction pathways for class IIa 
histone deacetylases. Curr Opin Pharmacol 10(4): 454-460. 
Pasumarthi, K. B. S. (2002). Cardiomyocyte Cell Cycle Regulation. Circulation Research 
90(10): 1044-1054. 
Pereira, A. H., C. F. Clemente, A. C. Cardoso, T. H. Theizen, S. A. Rocco, C. C. Judice, 
M. C. Guido, V. D. Pascoal, I. Lopes-Cendes, J. R. Souza and K. G. Franchini (2009). 
MEF2C silencing attenuates load-induced left ventricular hypertrophy by modulating 
mTOR/S6K pathway in mice. PLoS One 4(12): e8472. 
Pollock, R. and R. Treisman (1991). Human SRF-related proteins: DNA-binding 
properties and potential regulatory targets. Genes Dev 5(12A): 2327-2341. 
Porrello, E. R., A. I. Mahmoud, E. Simpson, J. A. Hill, J. A. Richardson, E. N. Olson and 
H. A. Sadek (2011). Transient regenerative potential of the neonatal mouse heart. Science 
331(6020): 1078-1080. 
Potthoff, M. J., M. A. Arnold, J. McAnally, J. A. Richardson, R. Bassel-Duby and E. N. 
Olson (2007). Regulation of skeletal muscle sarcomere integrity and postnatal muscle 
function by Mef2c. Mol Cell Biol 27(23): 8143-8151. 
 181 
Potthoff, M. J. and E. N. Olson (2007). MEF2: a central regulator of diverse 
developmental programs. Development 134(23): 4131-4140. 
Puri, P. L. and V. Sartorelli (2000). Regulation of Muscle Regulatory Factors by DNA-
Binding, Interacting Proteins, and Post-Transcriptional Modification. J Cell Physiol 185: 
155-173. 
Quandt, K., K. Frech, H. Karas, E. Wingender and T. Werner (1995). MatInd and 
MatInspector: new fast and versatile tools for detection of consensus matches in 
nucleotide sequence data. Nucleic Acids Res 23(23): 4878-4884. 
Ramachandran, B., G. Yu, S. Li, B. Zhu and T. Gulick (2008). Myocyte enhancer factor 
2A is transcriptionally autoregulated. J Biol Chem 283(16): 10318-10329. 
Rochais, F., K. Mesbah and R. G. Kelly (2009). Signaling pathways controlling second 
heart field development. Circ Res 104(8): 933-942. 
Sandmann, T., L. J. Jensen, J. S. Jakobsen, M. M. Karzynski, M. P. Eichenlaub, P. Bork 
and E. E. Furlong (2006). A temporal map of transcription factor activity: mef2 directly 
regulates target genes at all stages of muscle development. Dev Cell 10(6): 797-807. 
Santelli, E. and T. J. Richmond (2000). Crystal structure of MEF2A core bound to DNA 
at 1.5 A resolution. J Mol Biol 297(2): 437-449. 
Sartorelli, V., J. Huang, Y. Hamamori and L. Kedes (1997). Molecular mechanisms of 
myogenic coactivation by p300: direct interaction with the activation domain of MyoD 
and with the MADS box of MEF2C. Mol Cell Biol 17(2): 1010-1026. 
Schlesinger, J., M. Schueler, M. Grunert, J. J. Fischer, Q. Zhang, T. Krueger, M. Lange, 
M. Tonjes, I. Dunkel and S. R. Sperling (2011). The cardiac transcription network 
modulated by Gata4, Mef2a, Nkx2.5, Srf, histone modifications, and microRNAs. PLoS 
Genet 7(2): e1001313. 
Sebastian, S., H. Faralli, Z. Yao, P. Rakopoulos, C. Palii, Y. Cao, K. Singh, Q. C. Liu, A. 
Chu, A. Aziz, M. Brand, S. J. Tapscott and F. J. Dilworth (2013). Tissue-specific splicing 
of a ubiquitously expressed transcription factor is essential for muscle differentiation. 
Genes Dev 27(11): 1247-1259. 
Sengupta, A., V. V. Kalinichenko and K. E. Yutzey (2013). FoxO1 and FoxM1 
transcription factors have antagonistic functions in neonatal cardiomyocyte cell-cycle 
withdrawal and IGF1 gene regulation. Circ Res 112(2): 267-277. 
Shalizi, A. K. and A. Bonni (2005). Brawn for Brains: The Role of MEF2 Proteins in the 
Developing Nervous System. Curr Top Dev Biol 69: 239-266. 
 182 
Shen, H., A. S. McElhinny, Y. Cao, P. Gao, J. Liu, R. Bronson, J. D. Griffin and L. Wu 
(2006). The Notch coactivator, MAML1, functions as a novel coactivator for MEF2C-
mediated transcription and is required for normal myogenesis. Genes Dev 20(6): 675-
688. 
Shen, T., I. Aneas, N. Sakabe, R. J. Dirschinger, G. Wang, S. Smemo, J. M. Westlund, H. 
Cheng, N. Dalton, Y. Gu, C. J. Boogerd, C. L. Cai, K. Peterson, J. Chen, M. A. Nobrega 
and S. M. Evans (2011). Tbx20 regulates a genetic program essential to adult mouse 
cardiomyocyte function. J Clin Invest 121(12): 4640-4654. 
Skerjanc, I. S., H. Petropoulos, A. G. Ridgeway and S. Wiilton (1998). Myocyte 
Enhancer Factor 2C and Nkx2–5 Up-regulate Each Other’s Expression and Initiate 
Cardiomyogenesis in P19 Cells. J. Biol. Chem 273(52): 34904-34920. 
Snyder, C. M., A. L. Rice, N. L. Estrella, A. Held, S. C. Kandarian and F. J. Naya (2013). 
MEF2A regulates the Gtl2-Dio3 microRNA mega-cluster to modulate WNT signaling in 
skeletal muscle regeneration. Development 140(1): 31-42. 
Sorimachi, H. and Y. Ono (2012). Regulation and physiological roles of the calpain 
system in muscular disorders. Cardiovasc Res 96(1): 11-22. 
Sparrow, D. B., E. A. Miska, E. Langley, S. Reynaud-Deonauth, S. Kotecha, N. Towers, 
G. Spohr, T. Kouzarides and T. J. Mohun (1999). MEF-2 function is modified by a novel 
co-repressor, MITR. EMBO J 18(18): 5085-5098. 
Srivastava, D. (2006). Making or breaking the heart: from lineage determination to 
morphogenesis. Cell 126(6): 1037-1048. 
Svingen, T. and K. F. Tonissen (2006). Hox transcription factors and their elusive 
mammalian gene targets. Heredity (Edinb) 97(2): 88-96. 
Tassabehji, M., M. Carette, C. Wilmot, D. Donnai, A. P. Read and K. Metcalfe (1999). A 
transcription factor involved in skeletal muscle gene expression is deleted in patients with 
Williams syndrome. Eur J Hum Genet 7: 737-747. 
Thomas, N. A., M. Koudijs, F. J. van Eeden, A. L. Joyner and D. Yelon (2008). 
Hedgehog signaling plays a cell-autonomous role in maximizing cardiac developmental 
potential. Development 135(22): 3789-3799. 
Ticho, B. S., D. Y. Stainier, M. C. Fishman and R. E. Breitbart (1996). Three zebrafish 
MEF2 genes delineate somitic and cardiac muscle development in wild-type and mutant 
embryos. Mech Dev 59(2): 205-218. 
Tsukui, T., J. Capdevila, K. Tamura, P. Ruiz-Lozano, C. Rodriguez-Esteban, S. Yonei-
Tamura, J. Magallon, R. A. S. Chandraratna, K. Chien, B. Blumberg, R. M. Evans and J. 
 183 
C. I. Belmonte (1999). Multiple left-right asymmetry defects in Shh /  mutant mice 
unveil a convergence of the Shh and retinoic acid pathways in the control of Lefty-1. 
Proc Natl Acad Sci U S A 96: 11376-11381. 
Untergasser, A., I. Cutcutache, T. Koressaar, J. Ye, B. C. Faircloth, M. Remm and S. G. 
Rozen (2012). Primer3--new capabilities and interfaces. Nucleic Acids Res 40(15): e115. 
van Oort, R. J., E. van Rooij, M. Bourajjaj, J. Schimmel, M. A. Jansen, R. van der Nagel, 
P. A. Doevendans, M. D. Schneider, C. J. van Echteld and L. J. De Windt (2006). MEF2 
activates a genetic program promoting chamber dilation and contractile dysfunction in 
calcineurin-induced heart failure. Circulation 114(4): 298-308. 
VanDusen, N. J. and A. B. Firulli (2012). Twist factor regulation of non-cardiomyocyte 
cell lineages in the developing heart. Differentiation 84(1): 79-88. 
Vincent, S. D. and M. E. Buckingham (2010). How to make a heart: the origin and 
regulation of cardiac progenitor cells. Curr Top Dev Biol 90: 1-41. 
Vincentz, J. W., R. M. Barnes, B. A. Firulli, S. J. Conway and A. B. Firulli (2008). 
Cooperative interaction of Nkx2.5 and Mef2c transcription factors during heart 
development. Dev Dyn 237(12): 3809-3819. 
Vogler, G. and R. Bodmer (2015). Cellular Mechanisms of Drosophila Heart 
Morphogenesis. J Cardiovasc Dev Dis 2(1): 2-16. 
Vong, L. H., M. J. Ragusa and J. J. Schwarz (2005). Generation of conditional 
Mef2cloxP/loxP mice for temporal- and tissue-specific analyses. Genesis 43(1): 43-48. 
Voronova, A., A. Al Madhoun, A. Fischer, M. Shelton, C. Karamboulas and I. S. 
Skerjanc (2012). Gli2 and MEF2C activate each other's expression and function 
synergistically during cardiomyogenesis in vitro. Nucleic Acids Res 40(8): 3329-3347. 
Waardenberg, A. J., M. Ramialison, R. Bouveret and R. P. Harvey (2014). Genetic 
networks governing heart development. Cold Spring Harb Perspect Med 4(11): a013839. 
Wales, S., S. Hashemi, A. Blais and J. C. McDermott (2014). Global MEF2 target gene 
analysis in cardiac and skeletal muscle reveals novel regulation of DUSP6 by p38MAPK-
MEF2 signaling. Nucleic Acids Res 42(18): 11349-11362. 
Wang, C., S. Dostanic, N. Servant and L. E. Chalifour (2005). Egr-1 negatively regulates 
expression of the sodium-calcium exchanger-1 in cardiomyocytes in vitro and in vivo. 
Cardiovasc Res 65(1): 187-194. 
 184 
Wang, Y. X., L. X. Qian, Z. Yu, Q. Jiang, Y. X. Dong, X. F. Liu, X. Y. Yang, T. P. 
Zhong and H. Y. Song (2005). Requirements of myocyte-specific enhancer factor 2A in 
zebrafish cardiac contractility. FEBS Lett 579(21): 4843-4850. 
Watanabe, K., H. Takebayashi, A. K. Bepari, S. Esumi, Y. Yanagawa and N. Tamamaki 
(2011). Dpy19l1, a multi-transmembrane protein, regulates the radial migration of 
glutamatergic neurons in the developing cerebral cortex. Development 138(22): 4979-
4990. 
Wilson-Rawlins, J., J. D. Molkentin, B. L. Black and E. N. Olson (1999). Activated 
Notch Inhibits Myogenic Activity of the MADS-Box Transcription Factor Myocyte 
Enhancer Factor 2C. Mol Cel. Biol 19(4): 2853-2862. 
Wright, W. E., M. Binder and W. Funk (1991). Cyclic amplification and selection of 
targets (CASTing) for the myogenin consensus binding site. Mol Cell Biol 11(8): 4104-
4110. 
Xu, J., N. L. Gong, I. Bodi, B. J. Aronow, P. H. Backx and J. D. Molkentin (2006). 
Myocyte enhancer factors 2A and 2C induce dilated cardiomyopathy in transgenic mice. 
J Biol Chem 281(14): 9152-9162. 
Yu, J., I. de Belle, H. Liang and E. D. Adamson (2004). Coactivating factors p300 and 
CBP are transcriptionally crossregulated by Egr1 in prostate cells, leading to divergent 
responses. Mol Cell 15(1): 83-94. 
Yu, Y. T., R. E. Breitbart, L. B. Smoot, Y. Lee, V. Mahdavi and B. Nadal-Ginard (1992). 
Human myocyte-specific enhancer factor 2 comprises a group of tissue-restricted MADS 
box transcription factors. Genes Dev 6(9): 1783-1798. 
Yu, Z., T. G. Pestell, M. P. Lisanti and R. G. Pestell (2012). Cancer stem cells. Int J 
Biochem Cell Biol 44(12): 2144-2151. 
Zacchigna, S. and M. Giacca (2014). Extra- and intracellular factors regulating 
cardiomyocyte proliferation in postnatal life. Cardiovasc Res 102(2): 312-320. 
Zhang, C. L., T. A. McKinsey, S. Chang, C. L. Antos, J. A. Hill and E. N. Olson (2002). 
Class II Histone Deacetylases Act as Signal-Responsive Repressors of Cardiac 
Hypertrophy. Cell 110: 479-488. 
Zhang, X. M., M. Ramalho-Santos and A. P. McMahon (2001). Smoothened mutants 
reveal redundant roles for Shh and Ihh signaling including regulation of L/R asymmetry 
by the mouse node. Cell 105(6): 781-792. 
 185 
Zhu, B., B. Ramachandran and T. Gulick (2005). Alternative pre-mRNA splicing governs 
expression of a conserved acidic transactivation domain in myocyte enhancer factor 2 
factors of striated muscle and brain. J Biol Chem 280(31): 28749-28760. 
 
  
 186 
CURRICULUM VITAE 
 187 
  
 188 
 189 
 190 
 191 
